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1. Introduction 
1.1 Oncogenic Viruses 
The multistep nature of human carcinogenesis is described as the accumulation of 
‘oncogenic hits’ resulting from spontaneously or environmentally caused mutations, 
together with the host’s genetic background and the selective pressure of the tissue 
microenvironment (Mesri et al. 2014). Different mechanistic strategies are involved in 
cancer development leading to genetic changes and acquired characteristics, which 
were summarised and defined as the ‘hallmarks of cancer’ (figure 1) by Hanahan and 
Weinberg (Hanahan and Weinberg 2000).  
 
Figure 1. The hallmarks of cancer (Hanahan and Weinberg 2000). The hallmarks of 
cancer describe 6 characteristics occurring during the development of most cancers 
due to different mechanistic strategies. 
 
In 2012, the International Agency for Research on Cancer (IARC) has classified 6 
viruses as Group 1 carcinogens, described as being carcinogenic to humans, based 
on epidemiological and biological studies (Bouvard et al. 2009, Mesri et al. 2014). 
About 12 to 15% of human cancers worldwide are caused by oncogenic viruses. 
Historically, in 1911, the first oncogenic virus, avian Rous sarcoma virus, was identified 
by Peyton Rous, which was followed decades later by the identification of a series of 
oncogenic viruses, including cottontail rabbit papillomavirus and simian virus 40 
(SV40). Due to the identification of v-src as the viral oncogene of the Rous sarcoma 
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virus, Harold Varmus and Michael Bishop confirmed the theory of virus-associated 
oncogenesis (Stehelin et al. 1976).  
 
Table 1. Tumour viruses, associated cancers and viral oncogenes important in humans (Ajiro and 
Zheng 2014, Howley and Pfister 2015). The virus type is described with its abbreviation, its associated 
cancer and its viral oncogene. In addition, the asterisks indicate the members of the Group 1 
carcinogens defined by the International Agency for Research on Cancer. 
Tumour-virus Abbreviation Associated cancer(s) Viral oncogenes 
Human papillomavirus of 
genus alpha 
HPV* 
Cervical cancer, anal 
cancer, vaginal cancer, 
oropharyngeal cancer 
E5, E6, E7 
Human papillomavirus of 
genus beta 
HPV 
Skin cancer in 
Epidermodysplasia 
verruciformis patients 
E2, E6, E7 
Merkel cell polyomavirus MCPyV Merkel cell carcinoma T antigens 
Human T cell 
lymphotrophic virus, 
type-1 
HTLV-1* Adult T-cell lymphoma Tax 
Epstein-Barr virus EBV* 
Burkitt lymphoma, 
Hodgkin lymphoma, non-
Hodgkin lymphoma, 
nasopharyngeal cancer, 
T-cell and NK lymphoma 
LMP1 
Kaposi’s sarcoma herpes 
virus 
KSHV* 
Kaposi’s sarcoma, 
primary effusion 
lymphoma 
LANA, vFLIP, vCyclin, 
vGPCR, vIRF-1, K1 
Hepatitis B virus HBV* Hepatocellular carcinoma HBx 
Hepatitis C virus HCV* Hepatocellular carcinoma 
Core protein, NS3, 
NS4B, NS5A 
 
The confirmation of virus-associated cancer development in humans was obtained by 
findings such as the identification of Epstein-Barr virus (EBV) in Burkitt lymphomas 
(1965), the isolation of human T-cell lymphoma virus-1 (HTLV-1) from adult T-cell 
lymphomas, the association of cervical cancer with high-risk human papillomaviruses 
(HPV) and the discovery of several other cancer-inducing viruses including Merkel cell 
polyomavirus (more cancer associated viruses are shown in table 1) (Mesri et al. 
2014). All human tumour-associated viruses encode oncogenes or genes with 
oncogenic activities, which allow changes in the cellular machinery (compare to the 
‘hallmarks of cancer’). Therefore, host cell transformation and a persistent virus 
infection are two major events in virus-associated cancer development (Ajiro and 
Zheng 2014).     
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1.2 Discovery of Human Papillomaviruses 
In the ancient Greek and Romans, skin and genital warts were already noted and 
genital warts were supposed to be infectious and sexually transmitted. In 1907, first 
cell-free transmission experiments were performed in Italy and demonstrated the 
infectious potential of human warts (Ciuffo 1907). The infectious origin of genital warts 
and laryngeal papillomatosis was confirmed in the 1920’s (Syrjanen and Syrjanen 
2008). First viral particles of HPV were demonstrated in electron microscopy in 1949 
(Strauss et al. 1949). The successful transmission of the rabbit papillomavirus from 
wild cottontail rabbits to domestic rabbits and the observation that initial papillomas 
developed frequently into squamous cell carcinomas (SCCs) demonstrated the first 
hints for a carcinogenic potential of the virus (Rous and Kidd 1938). In 1965, first 
studies were able to describe the circularized, double-stranded DNA of HPV (Crawford 
1965, Klug and Finch 1965). Furthermore, the group of Harald zur Hausen identified a 
clear heterogeneity within the group of HPV due to hybridisation studies including 
material from cutaneous and genital warts, as well as cervical cancer biopsies (zur 
Hausen et al. 1974). Additionally, in the 1970’s experiments were performed 
demonstrating a relationship between papillomavirus infection and cervical cancer, 
which arose to the hypothesis that cervical cancer development results from HPV 
infection (zur Hausen 1977). In 2008, Harald zur Hausen got the Nobel prize for his 
discovery that high-risk HPV types are the causative agents of cervical cancer.  
 
1.3 The Family of Papillomaviruses 
Papillomaviruses (PV) infect a wide variety of animals as well as humans. Up to now, 
204 types of HPV (according to papillomavirus episteme, http://pave.niaid.nih.gov) 
have been identified on DNA sequence analysis. Homologous nucleotide sequences 
of the major capsid protein gene L1 were used to design a phylogenetic tree, which 
characterised HPV into five different genera (alpha, beta, gamma, mu and nu). A new 
HPV type is defined with 10% difference in the DNA sequence of L1 compared to the 
closest known HPV type. A difference between 2 to 10% defines a new subtype and 
less than 2% a new variant (de Villiers et al. 2004). Furthermore, HPV can be divided 
into cutaneous and mucosal types, depending on their site of infection, as well as in 
high-risk and low-risk types, referring to their oncogenic potential. Mucosal HPV types 
infect the non-keratinizing epithelium mainly of the anogenital tract and the oral lining, 
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while cutaneous types infect the keratinizing epithelium of the skin (Gomez 2007). The 
best-studied group is the genus alphaHPV, infecting the mucosal epithelium, 
comprising the high-risk types HPV16 and HPV18, which are accepted as oncogenic 
types found in mucosal cancer. The cutaneous epithelium-infecting betaHPV types 
gained attention, due to their involvement in the development of cutaneous SCCs (see 
section 1.8)  
 
1.4 Structure of Human Papillomaviruses  
HPVs are small (Ø 55 nm) non-enveloped, double-stranded DNA tumour viruses with 
an icosahedral capsid composed of 72 capsomers. The viral genome is circularized 
and about 8000 bp in size with 7 - 9 overlapping open reading frames (ORFs), 
encoding the viral proteins from one DNA strand (Pfister and Fuchs 1994). The 
genome is associated with histones, forming a nucleosome-like structure (Favre et al. 
1977, Pfister and zur Hausen 1978). The DNA strand can be divided into the coding 
region, including the early and the late region and the non-coding region (NCR) or 
upstream regulatory region (URR), which are separated by two polyadenylation sites 
(Pfister and Fuchs 1994, Zheng and Baker 2006). The coding region contains ORFs 
encoding specific viral proteins at different time points of the viral life cycle. Therefore, 
the respective proteins are named after their expression during the viral life cycle and 
are called ‘early’ and ‘late’ proteins (Gomez 2007).  
The early coding region contains typically the early proteins E1, E2, E4, E5, E6 and 
E7, which play an important role in viral transcription, replication and transformation 
(figure 2). Expression of the viral early gene products determines whether the infection 
is active or latent or whether it leads to malignant transformation. The late region 
encodes the structural proteins L1 and L2 responsible for the formation of the viral 
capsid (Gomez 2007). The NCR is located between the ORFs of the L1 and the E6 
protein and contains control elements, such as the origin of replication (ori) and 
promoters responsible for transcription of the polycistronic mRNAs (Akgül et al. 2003). 
The early promoter, located 3’ from the NCR, expresses the E1, E2/E4, E5, E6 and E7 
proteins from their respective mRNAs, whereas the late promoter is responsible for the 
transcription of the late proteins L1 and L2, but also for E1, E2 and E4 (Stubenrauch 
et al. 1992, Stubenrauch and Laimins 1999). Alternative splicing gives rise to a fusion 
protein E1^E4, which is involved in releasing infectious viral particles (Doorbar et al. 
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1991). Comparing related and more divergent PV types, the NCR shows the highest 
degree of variation in the viral genome (Gomez 2007). 
 
 
Figure 2: Schematic genome organisation of HPV8. Early and late proteins are indicated as arrows, 
whereby HPV8 lacks E5. The genome is presented as linearized version and has a size of 7654 bp. 
NCR: non-coding region. 
 
1.5 HPV viral life cycle 
Despite the heterogeneity of different HPV types, all types target keratinocytes of 
different epithelia, including the mucosa and skin. All these different HPV types are 
able to produce infectious virions by sharing specific features of reproduction. Most 
studies have focused on the analysis of high-risk HPV types, such as HPV16 (Doorbar 
2016). Information gained from these studies can be applied, with some modifications 
(here indicated for alpha and betaHPV), to the other groups of HPV.  
The general target of HPV is the basal layer of the stratified squamous epithelium. An 
initial HPV infection starts with the exposure of basal cells to infectious particles due to 
micro wounds. For high-risk alphaHPVs, the initial site of infection includes the cervical 
and anal transformation zones, whereas for betaHPVs, the hair follicles are an 
important site of infection (Iannacone et al. 2014, Quint et al. 2015).  
Basal cells possess proliferative potential, which is necessary for the viral life cycle of 
HPV due to its dependence on the replication machinery of the host cell (Quint et al. 
2015). The entry of viral particles into human keratinocytes is a multistep process 
starting with the attachment to heparin sulphate proteoglycans (HSPGs) either located 
on the surface of an epithelial cell or on the basement membrane. HSPGs interact with 
the L1 major capsid protein, initiating a series of conformational changes leading to 
cell binding and delivery of viral DNA into the cells. The most prominent HSPG in 
keratinocytes is syndecan-1, which functions as HPV attachment receptor (Schelhaas 
et al. 2012, Surviladze et al. 2015, Kines et al. 2016). Furthermore, laminin-5 has been 
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proposed to act as a transient receptor for virion binding, as it is secreted during 
epithelial wounding (Culp et al. 2006, Schelhaas et al. 2012). For infectious 
internalisation, integrin α6β4, a transmembrane glycoprotein receptor, appears to be 
involved as a secondary receptor. After skin injuries, keratinocytes produce more 
integrin α6β4, which is bound by HPV particles during wound healing and the particles 
are endocytosed to the microfilament network via hemidesmosomes (Evander et al. 
1997, Culp et al. 2006, Raff et al. 2013). The viral life cycle of alphaHPV results in 
productive infections and neoplasia, whereby betaHPV only lead to asymptomatic 
infections in the general population. BetaHPVs infect long-lived, slow-cycling 
epidermal stem (or stem-like) cells, populating the surrounding basal layer with 
transiently amplifying cells containing viral episomes (Quint et al. 2015). 
 
Figure 3. Infection site of betaHPV. BetaHPVs gain 
access to epithelial stem cells through microwounds 
or hair follicles. The bulge region of hair follicles 
contains epithelial stem cells (purple cells), which 
populate cutaneous epithelial sites, involved in initial 
betaHPV infection (Egawa et al. 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the basal cell layer, the viral genome is replicated and maintained as episomes at a 
low copy number (50 - 100 copies per cell). The early proteins E1 and E2 are 
expressed and bind specifically to the ori of replication to recruit cellular replication 
factors (Lazarczyk et al. 2009, Quint et al. 2015). This state is known as the 
amplification phase, which is followed by the maintenance phase. During cell division, 
viral DNA is distributed between both daughter cells, whereby one cell migrates and 
enters cell differentiation and one cell continues cell division in the basal cell layer 
providing a reservoir of viral DNA. Therefore, the maintenance phase ensures viral 
persistence and latent viral infection. During HPV infection, cell cycle exit is blocked 
and induction of S-phase is mediated by the early proteins E6 and E7 (Stubenrauch 
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and Laimins 1999, Moody and Laimins 2010). The E6 and E7 proteins are responsible 
for the re-entry of the infected cell into the cell cycle, allowing genome amplification 
(Quint et al. 2015). In high-risk alphaHPVs, E6 and E7 allow extensive cell proliferation 
associated with neoplasia, whereas in betaHPVs cell cycle re-entry and genome 
amplification is maintained without neoplasia. However, gene expression in betaHPVs 
can become deregulated, i.e. in association with UV irradiation and 
immunosuppression (Akgül et al. 2003, Howley and Pfister 2015, Quint et al. 2015). 
During the vegetative phase, the expression of regulatory viral proteins, including E4 
and E5 (only for some genera), increases in the stratum spinosum. In the upper layers 
of the stratified epithelium, viral genome expression is accelerated resulting in the 
amplification of thousands of copies per cell (McBride 2008, Doorbar et al. 2012). After 
genome amplification, the expression of the capsid proteins L1 and L2 is triggered in 
the most upper layers of the stratum spinosum, whereby expression in the stratum 
granulosum leads to virion assembly and the encapsidation of viral genomic DNA. The 
virus particles are released by shedding off keratinocytes from the stratum corneum 
(Lazarczyk et al. 2009, Quint et al. 2015).  
 
Figure 4. Life cycle of HPV. HPV infects the basal cells, where the early proteins are weakly expressed. 
The expression increases in the stratum spinosum and the vegetative viral DNA replication takes place. 
The expression of the structural proteins is restricted to the differentiated cells of the stratum 
granulosum, where the virus assembly takes place, the virus particles are then released with 
stratification. The viral proteins disturb the normal differentiation program, resulting in thickening of the 
suprabasal layers. (A) Early gene expression of E1, E2, E6 and E7, (B) viral genome amplification, (C) 
virion assembly and release (taken from Soave (2013)). 
 
1.6 HPV in anogenital cancer 
The alphaHPV types mainly infect the mucosa of the anogenital tract. A group of about 
30 HPV types infect the genital tract due to sexual contact. These HPV types can be 
divided into low-risk and high-risk HPV types according to their association with cancer. 
Introduction 
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The low-risk HPV types, only rarely found in malignant tumours and usually causing 
benign anogenital warts, include HPV types 6, 11, 40, 42, 43, 44, 54, 55, 57, 61, 71, 
81, 83, 84 and 89, whereas high-risk HPV types include types 16, 18, 26, 30, 31, 33, 
34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, 68, 70, 73 and 82 and cause anogenital 
cancer (Bouvard et al. 2009). The main representatives of the high-risk alphaHPV 
types are HPV16 and HPV18, which are most commonly associated with cervical 
cancer. More than 95% of cervical cancers, 50 - 90% of other anogenital cancers and 
20 - 30% of oropharyngeal cancers have been associated with persistent infection and 
genomic integration of high-risk HPVs (Ajiro and Zheng 2014, Hübbers and Akgül 
2015).  
Up to 80% of sexually active men and women acquire an anogenital HPV infection 
during their lifetime, however, most infections are transient and cleared by the immune 
system after a few months. Persistent infections can lead to the development of cancer 
precursor lesions, named intraepithelial neoplasia, which may result in invasive 
carcinomas of the anogenital tract. Cervical cancer is the most common cancer 
induced by HPV and is the second most prevalent cancer in women worldwide 
(Wieland et al. 2014). A total of 470,000 new cases of cervical cancer are diagnosed 
per year, however, cervical screening has reduced the incidence of HPV-associated 
cancers in the developed world. In 2008, the incidence rate in Germany was 9.5 per 
100,000 (Seifert and Klug 2014). In addition, persistent HPV infections are very 
common in immunosuppressed persons, such as HIV-positive patients (Esser et al. 
2015). For HIV-positive women, cervical cancer is an AIDS-defining clinical condition 
and HIV-positive men who have sex with men (MSM) have been identified as a high-
risk group to develop HPV-associated anal carcinoma  (Wieland et al. 2014, Esser et 
al. 2015). Two prophylactic vaccines for HPV are internationally available based on 
virus-like particles (VLP) of L1, the major virion protein. A bivalent vaccine containing 
VLPs of HPV16 and HPV18 and a quadrivalent vaccine containing VLPs of HPV6, 11, 
16 and 18. Both vaccines have been reported to reduce infection incidence and 
cervical lesions (Schiller and Muller 2015, Malik et al. 2016). However, to further reduce 
cases of HPV-associated cancer, a third nonavalent vaccine has been approved for 
use, which comprises the high-risk HPV types 16, 18, 31, 33, 45, 52 and 58, known to 
be associated with 90% of cervical cancers worldwide and the low-risk types HPV6 
and 11 (Riethmuller et al. 2015, Van Damme et al. 2016). 
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1.7 Head and neck cancers and HPV infection 
HPV infection does not only play a role in the development of genital cancers, but is 
also an etiological cause of some SCC of the head and neck (HNSCC). They are 
described as neoplasms originating from the mucosal surface of the oral cavity, 
oropharynx, hypopharynx, larynx and nasopharynx (Cleary et al. 2016). In 1983, it was 
suggested for the first time, that HPV is a causative agent of head and neck cancer, 
which was based on similar clinical features in oral and genital injuries, similarities in 
the epithelia and the affinity of HPV for epithelial cells (Syrjanen et al. 1983). Generally, 
every year about 270,000 cases of cancer of the oral cavity and 135,000 cases of 
pharyngeal cancers are diagnosed worldwide. It was shown that in 50% of HNSCC a 
HPV infection was present, with HPV16 being the most prevalent type (90%) (Kreimer 
et al. 2005). Most of the HPV-related HNSCC are oropharyngeal squamous cell 
carcinomas (OPSCC) located at the tonsils and the base of the tongue, whereas the 
involvement of HPV in other HNSCC is still under investigation. For oral squamous cell 
carcinoma (OSCC) an influence of HPV was already hypothesised in 1983, but until 
now it is not proved and accepted (Hübbers and Akgül 2015).   
 
1.8 Genus beta papillomaviruses and skin cancer development 
1.8.1 Non-melanoma skin cancer and cutaneous HPV 
Non-melanoma skin cancer (NMSC) is the most frequent malignancy in the Caucasian 
population with an incidence of about 30% of all human cancers (Nindl et al. 2007). 
Most lesions are found on sun-exposed body sites mostly affecting light-skinned and 
sun-sensitive individuals. NMSC is comprised of basal cell carcinoma (approx. 80% of 
cases), SCC (approx. 20% of cases), actinic keratosis and Merkel cell carcinoma (Nindl 
et al. 2007, Kolk et al. 2014, Vinzon and Rösl 2015). Main risk factors for the 
development of NMSC are UV irradiation, skin type and pigmentation, ionising 
radiation, immunosuppression, chemical carcinogens and the individual age (Nindl et 
al. 2007).  
Epidemiological and experimental data have advocated a potential carcinogenic role 
of betaHPV in the development of skin SCCs. A direct interaction of betaHPV and 
cancer development is accepted in immunosuppressed organ-transplant recipients 
(OTR) and Epidermodysplasia verruciformis (EV) patients (Patel et al. 2010). In 1922, 
EV was originally characterised by Lewandowsky and Lutz, who described a group of 
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patients having a predisposition to HPV infection. Two susceptibility gene loci were 
identified in EV patients, the first is located on chromosome 17q25 and the second has 
been mapped to chromosome 2p21-p24 (Ramoz et al. 2000, Ramoz et al. 2002). 
Recessive mutations in one of the two homologous genes EVER1 and EVER2, located 
on chromosome 17q25, increase when homozygous the susceptibility to betaHPV 
infection and therefore result in an enlarged risk for cutaneous SCC (Nindl et al. 2007, 
Quint et al. 2015). EVER1/2 code for transmembrane channel-like proteins belonging 
to a group of iron transporters located in the endoplasmic reticulum of keratinocytes. 
They form complexes with zinc-transporter-1 and may thereby maintain zinc 
homeostasis. A deregulation of the cellular zinc balance as a result of mutated EVER1 
and EVER2 genes may favour HPV infection in EV patients (Lazarczyk et al. 2009). 
Recent studies identified a new genetic aetiology in EV patients by detecting RHOH 
(ras homologue family member H) and MST1 (serine/threonine kinase 4) as two 
additional autosomal recessive defects leading to T-cell defects and increased 
susceptibility to persistent HPV infections (Crequer et al. 2012a, Crequer et al. 2012b).  
EV patients develop flat warts and macular, red, brown or achromic lesions (Majewski 
et al. 1997, Howley and Pfister 2015). In 30 - 60% of cases EV-associated lesions 
proceed into SCCs, 10 to 30 years after the development of benign skin lesions. The 
most frequent HPV types in EV patients are HPV5 and 8 found in 90% of cutaneous 
SCCs (Orth et al. 1978, Howley and Pfister 2015). Therefore, an interaction between 
UV irradiation and betaHPV infection is assumed in the transformation of cutaneous 
epithelial keratinocytes (Quint et al. 2015). In 2009, IARC classified HPV5 and HPV8 
as ‘possibly carcinogenic’ in EV patients (Bouvard et al. 2009). In contrast to genus 
alphaHPV, the genome of cutaneous HPV types is not integrated into the host genome 
and persists extrachromosomally (Favre et al. 1997). However, betaHPVs seem to 
possess carcinogenic properties due to their interference with cell cycle regulatory 
pathways, as well as by their property to inhibit normal DNA repair and apoptosis 
pathways in UV-damaged cells (Quint et al. 2015).  
Due to the oncogenic properties of betaHPV types, they seem to be an important factor 
for skin cancer development also in the general population. More than 80% of healthy 
individuals are positive for betaHPV DNA in skin swabs or plucked eyebrow hairs 
(Kohler et al. 2007, de Koning et al. 2009, Weissenborn et al. 2009b). The range of 
betaHPV types, present on different body sites can representatively be found in hair 
follicles of the eyebrow, as a hair follicle is considered to be the natural reservoir for 
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cutaneous betaHPV (Howley and Pfister 2015). In SCCs developed in the general 
population, the DNA of betaHPV types was detected with less than one copy per cell. 
However, betaHPV DNA was identified in precancerous actinic keratosis with up to 50 
copies per cell, representing an influence in the early stages of skin cancer 
development (Weissenborn et al. 2005). A study analysing the intrafamilial 
transmission of betaHPV pointed out that family members carry a similar spectrum of 
betaHPV types, which can be transferred to babies already soon after birth. 
Nevertheless, a persistent infection with a specific HPV type in a parent does not 
always result in an infection of a child with the same type. Therefore, regular exposure 
to cutaneous HPV does not necessarily result in the establishment of a persistent 
infection (Weissenborn et al. 2009a). Natural history studies of betaHPV infections 
demonstrated that it should be differentiated between transiently and persistently 
detectable HPV types, where persistent infections are more likely to have pathological 
consequences (Howley and Pfister 2015).  
In OTRs the frequency of SCC development is increased 65 - 250 times. OTRs 
frequently exhibit field cancerization of the skin from which multiple HPV-associated 
NMSCs develop (Nindl and Rösl 2008, Vinzon and Rösl 2015). The viral load of 
betaHPVs was determined in OTRs and immunocompetent patients by collecting 
eyebrow hairs and it spanned 7 orders of magnitude (Howley and Pfister 2015). The 
prevalence was highest for HPV5, HPV8 and HPV20. However, only the highest 
betaHPV loads in OTRs were close to those observed in EV patients (Dell'Oste et al. 
2009). In case control studies, high betaHPV loads were associated with cutaneous 
SCCs (Neale et al. 2013).  
Taken all together, a persistent presence and infection of the skin with betaHPV could 
facilitate the accumulation of genetic changes, over a long period, promoting the 
development of skin cancer especially in sun-exposed body sites.  
 
1.8.2 Transgenic mouse models to study HPV oncogene functions 
A number of transgenic mouse models have been established to analyse E6 and E7 
properties of high-risk HPV16 and HPV18, however, only a few in vivo models have 
been reported for betaHPV types. In 2006, a transgenic mouse line expressing HPV20 
E6 and E7 under the control of the K10-promoter in hairless SKH-hr1 mice (K10-
HPV20-E6/E7) was established, but those animals did not develop spontaneous 
tumours within the observation period of 2 years. After 9 weeks of chronic UVB 
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irradiation (90 to 200 mJ/cm2) with 3 treatments per week a slight increase in the 
tendency of papilloma development was observed compared to control animals. 
However, only 2 of 20 K10-HPV20-E6/E7 mice developed skin SCCs (Michel et al. 
2006). A HPV38 transgenic mouse expressing the oncoproteins E6/E7 under the 
control of the bovine homologue of the human K10-promoter did not develop 
spontaneous papillomas during the observation period of 2 to 2.5 years. However, 
treatment according to the two-step carcinogenesis protocol with 7,12-
dimethylbenzanthracene (DMBA) and 12-O-Tetradecanoylphorbol-13-acetate (TPA) 
led to the development of several papillomas after seven to eight weeks, where 3 of 8 
animals developed SCCs (Dong et al. 2005). Also K14-HPV38-E6/E7 transgenic mice 
showed no spontaneous tumour development during their lifespan, however, they were 
highly susceptible to DMBA/TPA treatment. Single UV irradiation of K14-HPV38-E6/E7 
transgenic mice led to accumulation of p21 and cell cycle arrest. Interestingly, chronic 
UV irradiation with 3 treatments per week for 20 weeks (UVB from 120 mJ/cm2 to 450 
mJ/cm2) induced the development of actinic keratosis and SCCs in 80% of transgenic 
animals (Viarisio et al. 2011). Our group developed HPV8 transgenic mice in FVB/n 
background in which oncogene expression is controlled by the human keratin-14 
promoter, which directs expression to the stratum basale, the hair follicle and to a 
lesser amount to the stratum spinosum of the epidermis. The K14-HPV8-CER mouse 
model expressing the complete early genome region (E1, E2/E4, E6, E7) was 
generated first (Schaper et al. 2005). A few years later, the K14-HPV8-E2 and the K14-
HPV8-E6 transgenic mouse lines, were also established (Pfefferle et al. 2008, 
Marcuzzi et al. 2009). For the K14-HPV8-CER and K14-HPV8-E6 transgenic mouse 
lines, 91% of all animals spontaneously developed single or multifocal benign tumours, 
which showed papillomatosis, acanthosis, hyperkeratosis and varying degrees of 
epidermal dysplasia, whereas 6% developed SCCs. In addition, a study performed by 
Hufbauer and colleagues, in which a knock-down of HPV8-E6 mRNA in K14-HPV8-
CER mice was induced by tattooing a HPV8-E6 specific siRNA, papilloma 
development was significantly reduced (Hufbauer et al. 2010b). Therefore, we 
concluded that E6 represents the main oncoprotein in murine skin, since K14-HPV8-
E6 mice represent a phenocopy of the K14-HPV8-CER mice. Three epidermal specific 
HPV8-E2 transgenic FVB/n mouse lines were generated having different E2 mRNA 
levels. The rate of tumour development correlated with mRNA expression levels. Only 
8% of the K14-HPV8-E2 transgenic animals with medium mRNA levels have 
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developed spontaneous papilloma and only 2 HPV8-E2 transgenic animals developed 
SCCs (Pfefferle et al. 2008). To test the synergistic effect of UV light, all three 
transgenic mouse lines were treated with UVA/B light. UV irradiation stimulated 
papillomatosis in HPV8-CER, -E2 and -E6 transgenic mice within 3 weeks, whereas 
the skin of FVB/n wild type littermates healed completely from UV-induced hyperplasia. 
Therefore, an early increase of viral oncogene expression seems to be important for 
the induction of papillomatosis (Hufbauer et al. 2010b). The influence of the 
transcription factor signal transducer and activator of transcription 3 (Stat3) was 
analysed in the background of the K14-HPV8-CER mouse line, by generating 
heterozygous Stat3+/- / HPV8 and homozygous Stat3+/+ / HPV8 mice. During an 
observation period of 12 weeks, only 13% of heterozygous Stat3+/- / HPV8 transgenic 
mice developed tumours, whereas 54% of Stat3+/+ / HPV8 mice showed tumour 
development in the same time. Therefore, Stat3 has a critical role in epithelial 
carcinogenesis mediated by HPV8 (De Andrea et al. 2010).  
 
1.9 Early proteins 
1.9.1 The E1-protein 
The early protein E1, representing the only protein with enzyme activity, is encoded by 
the largest and most conserved ORF, ranging in size from 600 to 650 aa, dependent 
on the type of HPV. The E1 protein is an ATP-dependent DNA helicase, which 
assembles at the viral origin, unwinds DNA by binding to and stimulation of 
Topoisomerase I and interacts with cellular DNA replication factors (Sun et al. 1990, 
Yang et al. 1993, Clower et al. 2006). E1 interacts with cyclin E-Cdk2 kinase, a key cell 
cycle regulator of the S-phase, building a complex responsible for cell cycle regulation 
of HPV replication (Cueille et al. 1998). Generally, the E1 protein is required during the 
viral life cycle a) to increase the episomal copy number after infection of basal 
keratinocytes, b) to maintain a constant level of episomes in epithelial cells prior to 
differentiation and c) to promote viral genome amplification in the upper most epithelial 
layers (Bergvall et al. 2013).  
 
1.9.2 The E2 protein 
The E2 protein possesses transcriptional regulation function due to its interaction with 
the DNA helicase E1 via its N-terminal domain, facilitating its binding to the viral ori of 
replication (Sedman and Stenlund 1995, Akgül et al. 2003). The DNA strand is 
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unwound and the cellular DNA polymerase is able to contact the viral genome. 
Furthermore, the E2 protein is able to bind as a dimer to a 12 bp palindromic sequence 
(ACC(N)6GGT), mostly located within the NCR of the HPV genome, via its C-terminal 
DNA binding/dimerization domain, thereby regulating viral transcription (Muller et al. 
2002, Akgül et al. 2003).  
In addition to its regulatory role at viral promoters, E2 has recently been described as 
a factor able to regulate also expression of cellular proteins. By binding to its 
recognition motif, HPV8-E2 was found to suppress the β4 integrin (Oldak et al. 2004) 
and to activate the promoter of the matrix-metalloproteinase 9 (Akgül et al. 2011b). 
HPV8-E2 is able to down-regulate epidermal AKT activity by decreasing AKT1 
isoforms leading to cutaneous differentiation changes (O'Shaughnessy et al. 2007).  
HPV5-E2-specific mRNA was shown to be present in the upper layers of the epidermis 
of an EV-associated benign cutaneous lesion (Haller et al. 1995). The E1 and E2 
proteins of HPV5 were identified as viral factors necessary for viral replication in 
complementation assays. The E8^E2C protein, representing a splice variant of the E8 
and E2 ORF acts as replication repressor (Sankovski et al. 2014). E2 proteins are able 
to tether the viral genome to host mitotic chromosomes to ensure persistent and long-
term maintenance of the viral genome during cell division, which is associated with 
complex formation of E2 with the cellular protein Brd4 (You et al. 2005, McBride 2013). 
E2 proteins of different genera are able to bind to different regions of mitotic 
chromosomes (Oliveira et al. 2006). HPV8-E2 binds most prominently to the 
pericentromeric regions of chromosomes overlapping the loci for ribosomal RNA genes 
as dimeric speckles and co-localises with the ribosomal transcription factor UBF1 and 
not with Brd4 (Poddar et al. 2009).  
 
1.9.3 The E4 protein 
The ORF of the E4 protein is located within the E2 ORF and is translated from a spliced 
mRNA (E1^E4), which contains the initiation codon and the first few amino acids from 
the E1 ORF (Chow et al. 1987, Doorbar 2013). The gene products of E1^E4 can be 
detected with the start of the vegetative viral genome amplification, giving the E4 
protein an important role during the later stages of the viral life cycle. The identification 
of the E4 protein in lesions became an important role, as it can serve as a biomarker 
of active HPV infection and serves as a marker for severity in the cervix (Doorbar 
2013). For betaHPV and other cutaneous HPV types, the E4 protein assembles into 
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distinctive cytoplasmic inclusion granules, first noticeable in the lower to mid epithelial 
layers. Furthermore, E1^E4 can interact with and reorganise the cytokeratin filaments 
within a cell (Doorbar et al. 1991). Generally, E4 is expressed before the late proteins 
L1 and L2 and is involved in cell cycle progression and exit. Therefore, it generally 
functions in viral release and transmission (Doorbar 2013). In skin tissues of EV 
patients and in intraepithelial precursor lesions of OTRs, the cytoplasmic expression 
of E4 could be associated with the onset of vegetative viral genome amplification by 
using antibodies raised against E4 of genus betaHPVs (Borgogna et al. 2012, 
Borgogna et al. 2014).  
 
1.9.4 The E6 protein 
The tumorigenic potential of alphaHPV types is partly dependent on the inactivation of 
the tumour suppressor proteins p53 and the retinoblastoma tumour suppressor protein 
(pRB) by E6 and E7, respectively (Münger and Howley 2002). However, recent studies 
demonstrated that interactions with proteins of the PDZ family are also important for 
immortalisation (Mantovani and Banks 2001). High-risk E6 proteins possess a PDZ 
binding motif at their C-terminal end, mediating its binding to the PDZ proteins hDlg1, 
hDgl4, hScrib or MAGI1 and MUPP1, thereby targeting them for degradation by 
ubiquitin ligases (Howie et al. 2009). HPV5 and HPV8-E6 proteins do not encode a C-
terminal PDZ-binding motif, but decreased expression of the PDZ domain protein 
Syntenin-2 was identified in HPV8-E6 expressing keratinocytes, representing the first 
PDZ domain protein controlled by HPV8 at transcriptional level (Lazic et al. 2012).  
Degradation of p53 is only achieved for high-risk HPV types. In the case of genus 
betaHPV, the E6 protein does not interact with E6AP and p53 is not degraded (Steger 
and Pfister 1992). However, HPV38 possesses transforming activity partly mediated 
by the accumulation of ΔNp73, an antagonist of p53/p73 functions involved in growth 
suppression and apoptosis, thereby targeting the same pathway as alphaHPV types 
(Accardi et al. 2006). An alternative deregulation of the cell cycle is achieved by E6 
proteins, due to their ability to activate telomerase in epithelial cells. E6 binds E6AP, 
which is crucial for hTERT regulation by E6, thereby activating telomerase and hTERT 
(Liu et al. 2005). Bedard and colleagues demonstrated that HPV38-E6 is able to 
activate telomerase by increased hTERT mRNA levels and other proteins involved in 
HPV16 E6 mediated activation of telomerase (Bedard et al. 2008). 
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Genus betaHPV E6 proteins bind to the transcriptional co-activator mastermind-like 
protein (MAML1), which is a transcriptional regulator involved in cellular signalling 
pathways (White et al. 2012a). The interaction between E6 and MAML1 inhibits Notch 
mediated transcription, which acts as a tumour suppressor in squamous epithelial cells 
and plays a role in keratinocyte differentiation by regulating the cell cycle inhibitor p21 
(Brimer et al. 2012, Meyers et al. 2013).  
Due to the prevalence of SCC in EV patients on sun-exposed body sites, it is 
suggested that a betaHPV infection synergises with the carcinogenic effect of UV light. 
Therefore, SCC development after betaHPV infection may result from the effect of the 
E6 proteins on DNA repair and on UV-induced apoptosis (Jackson and Storey 2000). 
For several E6 proteins, including HPV5 and HPV8, a degradation of the proapoptotic 
protein Bak was reported (Jackson et al. 2000). In addition, HPV5 and HPV8-E6 
proteins bind to the acetyltransferases CBP and p300 leading to delayed ATR 
activation. This effect leads to the accumulation of p53, reduced G1 arrest and thereby 
increases double-strand breaks and a delayed repair of DNA induced by UV (Howie et 
al. 2011, White et al. 2012a). For HPV8-E6 a specific lysine in the C-terminal part of 
the protein was identified, responsible for the prevention of DNA damage repair and 
p300 binding after UV irradiation. This study demonstrated first mechanistical in vivo 
data for the critical role of HPV8-E6 in HPV-driven skin carcinogenesis due to impaired 
DNA damage repair pathways (Hufbauer et al. 2015).   
 
1.9.5 The E7 protein 
The E7 proteins are divided into three parts: a) the conserved region (CR1), which is 
necessary for cellular transformation and the degradation of pRB in high-risk HPV 
types, b) the CR2, which contains a conserved pRB family binding site and a 
consensus casein kinase II (CKII) phosphorylation site and c) the C-terminal domain. 
This domain is involved in dimerization of E7 proteins and the association with cellular 
complexes and contains a zinc-binding domain out of two C-X-X-C motifs, which are 
separated by 29 - 30 aa (Jones and Munger 1996, Zwerschke and Jansen-Durr 2000, 
McLaughlin-Drubin and Münger 2009).  
Generally, transforming activities of different E7 proteins can be associated with their 
low-risk and high-risk classification, as high-risk HPV-E7 proteins possess higher 
transforming and immortalisation properties compared to low-risk types (Barbosa et al. 
1991). Furthermore, E7 interacts with pRB, which is destabilised by high-risk E7 
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proteins via proteasomal degradation, due to its interaction with the S4 subunit of the 
26S proteasome (Dyson et al. 1989, Boyer et al. 1996). Low-risk alphaHPV and 
betaHPV-E7 proteins bind pRB with an approximately 10-fold lower efficiency 
compared to high-risk HPVs (Iftner et al. 1988, Sang and Barbosa 1992, Schmitt et al. 
1994).  
The Leu-X-Cys-X-Glu (LXCXE) motif present in the CR2 homology domain is the 
association site of the E7 protein with pRB and the related pocket proteins, p107 and 
p130 (White et al. 2012b). Under normal conditions these proteins are able to regulate 
G1/S-phase entry and progression due to the regulation of the transcriptional activities 
of E2F transcription factors. The disruption of the pRB/E2F complex is induced by 
cdk4/6 and cdk2 mediated phosphorylation of pRB, thereby the released E2F is able 
to activate the necessary gene transcription for S-phase entry and progression. During 
HPV infection, high-risk E7 proteins associate with E2F-bound pRB in G1, causing 
disruption of the repressive pRB/E2F complex ending up in uncontrolled G1 exit and 
S-phase entry (Dyson et al. 1992). HPV8-E7 binds only weakly to pRB, however, it is 
able to deregulate G1/S transition control (Akgül et al. 2007). Additional binding 
partners of alpha and betaHPVs are UBR4 (p600) and its binding partner KCMF1 
suspected to function as E3 ubiquitin ligase (White et al. 2012b). Quantitative 2D 
differential gene expression (DiGE) gel approach combined with mass spectrometry 
led to the identification that actin binding/regulating proteins are modulated by HPV8-
E7 expression (Akgül et al. 2009). In addition, cDNA microarray analysis identified 
lipocalin-2 to be overexpressed in HPV8-E7 positive keratinocytes, which also 
correlated with HPV-positivity in cutaneous SCCs (Akgül et al. 2011a). 
HPV8-E7 is predominantly located in the nucleus, but was also found at lower levels 
in the cytoplasm (Sperling et al. 2012). This fact was verified by Onder and colleagues, 
who showed that HPV8-E7 is able to shuttle between the nucleus and the cytoplasm, 
with its predominant location in the nucleus. Within the zinc-binding domain, the HPV8-
E7 protein contains a nuclear localisation signal (NLS) for import and localisation in the 
nucleus, as well as a nuclear export signal (NES), responsible for its transport (Onder 
and Moroianu 2014, Onder et al. 2015). The expression of HPV8-E7 in primary 
keratinocytes causes polyploidy, which is associated with decreased levels of pRB and 
p21 (Akgül et al. 2007). Three-dimensional organotypic skin cultures (OSC) have been 
used to study the effects of HPV-E7 on keratinocyte growth and differentiation. The 
first study on keratinocyte transforming activities of betaHPV oncoproteins in OSC was 
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based on a collagen type I matrix. On top of these cultures primary human 
keratinocytes (PHK) expressing the E6/E7 genes of betaHPV types (HPV5, 12, 15, 17, 
20 and 38) and of HPV16 were seeded and differentiated. Under these conditions cell 
differentiation was disturbed to different degrees. Cultures expressing either 
oncoproteins of HPV5, 12 or 38 were less organised compared to control cultures, 
showing no cornified layer and only thin granular layers. In suprabasal layers 
degenerated changes were characterised by vacuolisation of the cytoplasm (Boxman 
et al. 2001). Using the OSC model, based on de-epidermalised human dermis, the 
keratinocytes of the regenerated epithelium expressing HPV8-E7 displayed 
hyperproliferation and were positive for both cyclin E and p16INK4a indicating that E7 
is able to overcome p16INK4a induced cell cycle arrest (Westphal et al. 2009). In 
addition, and most strikingly, keratinocytes lost their normal polarity and migrated 
downwards. Invasion was proved by the identification of a disrupted basement 
membrane in areas of invading keratinocytes due to immunohistochemical staining 
against basement membrane (BM) components, such as collagen VII, IV and     
laminin-5. This coincided with the overexpression of matrix metalloproteinase-1 (MMP-
1), MMP-8 and membrane type1-MMP (MT1-MMP) (Akgül et al. 2005, Smola-Hess et 
al. 2005). In addition, the E7 proteins of HPV5, HPV8 and HPV20 have been reported 
to possess an increased clonogenicity and were highly positive in tumour sphere 
assays, which coincided with increased stem cell-like keratinocytes possessing a 
higher expression of CD44 and EpCAM on their cell surface (Hufbauer et al. 2013).  
 
1.10 Human skin - organisation and structural components 
1.10.1 The organisation of the epidermis 
The skin represents an effective barrier preventing organisms from chemical and 
physical damage, including UV irradiation, from invading pathogens and unregulated 
loss of water and solutes (Proksch et al. 2008). The skin is a complex structure 
composed of three main layers, the stratified, cellular epidermis, the underlying dermis 
composed of connective tissue and the subcutaneous layer (subcutis), whereas 
epidermis and dermis represent the main structure of human skin. The epidermis 
consists of stratified squamous keratinizing epithelium, containing proliferating basal 
and differentiated suprabasal keratinocytes. Up to 95% of the epidermis are made up 
of keratinocytes, whereas Merkel cells, melanocytes and Langerhans cells are also 
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present (Kanitakis 2002). The epidermis is relatively thin (0.1 - 0.2 mm in depth) and 
is attached to the underlying dermis by the BM (Watt and Fujiwara 2011). 
The epidermis can be divided from top to bottom into stratum corneum, stratum 
granulosum, stratum spinosum and stratum basale. The stratum basale is made up of 
basal keratinocytes, which divide continually and migrate superficially forming the 
stratum spinosum. During the process of differentiation, the cells are getting highly 
organised, form cellular junctions between each other and secrete keratin proteins, 
contributing the development of an extracellular matrix (ECM). During this process, the 
cells finally reach the stratum corneum and can be shed from the surface, called 
keratinisation (Simpson et al. 2011). 
 
 
Figure 5. Schematic representation of the human skin (taken from (Simpson et al. 2011)). On the 
left the four main layers of the epidermis are visualised via haematoxylin and eosin (HE) staining of 
human skin, which are from top to bottom: stratum corneum, stratum granulosum, stratum spinosum 
and stratum basale. The stratum basale is the basal and proliferating cell layer of the epidermis, which 
stays in contact with the dermis through hemidesmosomes and integrin-based adhesions. Both 
interactions provide contact to the underlying extracellular matrix (ECM). During keratinocyte 
differentiation, each layer forms a specific architecture comprising the arrangement of the cytoskeleton 
as well as of cell junctions, including adherens junctions, tight junctions, desmosomes and gap junctions.  
 
Stratum corneum 
Stratum granulosum 
Stratum spinosum 
Stratum basale 
Basement membrane 
Dermis 
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To allow tissue integrity, two types of cell adhesions are achieved, either cell-cell 
adhesion, a connection of the intracellular cytoskeleton between cells, or the cell-
matrix adhesion, which is a connection of the cellular cytoskeleton with components of 
the ECM. Both connections are formed due to different types of cell adhesion 
molecules, including integrins and cadherins. Adherens and tight junctions are 
essential for the formation of adhesive contacts between two neighbouring cells. They 
are composed of transmembrane glycoproteins of the cadherin family, such as E-
cadherin, which interact with members of the catenin family including β-catenin. 
Generally, adherens junctions initiate and stabilize cell-cell adhesion, regulate the actin 
cytoskeleton, intracellular signalling and transcription (Hartsock and Nelson 2008). 
Tight junctions are composed of two types of transmembrane proteins, occludins and 
claudins, which associate with cytoplasmic proteins, including zona occuldens-1 (ZO-
1), belonging to the membrane-associated guanylate kinase homologs (MAGUK) 
family, which links tight junctions to the actin cytoskeleton and to adherens junctions 
(Simpson et al. 2011). 
 
1.10.2 Extracellular matrix 
The ECM of the dermis regulates and maintains tissue homeostasis and stabilizes the 
structural integrity of the skin. The ECM forms a complex network of macromolecules 
with specific biochemical and biomechanical properties regulating different cellular 
processes (Pickup et al. 2014). It is predominantly composed of fibrillar collagens, the 
BM and elastin fibres, which can be remodelled due to the degradation of structural 
proteins. Degradation is regulated by proteins of the family of MMPs, which are also 
essential to epidermal differentiation. An upregulation of MMPs is known to facilitate 
cancer development (Philips et al. 2011). The deposition of a specialised layer of ECM 
between the epidermis and the underlying dermis forms the BM. This amorphous, 
dense, sheet-like structure is composed of about 50 proteins, mainly collagen IV, 
laminin, HSPG, nidogen/entactin and minor constituents including Fibulins, which are 
able to interact with each other (Breitkreutz et al. 2013). However, collagen IV 
comprises about 50% of the BM and resembles a kind of scaffolding network (Kalluri 
2003). The maintenance of the normal structure of the BM is an important factor, 
whereby BM disruption is associated with different stages of invasive carcinoma 
(Barsky et al. 1983, Watt and Fujiwara 2011).  
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1.11 Mechanisms of keratinocyte invasion 
The process of cancer progression involves the ability of cancer cells to leave the 
primary tumour, moving through the ECM and invade the surrounding tissue to settle 
and grow at another body site. This process contains a complex series of cell-biological 
events and is called the ‘invasion-metastasis cascade’ (Guan 2015, Aneta et al. 2016). 
During tumour cell migration into the surrounding tissue several mechanisms of normal 
cell migration are activated to change the cellular shape, to create conditions allowing 
movement and to reorganise the surrounding tissues. Two patterns of invasive growth 
can be distinguished, collective (group) cell migration and single cell migration, which 
is dependent on the tissue microenvironment and on molecular changes of the cells 
(Krakhmal et al. 2015). In addition, tumour cell invasion is associated with changes in 
cell metabolism, characterised by switching from oxidative metabolism to aerobic 
glycolysis (Krakhmal et al. 2015, Liberti and Locasale 2016).  
 
 
Figure 6. Schematic representation of epithelial-mesenchymal transition (Kalluri and Weinberg 
2009). EMT describes a process in which polarised epithelial cells are converted into motile 
mesenchymal cells. The involved cells pass through several changes, which can be detected by 
epithelial and mesenchymal cell markers. A key molecular event of EMT is the downregulation of E-
cadherin which coincides with an upregulation of N-cadherin, describes as a ‘cadherin switch’. 
 
To shed off from the primary tumour, cells detach from the ECM resisting to anoikis 
and thereby activating a complex cell-biological program, described as epithelial-
mesenchymal transition (EMT) (Guan 2015). EMT describes the transformation of 
highly differentiated, polarised and organised epithelial cells into undifferentiated, 
mesenchymal-like cells possessing migratory and invasive properties (figure 6) 
(Profumo and Gandellini 2013). However, cells may show some epithelial and some 
mesenchymal characteristics, which is described as partial EMT (Lamouille et al. 
2014). Cadherin-mediated cell-cell adhesion is a highly dynamic process, which 
enables the reorganisation and movement of cells. A loss of cell-cell adhesions is 
associated with epithelial derived tumours, therefore EMT is associated with a down-
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regulation of E-cadherin. Furthermore, this downregulation coincides with an 
upregulation of N-cadherin, promoting cell motility and invasion. This phenomenon is 
representative for EMT and is also known as ‘cadherin switch’ (Lamouille et al. 2014). 
A decrease of E-cadherin causes an incorrect localisation of the adherens junction 
core proteins, α- and β-catenin, and the tight junction protein ZO-1 (Hartsock and 
Nelson 2008).  
Cell adhesion to the ECM is achieved by the interaction with integrins. Integrins are a 
family of transmembrane glycoprotein receptors consisting of α and β subunits. At least 
19 α and 8 β subunits build 24 different non-covalently bound integrin heterodimers. 
They are composed of a large extracellular binding domain, a single-membrane-
spanning transmembrane domain and a short intracellular cytoplasmic tail, forming 
links to cytoskeletal elements (Watt and Fujiwara 2011). Integrins are able to bind to 
ECM proteins including collagens, fibronectin and laminin and they play an important 
role in actin cytoskeleton assembly, as well as in cell adhesion and migration. Cell 
adhesion to the ECM is achieved by binding of the integrin extracellular domain to the 
ECM molecule, leading to the interaction of the intracellular domain with the 
cytoskeleton through intracellular structures called focal adhesions (Janes and Watt 
2006). The most prevalent integrins in the epidermis are integrin α2β1, a collagen 
receptor, integrin α3β1, predominantly a laminin-5 receptor and integrin α6β4, a 
laminin receptor. In addition, integrin αvβ5, a vitronectin receptor, is expressed at lower 
levels, whereas integrin α5β1 (fibronectin receptor) and αvβ6 (fibronectin and tenascin 
receptor) are induced in cell culture and wound healing (Watt 2002). Different studies 
showed that deregulation of integrin subunits are important during cancer development 
and metastasis processes (Pawelek and Chakraborty 2008). Integrins are also able to 
activate the synthesis of cyclins, inositol lipids, focal adhesion kinase (FAK) and MAPK, 
as well as MMPs (Brooks et al. 1996, Schlaepfer et al. 1998). 
A complete EMT implies several distinct molecular processes, including the activation 
of transcription factors, the expression of specific cell-surface proteins, the 
reorganisation and expression of cytoskeletal proteins and the production of ECM-
degrading enzymes, which ends with the degradation of the underlying ECM and the 
migration/invasion of keratinocytes (Kalluri and Weinberg 2009).  
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1.12 Aim of the study 
As described above, my group could show that HPV8-E7 induces keratinocyte invasion 
in in vitro OSC, which were composed of de-epidermalised human dermis as matrix 
(Akgül et al. 2005). No invasive phenotype was observed for different betaHPV 
oncoproteins in OSCs composed of a 100% collagen type I matrix (Boxman et al. 
2001). Both systems differed in the composition of the ECM and the presence of the 
epithelial basement membrane, which is only present on the de-epidermalised dermis 
at start of the experiment. Interestingly, OSCs based on a mixture of 50% collagen 
type I and 50% Matrigel (a gelatinous mixture of ECM proteins) triggered strong 
invasion of HPV8-E7 positive keratinocytes (figure 7, Akgül, personal communication). 
We therefore hypothesised that components of the ECM are critical for the induction 
of the invasive behaviour of HPV8-E7 positive keratinocytes. To answer this 
hypothesis, we first generated the K14-HPV8-E7 transgenic mouse model to proof the 
oncogenic potential of HPV8-E7 also in vivo in the murine skin. In addition, we 
analysed the effect of different ECM proteins and downstream pathways on the 
invasive capacity of HPV8-E7-positive cells. This work therefore provides further 
experimental evidence of an association between betaHPV infection and the 
development of cutaneous SCC. 
 
Figure 7. Invading HPV8-E7-positive cells in 50% collagen I and 50% Matrigel OSCs. 
Representative HE staining of OSCs established with keratinocytes expressing HPV8-E7 or empty 
vector pLXSN. The epithelium regenerated onto a matrix composed of 50% collagen I and 50% Matrigel 
showed increased invasive capacity of HPV8-E7 cells. In addition, invasion of empty vector cells was 
also triggered due to matrix composition (provided by Dr B. Akgül, magnification 200x). 
Material 
24 
 
2. Material 
 
2.1 Equipment 
Agfa CP1000     Agfa, Mortsel, Belgium 
Bioruptor ® PLUS      Diagenode, Liege, Belgium  
Bioruptor® Water cooler     Diagenode, Liege, Belgium  
Eppendorf Centrifuge 5417    Eppendorf, Hamburg, Germany 
Eppendorf Thermostat 5320    Eppendorf, Hamburg; Germany 
GelDoc Universal Hood  BioRad Life Science Research, 
Hercules, USA 
Glomax ® Luminometer Promega, Madison, USA 
Heraeus Megafuge 1.0R   Heraeus Instruments, Hanau, 
Germany 
Heraeus Multifuge L-R   Heraeus Instruments, Hanau, 
Germany 
Hettich Universal 320     Hettich, Tuttlingen, Germany 
Labovert FS       Leica, Wetzlar, Germany 
Lightcycler ®   Roche Applied Sciences, Mannheim, 
Germany 
NanoDrop®ND-1000 UV/VIS   PEQLAB, Erlangen, Germany 
spectralphotometer  
PowerPac 300  BioRad Life Science Research, 
Hercules, USA 
Protean II xi  BioRad Life Science Research, 
Hercules, USA 
Stericult 200 Incubator     Labotect, Göttingen, Germany  
T3 Thermocycler      Biometra, Göttingen, Germany 
Ultrapure water Milli-QPlusPF    Millipore, Eschborn, Germany 
Vortex VF2      Janke&Kunkel, Staufen, Germany 
      
2.2 Chemicals and Reagents 
All chemicals used in this study were purchased from Applichem (Darmstadt, 
Germany), Invitrogen (Karlsruhe, Germany), Merck (Darmstadt, Germany), Roth 
(Karlsruhe, Germany) and Sigma-Aldrich (Steinheim, Germany) and complied the 
reagent grade ‘p.a.’.  
 
Agarose      Sigma-Aldrich, Steinheim, Germany 
Ampicillin       Sigma-Aldrich, Steinheim, Germany  
β-Mercaptoethanol      AppliChem, Darmstadt, Germany 
Bradford-Solution     BioRad, München, Germany 
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Chloroform      Sigma-Aldrich, Steinheim, Germany 
Coomassie Blue     AppliChem, Darmstadt, Germany 
DMSO (Dimethylsulfoxide)    AppliChem, Darmstadt, Germany 
Ethanol      Roth, Karlsruhe, Germany 
Ethidium bromide     AppliChem, Darmstadt, Germany 
Fetal Calf Serum (FCS)     Invitrogen, Karlsruhe, Germany 
Formaldehyde      Merck AG, Darmstadt, Germany 
Glucose      AppliChem, Darmstadt, Germany 
Glycogen       AppliChem, Darmstadt , Germany 
Glycerol      AppliChem, Darmstadt, Germany 
Isopropanol      Roth, Karlsruhe, Germany 
LB-Agar       AppliChem, Darmstadt, Germany 
LB-Broth       Invitrogen, Karlsruhe, Germany 
NP-40       Sigma-Aldrich, Steinheim, Germany 
Phenol-Chloroform     Sigma-Aldrich, Steinheim, Germany 
Ponceau-Red      AppliChem, Darmstadt, Germany 
RNAlater      Qiagen, Hilden, Germany 
RNase free water     Qiagen, Hilden, Germany 
TEMED (N,N,N`,N`Tetramethylendiamin)  AppliChem, Darmstadt, Germany 
Tween 20      Serva, Heidelberg, Germany 
 
Plastic ware was purchased from Eppendorf (Hamburg, Germany), Falcon BD 
(Heidelberg, Germany), Sarstedt (Nümbrecht, Germany) and TPP (Trasadingen, 
Switzerland). BD BioCoat Laminin, Fibronektin, Collagen IV (Ø 10 cm) were ordered 
from BD Biosciences (Heidelberg, Germany).   
 
2.3 Kits 
BM Chemiluminescence Western Blotting Kit  Roche Diagnostics, Mannheim,  
       Germany 
DCTM Protein Assay Kit II   BioRad Life Science Research, 
Hercules, USA 
Dual-Luciferase ® Reporter Assay System  Promega, Madison, USA 
DyeEx 2.0 Spin Kit     Qiagen, Hilden, Germany 
GeneJET™ PCR Cloning Kit   Fermentas, St. Leon-Rot 
QIAquick Gel Extraction Kit   Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit   Qiagen, Hilden, Germany 
QIAamp DNA Mini and Maxi Kit   Qiagen, Hilden, Germany 
QIAprep Spin/QIAprep 8 Miniprep Kit   Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit    Qiagen, Hilden, Germany 
Quick Change® II XL Site-Directed   Agilent Technologies, Boeblingen,  
Mutagenesis Kit      Germany 
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Seahorse XF MitoStress Kit   Seahorse Biosciences, Copenhagen, 
       Denmark 
Sequencemix Big Dye ® Terminator  Applied Biosystems, Foster City, USA 
PierceTM BCA Protein Assay Kit   ThermoFisher, Waltham, USA 
 
2.4 Bacterial strain 
Epicurian coli ® XL1-Blue 
genotype: recA1, end A1, gyr96, thi-1, hsdR17, supE44, relA1, lac[F’proAB 
lacqZ_AM15 Tn10(Tet‘)] (Stratagene, La Jolla, USA) 
 
2.5 Eukaryotic cells 
C33a (ATCC: HTB-31) 
HPV-negative cell line derived from a cervical cancer (Auersperg 1969).  
 
N/TERT 
The immortalised cell line N/TERT was established from primary human 
foreskin keratinocytes due to overexpression of the telomerase gene (Dickson 
et al. 2000). 
 
Primary human keratinocytes (PHK) 
PHK were isolated from human foreskin tissue provided by Dr Ali Tok, Department 
of Dermatology, University Hospital Cologne. 
 
PT67 
A fibroblast cell line derived from NIH3T3 cells used for the production of 
infectious, non-replicative retroviruses. PT67 cells contain the gag-, pol- and 
env-genes of the Moloney-Murine-Leucemia-virus as stable integrated parts of 
their genome. The env-gene derived from type10A1 and encodes two surface 
proteins, which are able to bind the amphotropic cellular receptors RAM1 and 
GALV (Miller and Chen 1996). A transfection of those cells with an expression 
vector containing the retroviral packaging signal + together with the coding 
gene of interest and a selection marker, infectious, non-replicative viruses can 
be produced (Retro-XTM System, Clontech Palo Alto). 
 
RTS3b 
HPV-negative keratinocyte cell line, established out of a skin carcinoma of a 
kidney transplant recipient (Purdie et al. 1993). 
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2.6 Nucleic Acids 
2.6.1 Synthetic oligonucleotides 
The HPLC-purified oligonucleotides were ordered from Sigma-Aldrich (Steinheim). 
 
Oligonucleotides for quantitative real-time PCR 
Name Sequence 5’ → 3’ 
βCatenin 
(human) 
f: GCTTTCAGTTGAAGCTGACCA 
r: CAAGTCCAAGATCAGCAGTCTC 
E-cadherin 
(human) 
f: GAACGCATTGCCACATACAC 
r: AGCACCTTCCATGACAGACC 
Fibronectin 
(human) 
f: GAACTATGATGCCGACCAGAA 
r: GGTTGTGCAGATTTCCTCGT 
GAPDH 
(human) 
f: CTGACTTCAACAGCGACACC 
r: TGCTGTAGCCAAATTCGTTGT 
HPRT1 
(human) 
f: TGACACTGGCAAAACAATGCA 
r: GGTCCTTTTCACCAGCAAGCT 
HPRT1 
(murine) 
f: CCTAAGATGAGCGCAAGTTGAA 
r: CCACAGGACTAGAACACCTGCTAA 
HPV8-E7 
f: CCTGAAGTGTTACCAGTTGACCTGC 
r: CAGTTGCGTTGACAAAAAGACG 
Integrin α2 
(human) 
f: AACTCTTTGGATTTGCGTGTG 
r: TGGCAGTCTCAGAATAGGCTTC 
Integrin α3 
(human) 
f: ACTGTGAAGGCACGAGTGTG 
r: TGCTGGTTCGGAGGAATAG 
Integrin α5 
(human) 
f: CAACATCTGTGTGCCTGACC 
r: CCAGGTACACATGGTTCTGC 
Integrin α6 
(human) 
f: GCTGGTTATAATCCTTCAATATCAATTGT 
r: TTGGGCTCAGAACCTTGGTTT 
Integrin αv 
(human) 
f: GTTACTGAGAATGGGTCAAG 
r: CCAGGCCTTGAGGAACTGTG 
Integrin β1 
(human) 
f: CAAAGGAACAGCAGAGAAGC 
r: ATTGAGTAAGACAGGTCCATAAGG 
Integrin β4 
(human) 
f: CTGTGTGCACGAGGGACATT 
r: AAGGCTGACTCGGTGGAGAA 
Integrin β5 f: GTGAAAGATGACCAGGAG 
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(human) r: GTTGAAGGTGAAGTCCAC 
Integrin β6 
(human) 
f: CATTGAGTGCCACCTGTCAG 
r: GACACCAGTAGCTTCCAGATG 
N-Cadherin 
(human) 
f: AGTATCCGGTCCGATCTGC 
r: CTGTGGGGTCATTGTCAGC 
PIP5K1γ 
(human) 
f: AAGGAGGCCGAGTTCCTG 
r: CGGGTTCTGGTTGAGGTTC 
Snail 
(human) 
r: CTGTGGGGTCATTGTCAGC 
r: CATCTGAGTGGGTCTGGAGG 
Slug 
(human) 
f: TGGTTGCTTCAAGGACACAT 
r: GCAAATGCTCTGTTGCAGTG 
Twist 
(human) 
f: GTCCGCAGTCTTACGAGGAG 
r: CCAGCTTGAGGGTCTGAATC 
Vinculin 
(human) 
f: GATGAAGCTCGCAAATGGTC 
r: TCTGCCTCAGCTACAACACCT 
ZO-1 
(human) 
f: GAAGGAGTTGAGCAGGAAATCTA 
r: AGGACTCAGCAGTGTTTCACC 
 
Oligonucleotides for DNA sequencing 
Name Sequence 5’ → 3’ Position 
pJETseq GGAGCAGGTTCCATTCATTG 387-406 in pJET1/blunt 
 
Oligonucleotides for reverse transcription 
Name Sequence 5’ → 3’ 
Oligo-dT23-Primer (T)23V 
Random Nonamers (N)9 
 
Oligonucleotides for site-directed mutagenesis 
Name Sequence 5’ → 3’ 
HPV8-E7-L23A f: GAGATACAACCTGAAGTGGCACCAGTTGACCTGCTTTG 
HPV8-E7-L23A r: CAAAGCAGGTCAACTGGTGCCACTTCAGGTTGTATCTC 
pFN(0.2 kb)LUC-Sp1mut f: GGGGTGGTTCGGTTCGGGGACAGCCC 
pFN(0.2 kb)LUC-Sp1mut r: GGGCTGTCCCCGAACCGAACCACCCC 
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siRNAs for knock-down experiments 
The HPLC purified siRNA duplex were ordered from Qiagen (Hilden) with the following 
sense and antisense sequences. 
Name  Sequence 5’ to 3’ 
β-catenin sense CGGGAUGUUCACAACCGAATT 
β-catenin antisense UUCGGUUGUGAACAUCCCGAG 
ZO-1 sense AGUAUCUGAUAAUGAAGAATT 
ZO-1 antisense UUCUUCAUUAUCAGAUACUGG 
Integrin a3 sense CCAUCAACAUGGAGAACAATT 
Integrin a3 antisense UUGUUCUCCAUGUUGAUGGTG 
 
2.6.2 Cloning vectors 
pJET1.2/Blunt  
PCR products were ligated into pJET/Blunt vector (GeneJET™ PCR Cloning Kit, 
Fermentas, St. Leon-Rot) to prepare serial dilutions of PCR standards to generate a 
standard curve for qRT-PCR experiments. All introduced gene fragments are listed in 
section 2.7.1. 
 
2.6.3 Eukaryotic expression vectors 
pCMV2-FLAG 
This cloning vector (4.7 kb) contains a multiple cloning site, the CMV promoter and the 
SV40 origin of replication. In addition, this vector expressed a FLAG-tag N-terminal of 
the protein of interest.  
 
pLXSN  
The pLXSN vector is a retroviral expression vector (5.9 kb) which can be transfected 
into a packaging cell line. These cells secrete recombinant retroviruses into the 
supernatant, which can be used to transduce cells. The gene of interest is expressed 
under the control of the 5’-LTR promoter. Contains neomycin resistance gene 
(Clontech, Heidelberg). 
 
2.6.4 Reporter constructs 
pFN(1.2 kb) LUC 
This fibronectin promoter construct contains approximately 1.2 kb of the 5’ flanking 
region of the human fibronectin gene, originating from the human fibrosarcoma cell line 
HT-1080. This construct contains 69 bp of exon 1, a CAAT site located at -150 bp and 
the sequence ATATAA at -25 bp from the transcription start site. The fibronectin 
promoter was cloned into the SmaI site of the pGL3 basic luciferase reporter vector. 
This fibronectin promoter, as well as the deletional mutants, were kindly provided by 
the group of Jesse Roman (Michaelson et al. 2002).    
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pFN(0.5 kb) LUC 
The full length pFN(1.2 kb) LUC was digested with PvuII and HindIII. The resulting 
fibronectin promoter fragment extended to -510 bp and was religated into the pGL3 
basic luciferase reporter construct.  
 
pFN(0.2 kb)LUC 
To create the pFN(0.2 kb) LUC construct, the pFN(0.5 kb) LUC was digested with SacI 
and AatII, blunt ended and religated into the pGL3 basic luciferase reporter construct. 
 
pFN(0.2 kb)LUC-Sp1mut 
To create the pFN(0.2 kb)LUC-Sp1mut, the pFN(0.2kb)LUC construct was mutated at 
the Sp1 binding site by site-directed mutagenesis (present work). 
 
TOP-flash, FOP-flash 
This reporter construct contains two sets (with the second set in the reverse 
orientation) of three copies of the TCF binding site followed by the minimal HSV-tk 
promoter and luciferase reporter coding sequence, whereby FOP-flash contains 
mutated TCF binding sites (provided by Dr David Prowse, University of Hertfordshire, 
Hatfield, Hertfordshire, UK). 
 
pGL4.74[hRluc/TK] 
The pGL4.74[hRluc/TK] (4.2 kb) reporter construct encodes the luciferase reporter 
gene hRluc (Renilla reniformis) under the control of an HSV-TK promoter (Promega). 
 
2.6.5 Recombinant plasmids 
K14-HPV8-E7 
The K14-HPV8-E7 vector is based on the pGEM-3Z backbone, containing the K14 
promoter (2007bp, nucleotide 281-2288), the second intron of the rabbit β-globin gene 
(639bp, nucleotides 557 - 1196), the T7 primer, the K14-polyA signal (485 bp, 
nucleotides 4746 - 5231) and the SP6-primer. The HPV8-E7 gene (312 bp) was 
inserted between the T7 promoter and the polyA signal (kindly provided by Dr G. P. 
Marcuzzi, University of Cologne). 
 
pLXSN-8E7 
A retroviral expression vector based on pLXSN containing the ORF of HPV8-E7 
(nucleotides 623 - 986) of the pVE34 vector (Steger et al. 1990), which was cloned into 
the EcoRI and BamHI restriction sites of the pLXSN vector. 
 
pLXSN-8E7-L23A 
The retroviral vector pLXSN-8E7 was used for site-directed mutagenesis to introduce 
an amino acid exchange at position L23 to A (present work). 
 
pCMV-8E7-FLAG 
The early gene of HPV8-E7 was amplified via PCR and introduced into the pCMV2-
FLAG vector via the BamHI restriction site (present work).   
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pCMV-8E7-L23A-FLAG 
This vector is based on the pCMV-8E7-FLAG vector and an amino acid exchange was 
introduced via site-directed mutagenesis at position L23 to A (present work). 
 
pVE34 
The complete HPV8 sequence (nucleotides 1 - 5111) was cloned into pUC9 vector via 
BamHI (Steger et al. (1990). 
 
pVE34-L23A 
A site-directed mutagenesis was performed to introduce an amino acid exchange in 
the HPV8-E7 sequence at position L23 to A in the background of the pVE34 vector 
(present work). 
 
2.6.6 DNA markers and loading dyes 
6x DNA Loading Dye    Fermentas, St. Leon-Rot, Germany 
GeneRulerTM 1kb ladder    Fermentas, St. Leon-Rot, Germany 
 
2.6.7 Miscellaneous nucleic acids 
Adenosine 5’-triphosphate    Fermentas, St. Leon-Rot, Germany 
Deoxyribonucleotide triphosphates (dNTPs) Fermentas, St. Leon-Rot, Germany 
 
2.7 Transfection Reagents 
FuGene      Promega, Madison, USA 
Lipofectamine RNAiMAX    Invitrogen, Karlsruhe, Germany 
Transfast      Promega, Madison, USA 
 
2.8 RNA preparation 
Omniscript RT Kit     Qiagen, Hilden, Germany 
QIAshredder      Qiagen, Hilden, Germany 
RiboLockTM RNase Inhibitor   Fermentas, St. Leon-Roth, Germany 
RNase-free DNase Set    Qiagen, Hilden, Germany 
 
2.9 Proteins 
2.9.1 Enzymes 
Restriction enzymes were purchased from New England BioLabs (Frankfurt am Main, 
Germany) and Fermentas (St. Leon-Rot). 
Platinum® Taq DNA Polymerase   Invitrogen, Karlsruhe, Germany 
Proteinase K      Qiagen, Hilden, Germany 
T4-DNA Ligase     Fermentas 
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2.9.2 Antibodies 
Antibody Company Order Number Application 
α-ATP5B 
(rabbit) 
Sigma-Aldrich HPA001520 
WB: 1:1000 
IHC: 1:100 
α-β-Catenin 
(mouse) 
BD Biosciences 610153 
WB: 1:1500 
IHC: 1:200 
α-CD44 
(mouse) 
BD Biosciences 555479 FACS: 1:100 
α-Collagen IV 
(rabbit) 
kindly provided by Dr Gerhard Sengle, 
Department for Biochemistry, University of 
Cologne. 
IHC: 1:200 
α-E-cadherin 
(mouse) 
BD Biosciences 610181 IHC: 1:200 
α-EpCAM-PE 
(mouse) 
Miltenyi Biotec 130-091-253 FACS: 1:100 
α-Fibulin-2 
(rabbit) 
Santa Cruz sc-30176 IHC: 1:400 
α-Fibulin-2 
(rabbit) 
kindly provided by Dr Gerhard Sengle, 
Department for Biochemistry, University of 
Cologne. 
WB: 1:2000 
α-Fibronectin 
(rabbit) 
Sigma-Aldrich F3648; WB: 1:10,000 
α-Fibronectin EDA 
(mouse) 
Sigma-Aldrich FN-3E2 WB: 1:2000 
α-FLAG 
(mouse) 
Sigma-Aldrich F4042 
WB: 1:2000 
ICC: 1:1000 
α-GAPDH 
(mouse) 
Abcam ab9484 WB: 1:750 
α-Integrin α2-FITC 
(mouse) 
Abcam ab87027 FACS: 1:100 
α-Integrin α3 
(rabbit) 
Millipore Ab1920 
WB: 1:2000 
IHC: 1:400 
α-Integrin α3-FITC 
(mouse) 
Miltenyi Biotec 130-081-201 FACS: 1:100 
α-Integrin α5-PE 
(mouse) 
Miltenyi Biotec 130-097-225 FACS: 1:100 
α-Integrin α6-PE 
(mouse) 
Miltenyi Biotec 130-097-246 FACS: 1:100 
α-Pancytokeratin 
(rabbit) 
Santa Cruz sc-15367 IHC: 1:100 
α-PIP2 
(mouse) 
Santa Cruz sc-53412 IHC: 1:250 
α-PTRF 
(rabbit) 
Abcam ab48824 
WB: 1:2000 
ICC: 1:250 
α-pRB 
(rabbit) 
SantaCruz sc-50 WB: 1:1000 
α-Tubulin 
(rat) 
Abcam ab6160 WB: 1:10,000 
α-ZO-1 
(rabbit) 
Zymed Laboratories/ 
ThermoFisher 
61-7300 
WB: 1:2000 
IHC: 1:400 
WB: Western blot, IHC: Immunohistochemistry, ICC: Immunocytochemistry, FACS: Fluorescence-activated cell sorting 
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2.10 Staining reagents 
AEC       DCS, Hamburg, Germany 
DAPI       Merck, Darmstadt, Germany 
MitoTracker ® Green FM    ThermoFisher, Waltham, USA 
Hematoxylin solution    Sigma-Aldrich, Steinheim  
Kaiser’s glycerol gelatine    Merck, Darmstadt, Germany 
Liquid DAB Concentrated Substrate Pack Vector Laboratories, Burlingame, USA 
VECTASTAIN Elite ABC Kit (Universal)  Vector Laboratories, Burlingame, USA 
VECTASTAIN Elite ABC Kit (Goat IgG)  Vector Laboratories, Burlingame, USA 
 
2.11 Buffers and solutions 
For the preparation of the listed buffers and solutions, ddH2O was used. In the case of 
a special pH it was adjusted with concentrated HCl, if not stated differently. If a solution 
was autoclaved this was done at 120°C and 2 bar for 21 min. 
10x Citrate buffer 100 mM Citrate, pH 5.8 
Coomassie Staining Solution 50% Methanol, 10% acetic acid, 0.05% Coomassie 
brilliant blue 
De-Staining Solution 5% Methanol, 7 % acetic acid 
Ethidiumbromide Bath  0.5 µg ml-1 ethidiumbromide 
2x HBS 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4 x 12 
H2O, 50 mM HEPES, pH 7.05 (adjusted with NaOH), 
sterile filtered 
LSDB (low-salt-dilution-buffer) 20% glycerine, 50 mM Tris HCl pH 7.9, 0.1 % NP40, 
100 mM, 200 mM, 500 mM or 1M KCl 
Prior use protease inhibitors were added to LSDB 
Lysis buffer I    0.2 M NaOH, 1% SDS 
Lysis buffer II   100 mM NaCl, 10 mM EDTA, 0.2% SDS,  
     200 µg ml-1 Proteinase K 
5% dry-milk/TBST    5% (w/v) dry milk, in TBST 
Neutralisation buffer 3 M KAc, pH 4.8 
1x PBS 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 
mM KH2PO4 
Resuspension buffer  50 mM Glucose, 25 mM Tris, 10 mM EDTA, pH 6.8 
RIPA Buffer    50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.5% Na- 
     deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM  
     EDTA, 50 mM NaF 
SDS Electrophoresis Buffer 25 mM Tris-Base, 192 mM glycine, 0.1% SDS 
Separation gel 6 - 15% 6-15% Acrylamide, 0.2-0.4% Bisacrylamide, 25% 
Tris HCl/SDS, pH 8.8, 0.3% Ammoniumpersulfate, 
0.1% TEMED 
Stacking gel 3,9% 3.9% Acrylamide, 0.1% Bisacrylamide, 25% Tris 
HCl/SDS, pH 6.8, 0.3% Ammoniumpersulfate, 0.1% 
TEMED 
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Stripping Buffer 10% SDS, 62.5 mM Tris HCl, 100 mM β-
mercaptoethanol 
50x TAE-Puffer 2 M Tris-Acetate, 50 mM EDTA, pH 8.0 (adjusted 
with NaOH) 
TBST 10 mM Tris HCl, pH 8.0, 150 mM NaCl, 0.05% (v/v) 
Tween 20 
TE Buffer (pH 7.9) 10 mM Tris HCl, 1 mM EDTA, pH 7.9   
4x Tris HCl/SDS, pH 8.8  1.5 M Tris-Base, 0.4% SDS, pH 8.8 
4x Tris HCl/SDS, pH 6.8  0.5 M Tris-Base, 0.4% SDS, pH 6.8 
Tris/EDTA buffer 10 mM Tris Base, 1 mM EDTA solution, 0.05% 
Tween 20, pH 9.0 
1x Western blot transfer 25 mM Tris Base, 192 mM Glycine, 20% (v/v)  
buffer  methanol 
  
 
2.12 Media  
2.12.1 Media for cultivation of bacteria 
All media were sterilised by incubating at 2 bar, 120°C for 21 min in an autoclave.  
LB-Broth-Base (Luria-Burtani-Medium, pH 7.2) AppliChem, Darmstadt, Germany 
 1 % (w/v) tryptone, 1% (w/v) sodium chloride, 0.5% (w/v) yeast extract. 
Medium was cooled down to 50°C before ampicillin was added in a final 
concentration of 100 µg ml-1 (optional). 
 
LB-Agar (Luria-Burtani-Agar, pH 7.2) AppliChem, Darmstadt, Germany 
1% (w/v) tryptone, 1% (w/v) sodium chloride, 0.5% (w/v) yeast extract, 1.5% 
Bacto Agar. 
Agar was cooled down to 50°C before ampicillin was added in a final 
concentration of 100 µg ml-1 (optional) and poured into petri dishes. 
 
SOC Medium 
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) sodium chloride, 20 
mM glucose  
 
Ampicillin AppliChem, Darmstadt, Germany 
 Stock solution:  100 mg ml-1 in H2O, sterile filtered 
 Endconcentration:  100 µg ml-1 
 
2.12.2 Media for cultivation of eukaryotic cells 
Cell type Media 
C33a DMEM 
N/TERT KGM-Gold or RM+ 
PHK KGM-Gold 
PT67 DMEM 
RTS3b RM+ 
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RM+ Medium (DMEM+DMEM/Nut Mix F12)  Invitrogen, Karlsruhe, Germany 
DMEM 45% DMEM/Nut Mix F12 (1:1) Glutamax 45%, 
FCS     10%   
Penicillin   100 units ml-1  
Streptomycin  100 µg ml-1  
hydrocortisone   0.4 µg ml-1, 
choleratoxin    10-10 M, 
transferrin    5 µg ml-1, 
triiodothyronine   2x10-11 M, 
adenine    1.8x10-4 M, 
insulin    5 µg ml-1, 
epidermal growth factor  10 ng ml-1 
 
Dulbecco´s modified Eagle´s medium (DMEM) Invitrogen, Karlsruhe, Germany  
with GlutamaxTM, 4500 mg l-1 glucose without sodium pyruvate 
FCS    10%   Invitrogen, Karlsruhe, Germany  
Penicillin   100 units ml-1 Invitrogen, Karlsruhe, Germany 
Streptomycin  100 µg ml-1  Invitrogen, Karlsruhe, Germany 
 
Assay medium   
 XF Base Medium      Seahorse Biosciences,  
        Copenhagen, Denmark 
Freezing medium 
DMSO   10%   Invitrogen, Karlsruhe, Germany 
FCS    90%   Invitrogen, Karlsruhe, Germany 
 
Transport medium 
DMEM      Invitrogen, Karlsruhe, Germany 
 FCS     10%   Invitrogen, Karlsruhe, Germany 
 Penicillin    600 U ml-1  Invitrogen, Karlsruhe, Germany 
 Streptomycin   600 μg ml-1   Invitrogen, Karlsruhe, Germany 
 Gentamycin    250 μg ml-1  Invitrogen, Karlsruhe, Germany 
 Fungizone    2.5 μg ml-1   Invitrogen, Karlsruhe, Germany 
 
KGM-GOLD Bullet Kit     Lonza, Basel, Switzerland 
Trypsin 0.05%      Invitrogen, Karlsruhe, Germany 
Trypsin/EDTA      Lonza, Basel, Switzerland 
Trypsin Neutralisation Solution TNS   Lonza, Basel, Switzerland 
 
2.12.3 Antibiotics for cell culture  
G418-Sulfat       Roth, Karlsruhe, Germany 
An aminoglycoside antibiotic that blocks polypeptide synthesis by inhibiting the 
elongation step in both prokaryotic and eukaryotic cells. Resistance to G418 is 
conferred by the neomycin gene.  
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2.13 Mice 
Line Description Reference 
FVB/n wt wildtype mice 
Charles River, Sulzfeld, 
Germany 
K14-HPV8-E7 
FVB/n mice expressing the 
HPV8-E7 oncoprotein under 
the control of the human 
keratin-14 promoter. 
present work 
 
The generation of and the study with transgenic mice, as well as the UV irradiation 
protocols were approved by the governmental animal care office North-Rhine-
Westphalia (protocol no. 87–51.04.2010.A203) and were in accordance with the 
German Animal Welfare Act as well as the German Regulation for the protection of 
animals used for experimental purposes. 
 
2.14 Miscellaneous 
2.14.1 Patient material 
Donated skin, composed of epidermis and dermis, for the preparation of organotypic 
skin cultures was sourced from the European Skin Bank, Beverwijk, Netherlands.  
 
2.14.2 Organotypic skin cultures 
Organotypic skin cultures established with primary keratinocytes expressing E7 of 
HPV1, HPV5, HPV8, HPV20 or HPV38 (Westphal et al. 2009), as well as cultures 
expressing HPV8-E2, E6 or E7 (Akgül et al. 2005, Leverrier et al. 2007, Akgül et al. 
2011b) were kindly provided by Dr B. Akgül (Institute of Virology, University Hospital 
Cologne)  
 
2.14.3 EV skin lesions 
Nine different EV lesions with betaHPV typing and pathology results were kindly 
provided by Prof S. Majewski (Department of Dermatology, University of Warsaw, 
Poland). The study was approved by the local ethics committee at the Medical 
University of Warsaw. 
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Patient BetaHPV type  pathology 
EV-Pa1 HPV5,8,20,23,36,50    SCC 
 HPV5,8,20,23,36,50    cytopathic effect 
EV-Pa2 HPV5,36    SCC 
 HPV5,36   SCC / Bowen's disease 
EV-Pa3 HPV5,8,9,24   Bowen's disease 
EV-Pa4 HPV5,8,20,23,36,50    cytopathic effect 
 HPV5,8,20,23,36,50    Bowen's disease 
 HPV5,8,20,23,36,50    Bowen's disease / SCC 
 HPV5,8,20,23,36,50    SCC 
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3. Methods 
 
3.1 Experimental work in mice  
3.1.1 Generation of K14-HPV8-E7 transgenic mice 
The HPV8-E7 gene was amplified by PCR and inserted into the BamHI site of the 
K14CreERtam plasmid under the control of the human keratin-14 promoter 
(Vasioukhin et al. 1999). The BamHI site is located between the sequence of the 
second intron of the rabbit β-globin gene and the K14 polyadenylation sequence. The 
recombinant vectors K14-HPV8-E7 were digested with HindIII and SacI flanking the 
K14 expression cassette. The appropriate fragment was purified via agarose gel 
electrophoresis and membrane filtration. The linearized transgene was microinjected 
into the pro-nucleus of fertilised FVB/n oocytes, which were implanted into 
pseudopregnant surrogate mothers according to the protocol described by Hammes 
and Schedl (2000) to produce putative founder mice expressing the HPV8-E7 
transgene (Hammes 2000). Genomic DNA was isolated from tail biopsies of 3 week-
old mice with the “QIAamp DNA Mini Kit” (Qiagen) and “Proteinase K” (Qiagen) 
according to the manufacturer´s protocol to test for the presence of the transgene by 
PCR. To verify the presence of the HPV8-E7 transgene in any offspring tail biopsies 
were used to isolate genomic DNA used for PCR. The generation of the K14-HPV8-
E7 founder mouse was performed by the animal facility of the Centrum for Molecular 
Medicine Cologne (CMMC).  
 
3.1.2 UV-irradiation of mouse skin 
Before any treatment, mice were anesthetized with Ketamine-hydrochloride (Sigma-
Aldrich) and Xylazine-hydrochloride (Sigma-Aldrich) and shaved with an electric 
shaver (Wella). Skin UV radiation was performed by a UV device (UV801, Waldmann). 
Dorsal caudal UV-irradiation was performed at an age of 5 - 25 weeks. Mice were 
either irradiated once or repeatedly with 10 J/cm2 UVA and 1 J/cm2 UVB on a 4 cm2 
sized area, while the rest was covered with a UV-impermeable sheet (Marcuzzi et al. 
2009). Skin samples were taken 3, 5 or 7 weeks after the last UV irradiation. Mouse 
skin samples were taken by punch biopsies (4 mm diameter, Pfm medical Ag, Cologne, 
Germany) or by scissors. For RNA analysis samples were stored at -20°C in RNALater 
(Qiagen) according to the manufacturer’s protocol. For IHC experiments mouse skin 
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samples were formalin-fixed and embedded in paraffin. Samples were cut in 3 - 4 µm 
sections at the Institute of Experimental Medicine of the University Hospital of Cologne. 
 
3.1.3 Long-term observation 
For long-term observation, groups of 2 - 4 animals of FVB/n and K14-HPV8-E7he were 
kept in individually ventilated cages over an observation period of up to 28 weeks. Mice 
were inspected every 3 days to monitor the development of skin tumours. All skin 
alterations were examined histologically on HE stained paraffin sections for detailed 
diagnosis. The formation of skin alterations was monitored over time and the 
percentages of animals bearing skin changes were plotted as a Kaplan-Meier graph 
(GraphPad Software Inc., San Diego, USA).  
 
3.2 Bacterial culture 
3.2.1 Transformation of competent bacteria 
Plasmid DNA has been amplified in bacteria followed by purification. Therefore, DNA 
(ca. 100 ng) was added to either 50 µl of competent bacteria and incubated on ice for 
30 min. Then the bacteria-DNA mixture was subjected to a heat step at 42°C for 45 s 
and shifted back on ice for 3 min. 100 μl SOC medium was added followed by an 
incubation for 1 h at 37°C under agitation. 50 µl bacteria were plated onto ampicillin 
(100 µg ml-1) LB-agar plates and incubated over night at 37°C. 
 
3.2.2 Cultivation of bacteria for plasmid isolation 
All plasmids used in this project contained an ampicillin resistance gene, therefore 
transformed bacteria could be selected by the addition of 100 µg ml-1 ampicillin to the 
LB-medium and agar plates. For analytic plasmid isolation, 5 ml LB-ampicillin-medium 
in a 13 ml PE-tube (Sarstedt) was inoculated with one colony of the transformed 
bacteria picked from the LB-agar plates and incubated under rotation overnight at 
37°C. For preparative plasmid isolation, 200 ml LB-medium in a 1 l Erlenmeyer flask 
were inoculated with 1 ml of a fresh overnight culture and kept at 37°C under agitation 
overnight. For storage, 1 ml of a bacterial culture was mixed with 500 μl glycerol and 
stored at -80°C. 
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3.3 Cell culture 
All cell lines listed here were adherent cell lines, cultivated at 37°C, 6% CO2 and            
80 - 90% humidity with DMEM, RM+ or KGM-Gold medium. All operations with these 
cell lines were done under a laminar flow. 
 
3.3.1 Cultivation of cell lines 
Cells were passaged when they reached a density of 60 - 90%. After a washing step 
with PBS, 3 ml Trypsin/EDTA was added for 3 to 6 min at 37°C. As soon as the cells 
detached from the bottom of the flask they were resuspended in 7 ml fresh medium or 
3 ml neutralisation solution and seeded at the desired density in a new tissue culture 
flask. When needed, N/TERTs and PHKs were also cultured on coated cell-culture 
flasks (either coated with fibronectin, collagen IV or laminin, BD Biosciences) for 4 
days. Cell culture supernatants and cells extracts were generated and stored at -80°C 
for further experiments. 
 
3.3.2 Freezing of cell lines 
For long term storage cells were grown in 150 cm2 tissue culture flask until they 
reached a density of about 60 - 90%. Then the cells were washed with PBS and 
detached with 3 ml Trypsin/EDTA and mixed with 9 ml of the appropriate cell culture 
medium or 3 ml of neutralisation medium. After centrifugation at 300 x g for 5 min the 
pellet was resuspended in freezing medium, aliquoted into 1.5 ml in freezing vials and 
stored at -80°C. To adjust constant cell numbers per aliquot cells were counted by 
using the TC 10 automated cell counter (BioRad) and the corresponding counting 
slides (BioRad). 
 
3.3.3 Transfection of cells  
(a) Calciumphosphate transfection 
The day before transfection cells were counted and seeded at a density of 1.5 x 105 
cells / 6 well, 1 x 106 cells / 6 cm Ø-dish and 1.5 x 106 cells / 10 cm Ø-dish, respectively 
and incubated overnight at 37°C. The following day, the cells were washed with PBS 
and fresh medium was added 1 - 2 h prior transfection. For 1 ml of cell culture medium, 
100 µL transfection solution was used containing the DNA in 2x HBS buffer, 5% 2 M 
CaCl2. After adding 50 µl 2 M CaCl2, the mixture was vortexed immediately for 15 s 
and incubated at room temperature (rt) for 15 min, to allow formation of a precipitate. 
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The mixture was added drop wise to the cell culture medium, carefully agitated and the 
cells were incubated at 37°C. At the next day, the cells were washed with PBS to 
remove the precipitate and new medium was added. Cells were harvested 24 - 48h 
later.  
(b) Transfast 
For the transfection of PHK, cells were seeded to a density of 30%. The appropriate 
amount of DNA (2 µg for 6 wells) was added to 1 ml of serum-free medium. Two 
microliters of the Transfast reagent (Promega) was added and the mixture was 
incubated for 15 min at rt. The medium was removed from the cells and the DNA-
medium-Transfast mixture was added to the cells. Cells were incubated at 37°C 
overnight. 24 h post-transfection the medium was changed, 48 h after transfection cells 
were used for further experiments. 
(c) Transfection of PT67 cells with FuGene 
For the transfection of PT67 cells 770 µl medium without additives was mixed with       
30 µl FuGene reagent (Promega) in a 1.5 ml tube and incubated for 5 min at rt. Then 
the mixture was added to a second 1.5 ml tube containing 10 µg DNA and further 
incubated for 15 min at rt. Then, FuGene-DNA mixture was added to the cells and 
incubated overnight at 37°C. 
(d) Lipofectamine RNAimax 
SiRNA transfections were performed with “Lipofectamine RNAimax” (Invitrogen). For 
this purpose, 8 x 104 cells were seeded in a 6 well and incubated overnight at 37°C. 
The following day cells were washed once with PBS and fresh medium without 
antibiotics was added. 5 to 30 picomole siRNA were added to 250 µl medium without 
additives and 2 µl “Lipofectamine RNAimax” were added to another 250 µl medium 
without additives. After vortexing both tubes, the diluted “Lipofectamine RNAimax” was 
added to the diluted siRNA and incubated for 20 min at rt. The siRNA-Lipofectamine 
RNAimax complexes were then added to the cells. 
 
3.3.4 Production of recombinant retrovirus supernatants 
For the production of recombinant retroviruses, the Retro X-System (Clontech, Palo 
Alto, USA) was used. At first retroviral vectors were transfected into PT67 cells, which 
are able to produce infectious but replication-deficient retroviruses. Those retroviruses 
are able to infect different types of primary mammal cells to introduce an external gene 
into the mammalian genome. After integration of this external gene into the host 
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genome a stable expression is ensured. After transfection of PT67 cells, a selection 
with G418 (500 ng ml-1) in pLXSN-based vectors in 75 cm2 culture flasks was 
performed for 14 days and the remaining positive clones were used for expansion. For 
retroviral supernatants, cells were grown in 150 cm2 cell culture flasks at a density of 
80%, the medium was changed and 16 ml fresh DMEM medium was added. These 
cells were cultured at 32°C and 10% CO2 for 24h or 48h and supernatants were 
aliquoted and stored at -80°C. 
 
3.3.5 Creation of the stable-transfected PHK-pLXSN, PHK-pLXSN-8E7, 
PHK-pLXSN-8E7-L23A, N/TERT-pLXSN, N/TERT-pLXSN-8E7 and 
N/TERT-pLXSN-8E7-L23A 
One day before transduction 2 x 105 PHK and N/TERT cells were seeded in a cell 
culture dish (6 cm). The next day cells were incubated with 2 ml DMEM without 
additives but with 5 μg ml-1 polybrene (Sigma) for 10 min at 37°C. Four ml retroviral 
supernatant pLXSN, pLXSN-8E7 and pLXSN-8E7-L23A with 5 µg ml-1 polybrene 
(Sigma) was added to the cell culture dish. The cells were centrifuged at 300 x g for     
1 h at rt, washed twice with PBS and finally incubated with 4 ml normal cultivation 
media for 48h at 37°C. Since pLXSN encodes the neomycin resistance gene, selection 
of transduced cells was performed by adding G418 (Roth) to the media in a final 
concentration of 500 µg ml-1. As selection control, PHK and N/TERT cells without 
transduction were also incubated with media containing G418 (Roth) in a final 
concentration of 500 µg ml-1. After 48h cells reached a confluence of about 80% and 
were splitted in a 75 cm2 tissue flask. Usually after one week, selection media was 
exchanged to normal culture media when all control cells were killed. Transcription of 
stably transduced DNA was verified by qRT-PCR. 
 
3.3.6 Isolation of PHK from human foreskin 
Mitomycine treatment of 3T3 fibroblasts: 3T3 fibroblasts were adjusted to a cell 
density of 1 x 106 cells per millilitre and 4 µg ml-1 mitomycine (Sigma) was added. Cells 
were transferred to a falcon tube and incubated in a rotor for 2h at rt. Afterwards cells 
were centrifuged at 300 x g for 5 min and were either used directly or were frozen with 
a cell density of 2 x 106 cells in freezing medium.  
Isolation of keratinocytes: Foreskins arriving in transport media were washed two 
times with PBS and transferred into a 10 cm cell culture flask. The skin was minced 
with the aid of scalpels, resuspended in 4 ml of 0.25% trypsin and transferred into a 
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falcon. The minced skin was incubated at 37°C for 2 h. The trypsin was neutralised by 
DMEM/FCS media every 30 min and replaced by fresh 4 ml 0.25 % trypsin. The 
DMEM/trypsin/cell mixture was filtrated using a 70 µm Nylon filter (BD Biosciences) 
and centrifuged at 300 x g for 5 min. The cell pellet was resuspended in RM+ media 
and seeded with a density of 2 x 106 cells per 150 cm2 cell culture flask together with 
2 x 106 mitomycine treated 3T3 fibroblasts. First keratinocyte ‘islands’ can be seen 
after 5 - 7 days. The keratinocytes were cultivated until they reach a density of 70%. 
Then, residual fibroblasts were removed due to trypsin treatment for 2 min. 
Keratinocytes could be detached from the flask in a second and longer trypsin 
treatment round. The isolated PHK were separated into aliquots containing 5 x 105 
cells in CryoSFM (PromoCell) freezing medium. When cells were thawed, culturing 
was performed in KGM-Gold media.  
 
3.3.7 Organotypic skin cultures 
Human donor skin, stored in glycerol, composed of epidermis and dermis was washed 
two times in PBS and incubated in PBS containing 600 U ml-1 Penicillin, 600 μg ml-1 
Streptomycin, 250 μg ml-1 Gentamycin, 2.5 μg ml-1 Fungizone for 10 days at 37°C 
(Todd et al. 1993). After incubation, the epidermis was removed and the dermis 
washed twice in PBS. Then the dermis was cut in 1.5 x 1.5 cm squares, put into a 6 
well upside down (up: stratum reticulare) and a ring of stainless steel (Ø 1.2 cm) was 
placed in the middle of the dermis. Human primary fibroblasts were harvested, counted 
and 5 x 105 cells were resuspended in 1 ml keratinocyte media. One millilitre of this 
solution was added per stainless steel ring and keratinocytes media was additionally 
added into the 6 well. This set-up was incubated overnight at 37°C with 10% CO2. On 
the next day, media and steel ring were removed. The dermis was turned and the ring 
was placed on the upper site of the dermis. Keratinocytes cultured in KGM-Gold media 
were harvested, counted and a cell suspension containing 4 x 105 cells ml-1 was 
prepared. One millilitre of cell suspension was added to the steel ring, the 6 well was 
filled with keratinocyte media and this set-up was incubated at 37°C and 10% CO2 for 
one day. After the incubation period the steel ring was removed and the dermis was 
placed on a metal grid. The 6 well was filled with keratinocyte media until the bottom 
of the dermis was wetted. Every 2 days the medium was changed. Cultures were fixed 
in 4% formalin at day 14 and embedded in paraffin. The sections were stained with HE 
for histological examinations. 
Methods 
44 
 
3.3.8 Transient replication assay 
This method is modified from the experimental procedure performed by Ustav and 
Stenlund (1991). RTS3b cells were transfected with 12 µg of pVE34 and pVE34L23A 
vector. 72 h post-transfection cells were harvested by removing the cell media and 
washing the cells twice with PBS. Cells were removed with cell scraper, resuspended 
in 2 ml PBS and centrifuged at 3000 x g. For extraction of episomal DNA the cell pellet 
was resuspended in 200 µl ‘resuspension buffer’ (50 mM glucose, 25 mM Tris, 10 mM 
EDTA, pH 8.6) and lysed in 400 µl freshly prepared ‘lysis buffer I’ (0.2 M NaOH, 1% 
SDS) for 3 min at rt. 300 µl ‘neutralisation buffer’ (3 M KAc, pH 4.8) was added to the 
cell lysate and incubated on ice for 10 min. To remove cell fragments, the raw extract 
was centrifuged at 20,000 x g for 5 min. The supernatant was mixed in a new reaction 
tube with 540 µl isopropyl alcohol and again centrifuged at 20,000 x g for 15 min. For 
the removal of protein residues, the pellet was resuspended in 200 µl ‘lysis buffer II’ 
(100 mM NaCl; 10 mM EDTA; 0,2% SDS; 200 µg ml-1 Proteinase K) and incubated at 
37°C for 1 h. After that a phenol extraction and ethanol precipitation was performed. 
The DNA pellet was resuspended in 20 µl RNaseA solution (0.0625 mg ml-1) and 10 µl 
of this solution were used for a restriction digest with the restriction endonuclease DpnI. 
This enzyme cuts DNA, which is methylated at the adenosine of the 5’-GATC-3’ motif. 
The transfected DNA originates and was isolated from dam+-bacteria and is therefore 
methylated at this 5’-GATC-3’ motif. Therefore, after DpnI digestion only newly 
replicated, non-methylated DNA remained. 
 
3.3.9 Seahorse XF MitoStress Test 
Measurement of intact cellular respiration was performed using the Seahorse XF96 
analyser (Seahorse Bioscience). N/TERT-8E7 and control cells (grown in RM+) were 
seeded into a Seahorse XF96 cell culture microplate at a cell density of 25,000 cells 
per 96-well 16h prior measurement. Directly prior to the respiration assay, cells were 
rinsed and cultured in assay medium supplemented with 5 mM glucose, 10 mM sodium 
pyruvate (Sigma-Aldrich) and 2 mM glutamate according to the manufacturer’s 
protocol. Cells were incubated at 37°C in a CO2-free incubator for 1h prior to 
measurement. Oxygen consumption rate (OCR), extracellular consumption rate 
(ECAR) and proton production rate were measured under basal conditions and in the 
presence of oligomycin, a complex V inhibitor (1 µg ml-1), the complex III inhibitor 
antimycin A (0.5 µM), the complex I inhibitor rotenone (0.5 µM) and the mitochondrial 
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uncoupler carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (1.5 µM, 
Sigma-Aldrich) to assess maximal oxidative capacity. After respiration assay, media 
was aspirated, wells were washed once with PBS and total protein concentration was 
determined by using the DCTM Protein Assay Kit II (BioRad). N/TERT-8E7 and control 
cells were measured in triplicate, normalised to total protein content and parameters 
were assessed subsequent to the subtraction of non-mitochondrial respiration from 
each value by the aid of the Seahorse Report Generator. The spare respiratory 
capacity is defined as the difference between maximal and basal respiration.  
 
3.3.10 Transient reporter gene assays 
For transient reporter gene assays, keratinocytes were transiently transfected in 
duplicate in 6 well dishes using the corresponding transfection reagent with 1 µg of 
luciferase reporter construct (TOP-flash, FOP-flash, pFN(1.2 kb)LUC, pFN(0.5 
kb)LUC, pFN(0.2 kb)LUC, pFN(0.2 kb)LUC-SP1mut) and 0.25 to 1 µg of pLXSN or 
pLXSN-8E7 together with 0.25 µg reporter plasmid coding for renilla luciferase. The 
assays were performed using the Dual-Luciferase® Reporter Assay System 
(Promega) according to the manufacturer’s protocol. Luciferase assays were 
measured 48 h post-transfection and normalised to renilla values. For TOP-flash/FOP-
flash activation, transfected RTS3b cells were stimulated with Wnt3a (50 ng ml-1, 
dissolved in PBS, R&D Systems) 6h prior harvesting. Luciferase activity was measured 
using the Glomax® Luminometer (Promega). 
 
3.4 RNA methods 
3.4.1 Total RNA Isolation 
Total RNA isolation from cells or mouse skin was done by using the ‘RNeasy Mini Kit’ 
(Qiagen) combined with the ‘QIAShredder’ (Qiagen) system.   
From cells: Cells were plated in 6 wells for RNA isolation. At the desired density and 
time point the medium was aspirated and cells were either pelleted and stored at -80°C 
until use or directly taken up in RLT buffer. For cell lysis, resuspended cells were 
pipetted directly into a QIAshredder. The following steps were performed according to 
the manufacturer’s protocol. DNA digestion was performed on column using ‘RNase-
Free DNase Set’ (Qiagen).  
From mouse tissue: For RNA isolation from mouse skin, biopsy samples were stored 
in RNALater (Qiagen) and transferred into a tube containing a steel ball and RLT buffer 
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from the ‘RNeasy Mini Kit’ (Qiagen). Skin biopsies were homogenized in a swing mill 
(Mixer Mill 301, Retsch, Haan) at 30 Hz for 3 min. For full homogenization of the mouse 
skin, tubes were turned around and shaken for another 3 min at 30 Hz. When using 
“miRNeasy Mini Kit” (Qiagen) DNA digestion was performed on column using RNase-
Free DNase Set (Qiagen). RNA was dissolved in 30 - 50 μl RNase-free H2O. 
RNA concentration and degree of purity was determined spectrophotometrically at a 
wavelength of 260 nm and 280 nm using a NanoDrop®ND-1000 UV/Vis spectral 
photometer (PEQLAB).  
 
3.4.2 Reverse transcription of mRNAs 
Total RNA was isolated as described in 3.5.1 and DNA was digested during isolation. 
One microgram of DNA-free RNA was reverse transcribed using “Omniscript RT Kit” 
(Qiagen) in a total volume of 20 µl with 10 µM random nonamers (TIB MOLBIOL),           
1 µM oligo-dT23-primer (Sigma-Aldrich) and 10 units RiboLockTM RNase Inhibitor 
(Fermentas). The reaction was carried out at 37°C for 1h, afterwards reverse 
transcriptase was inactivated at 95°C for 10 min. 
 
3.5 DNA methods 
3.5.1 DNA standard methods 
The methods mentioned below were performed according to the protocols from 
Sambrook (1989). 
 DNA digestion by restriction nucleases 
 Dephosphorylation of 5‘-end DNA fragments by alkaline phosphatase 
 Ligation of DNA by T4-Ligase 
 Determination of DNA concentration via NanoDrop® 
 Agarose gel electrophoresis 
 
3.5.2 Plasmid preparation 
Plasmid isolation for analytic and preparative was done using the ‘Plasmid Maxi Kit’ 
from Qiagen according to the manufacturer’s protocol. This kit is based on the 
extraction method from Birnboim and Doly (1979) and the property of DNA to bind on 
anion exchange columns. 
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3.5.3 Isolation of DNA from agarose gels 
Following electrophoretic separation, the desired DNA band was cut out from the 
agarose gel with a scalpel under long-wave UV (365 nm). DNA was isolated from 
agarose gel with “QIAEX II Gel Extraction Kit” (Qiagen) as described in the 
manufacturer’s protocol. 
 
3.5.4 Polymerase chain reaction (PCR) 
Amplification of defined DNA fragments was done by the PCR described by Mullis and 
Faloona (1987). The reaction was performed using 50 - 100 ng DNA as template in a 
total volume of 20 µl containing 1 unit Taq DNA Polymerase and the associated buffer 
with (NH4)2SO4 (Fermentas), 1 mM MgCl2, 5% DMSO (Applichem) 0.5 µM forward and 
backward primer each and 0.2 mM deoxynucleotide triphosphates each (Fermentas).  
PCR conditions  1x  94°C   3 min 
     94°C   30 s 
    30x Tann   30 s 
     72°C   60 s 
    1x 72°C  5 min 
    1x 4°C  ∞ 
 
3.5.5 Quantitative real-time polymerase chain reaction (qRT-PCR) 
The mRNA levels were quantified via qRT-PCR using the LightCycler System (Roche 
Diagnostics, Mannheim, Germany). Five microliters of a 1:50 dilution of cDNA 
(prepared as described 3.4.2) were used in a total volume of 20 µl containing: 1.25 
units Platinum Taq Polymerase, 4 mM MgCl2, 1.6 µl of a 1:1000 dilution of                
SybrGreen I (Sigma-Aldrich), 5% DMSO (Applichem), 0.5 µM each of forward and 
reverse primer, 500 ng µl-1 non-acetylated bovine serum albumin (Fermentas) and 0.2 
mM dNTPs each (Fermentas). Sample measurement was performed in duplicate 
together with a cDNA or plasmid dilution series. The fluorescence was detected once 
per cycle at the end of the elongation period.  
PCR conditions  1x 95°C   1 min 
    40x 95°C (20°C/s) 1 s 
     Tann (20°C/s)  5 s 
     72°C (20°C/s) 5 s 
Therefore, a melting curve protocol was carried out including 15 s at 95°C, 20 s at 70°C 
(20°C/s) and 1 s at 95°C (0.2°C/s). Fluorescence measurement was continuously done 
during heating to 95°C. At the end, the samples were cooled down to 40°C for 10 s. All 
mRNA levels were normalised to the mRNA levels of HPRT1 or GAPDH. 
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3.5.6 Site-directed mutagenesis 
For the introduction of amino acid changes in a protein sequence, mutation was 
performed using the ‘Quick Change® II XL Site-Directed Mutagenesis Kit’ (Agilent 
Technologies). For the mutation of HPV8-E7wt into HPV8E7-L23A in pLXSN-8E7, 
pCMV2-FLAG-8E7 and pVE34-L23A the specific primers were used (see section 
2.6.1). The protein-encoding plasmids and the corresponding complementary 
oligonucleotides were used in a PCR reaction containing 25 - 50 ng µl-1plasmid DNA, 
forward and reverse primer (125 ng µl-1), 10 mM dNTPs, QuikSolution and 2.5 U µl-1 
PfuUltra HF DNA-Polymerase. A PCR was performed with the following conditions: 
    1x 95°C 1 min 
     95°C 50 s 
    18x 60°C  50 s 
     68°C  1 min/kb 
   Final step 68°C 7 min 
 
PCR conditions were adapted to the size of the plasmid. To destroy the non-mutated 
plasmid DNA, the sample of the PCR reaction was then incubated with 1 µl DpnI at 
37°C for 30 min. 5 µl of this mixture were transformed with 50 µl competent E.coli XL1-
bacteria. The new constructs were verified by sequencing analysis.   
 
3.5.7 DNA Sequencing 
The method used for DNA sequencing was based on the principle of the chain-
termination-sequencing from Sanger and colleagues (1977). For DNA sequencing 3 to 
10 pmol of the primer, 200 - 500 ng plasmid DNA and 2 µl BigDye were mixed in a total 
volume of 5 µl and a PCR with the following conditions was performed. 
PCR conditions  1x  94°C   10 s 
     94°C   10 s 
    30x 60°C   10 s 
     60°C   3 min 
    1x 4°C  ∞ 
The analysis of the sequence was done with the DNA Sequencer ABI 3130XL (Applied 
Biosystems, Genetic Analyzer, Darmstadt, Germany) and the evaluation was done 
using SeqMan Pro® Lasergene (DNAstar). 
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3.6 Protein methods 
3.6.1 Protein Isolation 
Cells were pelleted and stored at -80 °C until use. The thawed cell pellet was 
resuspended in either 100 - 400 µl RIPA buffer or 100 - 400 µl LSDB containing 1 mM 
PMSF, 1 mM OV, 50 mM NaF, 1 mM DTT and 1x cOmpleteTM protease inhibitor 
cocktail (Roche) and incubated on ice for 30 min. Then the cells were sonificated and 
centrifuged at 15,000 x g, at 4°C for 15 min. Supernatants were pipetted in new tubes 
and were ready for use. Protein concentrations were determined via PierceTM BCA 
Protein Assay Kit (ThermoFisher) according to the manufacturer’s protocol.  
 
3.6.2 Western Blot Analysis 
For Western blot analysis protein extracts were separated with SDS-PAGE. The SDS-
gel was transferred to a nitrocellulose membrane (Protan BA85 Nitrocellulose), which 
was set between two Whatman paper and flanked by two sponges. The set-up was 
blotted at a voltage of 30 V overnight. To prevent unspecific binding of antibodies, the 
membrane was incubated with 25 mL of blocking solution for 1h. Then, the membrane 
was carefully overlaid with 4 mL containing the diluted 1st antibody in 5% dry milk in 
TBST for 2h at rt or overnight at 4°C. After three washing steps (5 min each) with TBST 
the membrane was incubated with 4 ml containing the 2nd antibody in the appropriate 
dilution for 1h at rt. After 3 x 5 min washing with TBST, the membrane was overlaid 
with 1 ml of BM Chemiluminescence blotting substrate for 2 min. The solution was 
carefully removed and the chemiluminescence signals were either detected upon 
exposure to an ECL-hyperfeature (Amersham, Freiburg, Germany) or with the GelDoc 
system from BioRad (Hercules, USA). Protein bands were quantified using ImageJ. 
 
3.6.3 Co-Immunoprecipitation (Co-IP) 
For each sample 10 µl of α-FLAG M2 affinity resin (Sigma) was equilibrated with            
0.1 M LSDB buffer (1 mM DTT, 1 mM PMSF) and centrifuged at 7000 rpm for 2 min at 
4°C. The beads were resuspended in 85 µl 0.1 M LSDB (1 mM DTT, 1 mM PMSF) and 
transferred into a new tube. 300 to 500 µg of whole protein lysate containing FLAG-
fusion proteins were added to the beads and filled up to a volume of 1 ml with LSDB 
(1 mM DTT, 1 mM PMSF). The mixture was incubated for 3h at 4°C in a rotor and 
afterwards centrifuged at 7000 x g for 5 min at 4°C. The supernatant was removed and 
the sample was washed five times with 1 ml of 0.1 M LSDB (1 mM DTT, 1 mM PMSF). 
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After the last washing step, the beads were resuspended in 30 µl of 0.1 M LSDB buffer, 
10 µl of 4x SDS loading puffer was added and the sample was incubated at 95°C for 
5 min. After centrifugation at 7000 x g for 5 min, the supernatant was transferred and 
separated onto a SDS-PAGE.  
  
3.6.4 Immunocytochemistry (ICC) 
Cells were seeded onto glass slides and incubated overnight, reaching a cell density 
of 30%. Then, the cells were washed two times with PBS and fixed with 4% 
Paraformaldehyde for 10 min. Afterwards the cells were washed with PBS. 
Permeabilisation of cells was performed with 0.1% Triton-X100 (diluted in PBS) and 
afterwards washed with PBS. Cells were blocked with 10% FCS in PBS for 30 min and 
incubated overnight with the first antibody diluted in PBS at 4°C. Again cells were 
washed with PBS and the second antibody was applied, diluted in PBS for 1h at rt. 
After washing, cells were counterstained with DAPI and embedded with Immunomount 
(ThermoScientific) on a slide. In case of mitochondrial staining, cells were incubated 
with a final concentration of 10 mM MitoTracker (ThermoFisher) in serum-free media 
for 30 min at 37°C prior fixation. 
 
3.6.5 Immunohistochemistry (IHC) 
Deparaffinization of 4 µm thick tissue sections was done by incubation in Xylol two 
times for 5 min. Samples were hydrated through a descending alcohol series (100%, 
90%, 70%; 5 min each) and endogenous peroxidases were inactivated by incubation 
in 3% H2O2 in Methanol for 20 min. Antigen unmasking was performed by either a) by 
boiling the tissue sections in citrate buffer in a pressure cooker for 4 min in a microwave 
b) by boiling in Tris/EDTA puffer in a pressure cooker for 4 min in a microwave c) with 
protease treatment (5 mg/ml) for 10 min at 37°C or with d) trypsin treatment (0.05%) 
for 10 min at 37°C. Further incubation steps were performed in a humid chamber to 
prevent dehydration. VECTASTAIN Elite ABC Kit: Blocking of unspecific antigen sites 
was done with 50% horse serum or 50% rabbit serum in PBS for 60 min. Incubation of 
primary antibody (see section 2.9.2) was done in 2% horse or rabbit serum overnight 
at 4°C, followed by three washes with PBS. Detection of primary antibody was done 
with the “VECTASTAIN Elite ABC Kit (Universal) or (Goat IgG)” (Vector Laboratories, 
Burlingame, USA), which was used as described in the manufacturer’s protocol. Either 
DAB staining with the “Liquid DAB Concentrated Substrate Pack” (BioGenex, San 
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Ramon, USA) or AEC staining using the ‘AEC-2-Components kit’ (DCS, Hamburg, 
Germany) was performed. Sections were counterstained with haematoxylin and 
dehydrated with an ascending alcohol series (70%, 90%, 100%; 3 min each). After a 
final incubation in Xylol for 5 min, sections were embedded with mounting medium 
“DePeX” (Serva Electrophoresis, Heidelberg). 
 
3.6.6 Immunofluorescence staining 
Deparaffinization of 4 µm thick tissue sections and antigen unmasking was performed 
as described in section 3.6.5. The tissue was blocked with 20% FCS in PBS for 30 
min. The primary antibody was incubated in 2% FCS in PBS overnight. After PBS 
washing, the secondary antibody was applied for 1 h at rt. Tissue was counterstained 
with DAPI after washing and embedded with Immunomount (ThermoScientific).  
 
3.7 Statistical analysis 
All experiments were repeated at least three times. qRT-PCR data were expressed as 
mean±SD. Immunoblots and images of immunohistochemical analysis are from a 
representative experiment, which was qualitatively similar in the replicate experiments. 
Statistical significance was determined with an unpaired 2-tailed Student’s t-test. The 
asterisks shown in the figures indicate significant differences between experimental 
groups (*p<0.05, **p<0.01, ***p<0.001, see figure legends).  
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4. Results 
 
4.1 Oncogenic potential of HPV8-E7 in the skin of transgenic mice 
4.1.1 Tumour development in K14-HPV8-E7 transgenic mice 
To characterise the tumorigenic potential of HPV8-E7 in vivo, a transgenic mouse line 
was generated expressing the viral gene under the control of the human keratin-14 
promoter, which allows its expression in all proliferation competent keratinocytes. The 
HPV8-E7 (8E7) ORF was introduced into the K14-CreERtam plasmid (Vasioukhin et 
al. 1999) and the recombinant expression cassette (figure 8 A) was microinjected into 
the pronucleus of fertilized mouse oocytes of the FVB/n background. These oocytes 
were implanted into pseudopregnant surrogate mothers to produce putative founder 
mice. Transgene-positive offspring was identified by PCR, resulting originally in two 
8E7 positive founder mice (M41 and M46) (figure 8 A). However, only the M46 survived 
and was used to establish the K14-HPV8-E7 hemizygous (he) and later the 
homozygous (ho) mouse line. The 8E7 mRNA expression in both lines was determined 
by qRT-PCR in untreated back skin. To investigate whether 8E7 expression leads to 
spontaneous tumour development, a group of K14-HPV8-E7 mice of different litters 
was observed within an observation period of 28 months (figure 8 B). In this group, 6 
of 14 (43%) mice developed spontaneous tumours, forming an eversion of the skin, 
mostly located between the head and front legs or in the neck. Previous work from our 
department demonstrated that UVB irradiation activates the K14 promoter thereby 
increasing HPV8 oncogene expression in the skin (Hufbauer et al. 2010a). As no 
papillomatosis was observed after a single UVA/B treatment, but historically did so in 
our K14-HPV8-CER, -E6 and -E2 mice (Schaper et al. 2005, Pfefferle et al. 2008, 
Marcuzzi et al. 2009), we changed the irradiation protocol and treated the K14-HPV8-
E7 mice chronically with 6 doses of UVA/B separated by 3 weeks each. The treated 
skin was taken 3 weeks after the last exposure and expression levels were determined 
by qRT-PCR (figure 8 C).  
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Figure 8. Different 8E7 expression levels in K14-HPV8-E7 transgenic mice. (A) Schematic 
representation of the K14-HPV8-E7 construct. The 8E7 ORF was inserted into the BamHI restriction 
site of the K14CreERtam plasmid located between the sequence of the second intron of the rabbit β-
globin gene and the K14-polyadenylation site. The recombinant plasmid K14-HPV8-E7 was digested 
with SacI and HindIII and the transgene-containing fragment was used to generate transgenic founder 
mice. K14-HPV8-E7 founder mice (M41 and M46) were analysed for the presence of the transgene DNA 
by testing for the K14-Promoter, 8E7 and K14-polyA sequences. (+) positive control, (-) negative control, 
(41, 46) transgene positive mice, (-M) transgene negative mouse. (B) A group of 14 K14-HPV8-E7he 
mice of different litter were observed over a period of 28 months. The spontaneous tumour development 
is represented as a Kaplan-Meier curve, in which tumour-free survival was determined. 100% of FVB/n 
wt represents no tumour development. 40% of K14-HPV8-E7he mice developed spontaneous tumours 
after 18 ± 3.6 months. (C) Mice were irradiated either once at an age of 6 weeks and samples were 
taken after 3, 5, 7 and 9 weeks. Or mice were treated chronically, 6 doses of UV irradiation separated 
by 3 weeks, starting at an age of 6 weeks. Samples were taken 3 weeks after the last treatment. (D) 
qRT-PCR determined 8E7 transcripts per 1000 transcripts of HPRT1 in K14-HPV8-E7he and K14-HPV8-
E7ho transgenic mice comparing untreated and UVA/B treated skin, as well as transcript levels in 
untreated hemizygous K14-HPV8-CER transgenic mice.  
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The skin of untreated hemizygous mice (K14-HPV8-E7he) showed 0.8 transcripts of 
8E7/1000 transcripts of HPRT1 and chronic treatment led to an 8-fold increase in 8E7 
expression levels (6.3 transcripts 8E7/1000 HPRT1 transcripts) (figure 8 D). 
Homozygous mice (K14-HPV8-E7ho) treated only once with UVA/B showed 5-fold 
increased 8E7 expression (5.5 transcripts 8E7/1000 transcripts HPRT1) as compared 
to untreated animals (1.1 transcripts 8E7/1000 transcripts HPRT1, figure 8 D). For 
chronically irradiated animals the number of transcripts was increased to 18.3/1000 
transcripts of HPRT1, however, this value was about 90 times less compared to the 
8E7 expression levels in untreated skin of K14-HPV8-CER transgenic mice.  
Figure 9. Untreated skin of FVB/n wt, K14-HPV8-E7he, K14-HPV8-E7ho and spontaneous tumour 
of K14-HPV8-E7he transgenic mice. Skin samples were taken at an age of 9 weeks. The untreated 
skin of K14-HPV8-E7he and K14-HPV8-E7ho transgenic mice did not show any significant differences 
compared to skin of FVB/n wt mice. Representative spontaneous tumour of K14-HPV8-E7he mouse 
taken at an age of 20 months (magnification 100x, 200x). 
 
4.1.2 HPV8-E7 induces keratinocyte invasion in transgenic skin 
The skin of untreated K14-HPV8-E7he (n=5) and K14-HPV8-E7ho (n=5) mice does not 
show any prominent differences compared to the skin of FVB/n wt mice (5/5) (figure 
9). Spontaneous tumours of K14-HPV8-E7he show mild skin hyperplasia at an age of 
18 ± 3.6 months (figure 9). A single UVA/B irradiation cycle of K14-HPV8-E7he (n=4) 
and K14-HPV8-E7ho (n=4) skin led to the development of skin hyperplasia within the 
interfollicular epidermis after 3 weeks. Additionally, epidermal cysts, which originate 
from the root sheets of the hair follicles were formed. However, these alterations 
weakened back and regressed 5 - 7 weeks after treatment (figure 10). Chronically 
treated FVB/n wt mouse skin (5/5) healed from UV-induced hyperplasia three weeks 
after the last treatment. In chronically UV treated K14-HPV8-E7he mice (8/10) mild 
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hyperplasia developed, which was clearly demarcated from the underlying dermis 
without any signs of malignancy. The skin of chronically irradiated K14-HPV8-E7ho 
developed flat or polypus skin tumours (15/20), which showed strong hyperplasia and 
intra-epidermal atypical keratinocytes (figure 12). Downward migrating cells showed 
nuclear hyperchromatism and pleomorphism with dyskeratosis (5/15). Those cells 
were stained positive with a pan-cytokeratin antibody (recognising an internal region 
of keratin-10) and confirmed that disordered squamous cells originated from the 
overlying epidermal sheets (figure 12). Furthermore, areas with a carcinoma in situ 
showed irregular sheets or islands of atypical squamous cells that invade the subjacent 
dermis (figure 12). In these areas the basement membrane was locally disrupted or 
completely absent as evidenced by collagen IV staining shown in figure 13. Taken 
together, these data demonstrated that although transgene expression was found to 
be relatively low, we could determine an oncogenic potential of 8E7 in vivo.  
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Figure 10. HE staining of 1x UVA/B treated K14-HPV8-E7he and K14-HPV8-E7ho transgenic mice. 
Mice were treated once with UVA/B with an age of 6 weeks and skin samples were taken 3, 5 and 7 
weeks after treatment. On the left site, HE staining of 1x UV treated K14-HPV8-E7he mice are shown, 
on the right, HE staining of the skin of 1x UVA/B treated K14-HPV8-E7ho mice are presented. Mice 
developed skin hyperplasia within the interfollicular epidermis 3 weeks after treatment, which regressed 
after 5 - 7 weeks (magnification 100x).  
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Figure 11. HE staining of chronically UVA/B irradiated skin of K14-HPV8-E7he and K14-HPV8-E7ho 
transgenic mice. Mice were treated with UVA/B chronically every 3 weeks starting at age of 6 weeks. 
Skin samples were taken after 6 rounds of irradiation and 3 weeks after the last treatment. 
Representative images for each group are presented (magnification 100x, 200x).  
 
Results 
58 
 
 
Figure 12. Carcinoma in situ formation in skin of chronically irradiated K14-HPV8-E7ho transgenic 
mice. Representative images of pan-cytokeratin staining of untreated and chronically irradiated skin of 
FVB/n wt and K14-HPV8-E7ho mice are shown. Atypical downward migration of cells in chronically 
irradiated skin of K14-HPV8-E7ho is indicated by black arrows (magnification 200x, 400x). 
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Figure 13. Degradation of the basement membrane at skin areas with carcinoma in situ 
formation. Representative immunofluorescence staining for collagen IV on skin of chronically irradiated 
FVB/n wt and K14-HPV8-E7ho mice tissue with carcinoma in situ. The BM is indicated by a white arrow 
in the FVB/n wt section. The absence and disruption of BM is indicated by orange arrows in the sections 
of K14-HPV8-E7ho mice (magnification 200x).    
 
 
4.2 Deregulation of cell-cell junctions in HPV8-E7 positive skin 
models 
Invasive growth is a main characteristic of tumour progression, which occurs either as 
single cell or collective cell movement, allowing cancer cells to invade through the ECM 
and thus spread to adjacent tissues. Common pathological consequences of invading 
cells are changes in cell-cell contacts and the remodelling of cell-matrix adhesions 
(Aneta et al. 2016).  
 
4.2.1 HPV8-E7 mediates overexpression of β-catenin in OSCs 
A reorganisation of cell-cell adhesion complexes by changing β-catenin expression or 
localisation plays an important role in EMT. To analyse a specific role of β-catenin in 
HPV8-E7-mediated changes of adherens junctions, β-catenin expression and 
localisation were analysed in de-epidermalised OSCs expressing 8E7 and compared 
to empty vector or E2 or E6 positive cultures. The empty vector (pLXSN) control 
showed a β-catenin staining restricted to the granular layer of the regenerated 
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epithelium (figure 14 A). In HPV8-E2 and HPV8-E6 OSCs the staining of the granular 
layer was absent. Interestingly, the regenerated epithelium of 8E7 OSCs showed a 
strong overexpression of β-catenin, by diffuse cytoplasmic staining in the suprabasal 
layers and strong membrane-tethered staining in the upper squamous layers (figure 
14 A). Due to strong overexpression of β-catenin in OSCs expressing 8E7, in a next 
step β-catenin expression levels were determined in OSCs repopulated with 
keratinocytes expressing E7 of HPV1 (µHPV) and HPV5, HPV8, HPV20 and HPV38 
(βHPV) (figure 14 B). OSCs repopulated with keratinocytes expressing the empty 
retroviral vector pLXSN were used as controls where expression was restricted to the 
upper layer of the regenerated epithelium. The β-catenin localisation and staining 
intensity in OSCs expressing HPV1-E7 and HPV38-E7 was not affected, compared to 
the control. HPV20-E7 expression led to a reduction of β-catenin expression. However, 
β-catenin staining was repeatedly strong in 8E7 expressing OSCs, as shown in figure 
14 B. This culture showed a diffuse cytoplasmic staining in the lower suprabasal layers 
and membrane-tethered staining in the upper squamous layers. Strong membrane-
tethered β-catenin staining was also found in OSCs repopulated with HPV5-E7 positive 
keratinocytes, comparable to the staining intensity of HPV8-E7.  
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Figure 14. HPV5-E7 and HPV8-E7 increase β-catenin expression levels. (A) Representative 
stainings of total β-catenin expression in OSCs established with HPV8 early proteins E2, E6, E7 or 
empty vector control. Increased β-catenin expression was determined for OSCs expressing 8E7. (B) 
Representative immunohistochemical staining of OSCs expressing either empty vector or either E7 of 
HPV1, HPV5, HPV8, HPV20 or HPV38 against total β-catenin. Increased β-catenin expression was 
observed for HPV5-E7 and HPV8-E7. Tissues were counterstained with haematoxylin. Dashed lines 
represent the basement membrane zone, e: regenerated epithelium, d: dermis (magnification 400x). 
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Figure 15. Elevated levels of actin in HPV5-E7 and HPV8-E7 expressing OSCs. Representative 
images of actin staining. Actin was fluorescently stained on OSCs established with either HPV1, 5, 8, 
20 or 38 E7 expressing keratinocytes. Elevated levels of actin were detected in the upper squamous 
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cell layers of the regenerated epithelium of OSCs established with either HPV5-E7 and HPV8-E7 
(indicated by white arrows). Counterstaining was performed with DAPI. Dashed lines represent the 
basement membrane zone, e: regenerated epithelium, d: dermis (magnification 200x).  
 
To analyse the influence of overexpressed β-catenin on the actin cytoskeleton, OSCs 
expressing different E7 proteins, were fluorescently stained against actin (figure 15). 
Only OSCs expressing HPV5-E7 and HPV8-E7 showed enhanced membrane-
tethered actin levels in the upper squamous cell layers. This strong staining was not 
detectable in the other OSCs expressing either empty vector control or E7 of HPV1, 
20 and 38. Therefore, a direct role of HPV5-E7 and HPV8-E7 on β-catenin and actin 
localisation and expression was determined in differentiating keratinocytes.  
 
4.2.2 Overexpressed β-catenin is not active in the Wnt signalling 
pathway  
Beside its role at adherens junctions, non-phosphorylated β-catenin can act as 
transcription factor within the canonical Wnt pathway, through translocation from the 
cell membrane to the nucleus, where it can activate promoters containing T-cell factor 
(TCF) responsive elements (Staal et al. 2002). Ligation of Wnt proteins to their 
respective dimeric cell surface receptors activates Wnt signalling and stabilises β-
catenin (Komiya and Habas 2008). To further analyse whether β-catenin is 
transcriptionally active due to its translocation into the nucleus, immunohistochemical 
staining of OSCs against non-phosphorylated β-catenin was performed by staining 
with the αABC β-catenin antibody, as shown in figure 16. The staining pattern of non-
phosphorylated β-catenin overlapped the pattern of total β-catenin, being membranous 
and suprabasal in control and 8E7 expressing OSCs. As no active nuclear β-catenin 
was detected, it was suggested that β-catenin does not act within the canonical Wnt 
pathway in regenerated epithelium of OSCs repopulated with 8E7-positive 
keratinocytes. 
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Figure 16. No nuclear translocation of β-catenin. Representative images of non-phosphorylated        
β-catenin in OSCs expressing either E7 of HPV1, HPV5, HPV8, HPV20 or HPV38. Membranous, 
suprabasal staining of non-phosphorylated β-catenin. Tissue was counterstained with haematoxylin. 
Dashed lines represent the basement membrane zone, e: regenerated epithelium, d: dermis 
(magnification 400x). 
 
To further confirm that accumulated β-catenin is not active within the Wnt pathway, 
PHK were transfected with expression vectors for 8E7 together with either the β-
catenin responsive TCF reporter plasmid (TOP-flash) or its negative control plasmid 
(FOP-flash). TOP-flash is a TCF reporter plasmid, which contains two sets (with the 
second set in the reverse orientation) of 3 copies of wt TCF binding sites driven by the 
thymidine kinase minimal promoter and upstream of a luciferase reporter gene, 
whereas FOP-flash contains mutated TCF binding sites. No significant difference in 
TOP-flash and FOP-flash luciferase activity was measured after 48h, which was 
confirmed in RTS3b cells (figure 17 A). The mRNA expression levels of the Wnt/β-
catenin target genes c-myc and CD44, measured via qRT-PCR, were not changed in 
RTS3b cells transfected with 8E7, as demonstrated in figure 17 B. To verify the 
functionality of the Wnt signalling pathway in RTS3b cells, the activity of the TOP-flash 
and FOP-flash plasmids was evaluated after incubation of the cells with Wnt3a for 6h 
(Maubant et al. 2015). The promoter activity of the TOP-flash construct was 
significantly stimulated after Wnt3a treatment (**p=0.0045), whereas FOP-flash 
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showed no increased activity (figure 17 C). Additionally, protein expression of the β-
catenin target c-myc was increased after Wnt3a treatment (figure 17 D). Taken 
together, these data indicate that the canonical Wnt/β-catenin signalling pathway is not 
affected in HPV8-E7 positive keratinocytes.  
 
Figure 17. The canonical Wnt pathway is not activated by overexpressed β-catenin in HPV8-E7 
expressing keratinocytes. (A) RTS3b cells and PHK were transfected with luciferase constructs, TOP-
flash or FOP-flash, together with 8E7 expression vectors. Luciferase activity was normalised to protein 
levels, whereby luciferase activity of control cells was set as 1. No significant difference between TOP-
flash and FOP-flash luciferase activity was determined. (B) mRNA expression levels of c-myc and CD44 
were determined by qRT-PCR in 8E7 positive cells. No altered gene expression could be induced by 
8E7. mRNA expression levels of target genes were normalised to transcript levels of GAPDH. mRNA 
expression levels in control cells were set as 1. (C) The stimulation of β-catenin/TCF signalling by Wnt3a 
was tested in RTS3b cells due to the transfection of either TOP-flash or FOP-flash and a Wnt3a 
treatment for 6h prior harvesting. Luciferase activity of control cells was set as 1. A significant stimulation 
was determined in TOP-flash (**p=0.0045) transfected cells. (D) Increased protein level of the β-catenin 
target gene c-myc was determined in Western blot analysis after Wnt3a treatment. Tubulin was used as 
loading control.  
 
4.2.3 HPV5-E7 and HPV8-E7 increase expression levels of the 
junctional protein ZO-1 
Having identified a strong upregulation of β-catenin at the cell membrane, we next 
tested whether the expression pattern of ZO-1 bridging between the tight junctions and 
the actin cytoskeleton was also changed. Therefore, HPV-E7 expressing OSCs were 
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stained immunohistochemically against ZO-1. In OSCs expressing HPV1-E7, HPV20-
E7 and HPV38-E7, as well as in the control culture, ZO-1 expression was found in the 
uppermost layer of the regenerated epithelium. In contrast, HPV5-E7 and HPV8-E7 
positive OSCs showed strong expression of ZO-1 throughout the regenerated 
epithelium (figure 18).  
 
Figure 18. Increased expression of ZO-1 induced by HPV5-E7 and HPV8-E7. Representative IHC 
against ZO-1 expression in OSCs expressing either empty vector control or E7 of HPV1, HPV5, HPV8, 
HPV20 or HPV38. Strong expression of ZO-1 was determined in OSCs established with HPV5-E7 and 
HPV8-E7. Tissues were counterstained with haematoxylin. Dashed line shows basement membrane 
zone, e: regenerated epithelium, d: dermis (magnification 400x). 
 
To confirm increased expression of β-catenin and ZO-1 triggered by 8E7, mRNA 
expression levels were determined via qRT-PCR in N/TERT keratinocytes grown in 
KGM-Gold medium. A significant increase in mRNA levels could be found for both 
junctional proteins. β-catenin and ZO-1 were increased about 1.5 times (**p=0.004) 
and 2.5 times (***<0.001) in 8E7 positive keratinocytes, respectively (figure 19 A). 
Under differentiating conditions, induced by the exposure to high extracellular calcium, 
β-catenin and ZO-1 expression was elevated in 8E7-positive keratinocytes (Akgül, 
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personal communication). Next, it was tested whether the knockdown of β-catenin and 
ZO-1 has an effect on proliferation or differentiation of 8E7 expressing keratinocytes. 
Western blot analysis confirmed the knockdown efficiency of the target-specific siRNAs 
used. As presented in figure 19 B, knockdown of β-catenin or ZO-1 did not affect the 
expression levels of the proliferating cell nuclear antigen (PCNA, a marker for cell 
proliferation) compared to cells transfected with a control siRNA (si-scramble). 
However, Western blot analysis of the epidermal differentiation marker loricrin showed 
a strong downregulation in empty vector and 8E7 expressing N/TERTs after 
knockdown of β-catenin and ZO-1, respectively (figure 19 B). 
 
Figure 19. Increased expression of the junctional proteins β-catenin and ZO-1 in N/TERT-8E7 
cells. (A) qRT-PCR measurement determined elevated mRNA expression levels of β-catenin 
(**p=0.004) and ZO-1 (***p<0.001) in N/TERT-8E7 cells compared to their control. (B) Control (si-
scramble) and β-catenin and ZO-1 knockdown cells were analysed for changed proliferation and 
differentiation profiles by immunoblotting for PCNA and loricrin, respectively. Tubulin was used as 
loading control. 
 
 
4.2.4 Overexpression of β-catenin and ZO-1 in HPV8 transgenic mice 
and in skin of EV patients 
To confirm the increased expression of β-catenin and ZO-1 in vivo, skin of K14-HPV8-
CER and wt mice was immunohistochemically stained against both factors. Skin of 
K14-HPV8-CER mice was strongly stained for total β-catenin and ZO-1 (figure 20 A). 
The skin of FVB/n wt animals showed only weak to moderate staining in the 
interfollicular epidermis for β-catenin and ZO-1. In addition, β-catenin and ZO-1 
expression levels were also determined in lesional skin of EV patients, which were 
positive for HPV5 or HPV8. Normal human skin was stained against β-catenin and 
showed regular membrane-tethered expression, however, in skin of EV patients the 
expression was elevated at the most superficial cell layers (figure 20 B). The 
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expression pattern of β-catenin in EV skin was similar to the staining of OSCs 
established with HPV5 and HPV8-E7 expressing keratinocytes. The staining against 
ZO-1 showed only a light expression in normal human skin, whereas elevated levels 
were detected in skin of EV patients. Therefore, increased levels of β-catenin and      
ZO-1 could also be confirmed in murine and human HPV-positive skin.  
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Figure 20. Increased expression of β-catenin and ZO-1 in HPV8 positive murine skin and human 
skin of EV-SCC. Representative immunohistochemical staining against β-catenin and ZO-1. (A) 
Elevated levels were determined in skin of K14-HPV8-CER transgenic mice compared to wt skin and 
(B) in human skin of EV-SCC (positive for HPV5, 8, 20, 23, 36, 50) compared to normal human skin. 
Tissue was counterstained with haematoxylin (magnification 400x). 
Results 
70 
 
4.3 Regulation of HPV8-E7 mediated invasion through 
keratinocyte-extracellular matrix (ECM) interaction 
4.3.1 ECM proteins trigger HPV8-E7 mediated keratinocyte invasion  
The importance of the matrix composition for HPV8-E7-mediated keratinocyte invasion 
was demonstrated by OSCs composed of 50% collagen I and 50% Matrigel, as 
described in the aims (see section 1.12). To establish an in vitro quantifiable invasion 
assay, Boyden chambers coated with Matrigel were used to test the invasive capacity 
of PHK expressing HPV8 oncogenes. The degree of invasion measured for PHK-8E7 
(**p=0.0014) and PHK-8CER (**p=0.0091) was twofold higher compared to PHK 
expressing either HPV8-E2 or -E6 (figure 21 A).  
To bypass potential variations between pools of PHK from different donors a stable 
cell line model of N/TERT keratinocytes expressing 8E7 and empty vector control was 
established. The 8E7 expression level in N/TERTs was determined by qRT-PCR, 
detecting 1.5 transcripts of 8E7 per GAPDH transcripts (***p<0.001, figure 21 B). 
To further address the mechanism through which 8E7 triggers cell invasion, also 
N/TERTs were tested in Boyden chamber assays. Isogenic N/TERT-8E7 cells grown 
in RM+ medium did not show an enhanced invasive behaviour, when compared to the 
matched control cell line N/TERT-pLXSN. Interestingly, N/TERT-8E7 cells grown in 
KGM-Gold medium showed a 2-fold increase of invading cells (*p=0.0295, figure 21 
C). This invasive capacity was comparable to the level of PHK-8E7 cells, which 
indicates that invasion in 8E7-expressing cells is exhibited only in KGM-Gold medium. 
All following experiments with N/TERT-8E7 were therefore performed in KGM-Gold 
medium. These data indicated that HPV8-E7-mediated invasion is triggered in cells 
with basal cell characteristics.  
In order to identify the ECM proteins responsible for triggering invasion, Boyden 
chambers were either coated with collagen IV, laminin or fibronectin and used to assay 
N/TERT-8E7 cells. N/TERT-8E7 showed an about 2-fold enhanced invasion on all 
three matrices when compared to their matched controls (collagen IV: *p=0.0269, 
laminin: *p=0.0303, fibronectin: ***p<0.001, figure 21 D).   
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Figure 21. Invasive capacity of HPV8-E7 positive keratinocytes on ECM proteins. (A) Invasion 
capacity of PHK expressing either HPV8-E2, HPV8-E6, HPV8-E7 (**p=0.0014) or HPV8-CER 
(**p=0.0091) grown in KGM-Gold media, were analysed via Matrigel-coated Boyden chamber invasion 
assays and compared to empty vector. (B) qRT-PCR determining the absolute values of HPV8-E7 
transcripts per GAPDH mRNA levels in N/TERT-8E7 (***p<0.001) cells compared to its empty vector 
control. (C) Determined invasive properties of isogenic N/TERT-8E7 cells grown either in RM+ or KGM-
Gold (*p=0.0295) media by Matrigel-based Boyden chamber invasion assays. (D) Increased invasive 
capacity of N/TERT-8E7 cells tested on Boyden chamber invasion assays either coated with collagen 
IV (*p=0.0269), laminin (*p=0.0303) or fibronectin (***p<0.001).  
 
 
4.3.2 A Cadherin switch increases motility of HPV8-E7 expressing cells 
on a fibronectin matrix 
A cadherin switch associated with a decrease in E-cadherin and a subsequent 
increase in N-cadherin expression depicts a fundamental effect on cell phenotype and 
is considered to be a key molecular event during the first steps of cell invasion (van 
Roy 2014). E-cadherin staining intensity in OSCs established with PHK expressing 
8E7 was significantly reduced compared to the control culture (figure 22).  
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Figure 22. Decreased E-cadherin expression in regenerated epithelium of OSCs expressing 
HPV8-E7. Representative immunohistochemical staining of E-cadherin in OSCs repopulated with 
HPV8-E7 expressing keratinocytes or empty vector control. Decreased expression of E-cadherin at cell-
cell junctions in suprabasal layers of HPV8-E7 OSCs. Tissue was counterstained with haematoxylin. 
Dashed line shows basement membrane zone (magnification 400x).  
 
To identify the ECM protein triggering a cadherin switch in 8E7expressing 
keratinocytes the mRNA levels of E-cadherin and N-cadherin were measured via qRT-
PCR in cells grown on cell culture plates coated either with collagen IV, laminin or 
fibronectin. Cells cultured on collagen IV showed a significant increase in E-cadherin 
(2-fold, *p=0.0138) and N-cadherin (1.5-fold, ***p<0.001) mRNA expression levels 
compared to the control culture (figure 23 A and B). When cells were grown on laminin, 
a significant twofold increase of N-cadherin (*p=0.0487) expression was detected. 
Interestingly, E-cadherin (***p<0.001) expression level was reduced by 50% in 
N/TERT-8E7 cells, when grown on fibronectin, which coincided with a 2-fold increase 
of N-cadherin (***p<0.001) expression (figure 23 A and B). The switch from E-cadherin 
to N-cadherin in N/TERT-8E7 cells grown on fibronectin was not associated with 
significant changes of the E-cadherin-regulating transcription factors Slug, Snail, and 
Twist. Also the mesenchymal and EMT marker vimentin was not changed upon 8E7 
expression (figure 23 C). Thus, only fibronectin could be identified as an ECM protein 
inducing the cadherin switch in 8E7-positive keratinocytes.  
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Figure 23. HPV8-E7 mediated EMT is induced upon cultivation on fibronectin. (A) mRNA 
expression levels of E-cadherin and N-cadherin in N/TERT-8E7 cells were determined via qRT-PCR. E-
cadherin levels were upregulated in 8E7 expressing cells grown on collagen IV (*p=0.0138) and 
repressed on fibronectin (***p<0.001). N-cadherin mRNA expression levels were increased in N/TERT-
8E7 cells when grown either on collagen IV (***p<0.001), laminin (*p=0.0487) or fibronectin (***p<0.001). 
In addition, mRNA expression levels of EMT associated transcription factors, including Slug, Snail, 
vimentin and Twist are illustrated for N/TERT-8E7 and control cells grown of collagen IV, laminin and 
fibronectin. mRNA expression levels of target genes were normalised to GAPDH mRNA levels and 
relative gene expression levels of the controls were set as 1. COL IV: collagen type IV; LAM: laminin; 
FN: fibronectin 
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4.3.3 Expression and secretion of fibronectin is altered by HPV8-E7 
In HPV8-positive skin SCCs, the upregulation of fibronectin in peritumoral areas was 
significantly increased compared to betaHPV negative skin SCC. Furthermore, this 
upregulation of fibronectin could be confirmed in Western blot analysis of tissue 
extracts (cooperation Dr B. Akgül, Institute of Virology, Cologne with Prof C. Mauch 
and Dr P. Zigrino, Department of Dermatology, Cologne). 
The increased deposition of fibronectin in the tumour matrix of HPV8 positive skin 
SCCs might be due to increased fibronectin expression and secretion from 8E7-
positive keratinocytes. Therefore, mRNA expression levels of fibronectin in N/TERT 
keratinocytes expressing 8E7, grown on different matrices, were determined by qRT-
PCR (figure 24 A). Elevated levels of fibronectin mRNA could be detected in N/TERT-
8E7 positive cells grown either on collagen IV (3-fold increase, **p=0.006), laminin (3-
fold increase, ***p<0.001) or fibronectin (3-fold increase, ***p<0.001). In addition, 
secretion of fibronectin by N/TERT-8E7 cells was determined in cell culture 
supernatants by immunoblotting. Fibronectin generates two isoforms due to alternative 
splicing, which contain an extra domain A (EDA) or B (EDB). The fibronectinEDA plays 
an important role in wound healing, cell spreading and invasion (Sun et al. 2014). 
Significantly higher levels of total fibronectin and fibronectinEDA were secreted by 
N/TERT-8E7 grown on laminin, collagen IV and fibronectin compared to their control 
(figure 24 B). In addition, to test whether 8E7-positive keratinocytes are able to 
stimulate fibronectin expression in fibroblasts, fibroblasts were treated with conditioned 
media from N/TERT-8E7 cells for 48h after which cell extracts were tested by Western 
blotting. As shown in figure 24 C, treatment of fibroblasts with conditioned media led 
to an increased expression of total fibronectin and fibronectinEDA.  
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Figure 24. Increased fibronectin production and secretion by HPV8-E7. (A) qRT-PCR was 
performed to determine mRNA expression levels of fibronectin (FN) in N/TERT-8E7 cells grown on 
different matrices. Increased levels of fibronectin mRNA could be detected for N/TERT-8E7 cells either 
grown on collagen IV **p=0.006), laminin (***p<0.001) or fibronectin (***p<0.001). mRNA expression 
levels were normalised to transcript levels of GAPDH. Fibronectin mRNA expression level in control 
cells grown on laminin were set as 1. (B) Representative image of Western blot analysis showing 
secreted levels of total fibronectin and fibronectinEDA from N/TERT-8E7 cells. Equal loading was verified 
by Coomassie staining. (C) Total fibronectin and fibronectinEDA protein expression in primary fibroblasts 
stimulated with conditioned media from N/TERT-8E7 and control cells was determined via Western blot 
analysis. Equal loading was confirmed by immunoblotting for tubulin. COL IV: collagen type IV; LAM: 
laminin; FN: fibronectin 
 
 
4.3.4 Regulation of the fibronectin promoter by HPV8-E7 
To clarify the mechanism by which 8E7 induces fibronectin expression, we next tested 
whether fibronectin promoter activity is induced by 8E7. Luciferase promoter assays 
were performed with promoter constructs containing either the 1.2 kb promoter 
fragment of the human fibronectin promoter (pFN(1.2 kb)LUC) or the deletional 
mutants pFN(0.5 kb)LUC or pFN(0.2 kb)LUC (kindly provided by Dr J. Roman) 
(Michaelson et al. 2002). Keratinocytes were transiently transfected with the fibronectin 
promoter constructs together with increasing amounts of the pLXSN-8E7 or empty 
vector pLXSN. All tested fibronectin promoter constructs could dose-dependently be 
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activated by 8E7 (figure 25). A significant 2-fold activation was measured in all 
constructs (pFN(1.2 kb)LUC: *p=0.0427; pFN(0.5 kb)LUC: *p=0.032; pFN(0.2 kb)LUC: 
*p=0.0136). In order to predict transcription factors involved in 8E7-mediated activation 
of the fibronectin promoter, the 0.2 kb promoter proximal sequence was analysed using 
the TRANSFAC® database (http://www.biobase-international.com). This analysis led 
to the identification of a putative Sp1 binding site (5‘-(G/T)GGGCGG(G/A)(G/A)(C/T)-
3’) at position -134GGGGCGGGGC-127 (Cawley et al. 2004). To test whether these Sp1 
motifs have a role in mediating the 8E7 response, the pFN(0.2 kb)LUC construct was 
mutated at these sites (figure 26 A) and tested in luciferase assays. These luciferase 
promoter assays were performed in PHK co-transfected with the fibronectin constructs 
and 1 µg of pLXSN-8E7. The mutation of the Sp1 sites did not affect the overall activity 
of the fibronectin promoter (data not shown). Subsequent co-transfection experiments 
revealed that the 8E7-mediated activation of the 0.2 kb promoter fragment was 
abolished in the presence of mutated Sp1 sites within the pFN(0.2 kb)LUC-Sp1mut 
construct (figure 26 B).  
 
Figure 25. The fibronectin promoter activity is increased by HPV8-E7. Fibronectin promoter 
constructs were transfected into keratinocytes with increasing amounts of expression vector for 8E7. All 
fibronectin promoter constructs could be dose-dependently activated in the presence of increasing 
amounts of 8E7. Expression level of the corresponding co-transfected empty vector (control) was set as 
1. FN: fibronectin 
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Figure 26. Fibronectin promoter activation by HPV8-E7 is dependent on functional Sp1 binding 
sites. (A) Schematic representation of putative transcription factor binding sites within the 200 bp 
fragment of the human fibronectin promoter. NF-YA, RREB, Churchill and Sp1 binding sites (BS) were 
predicted using TRANSFAC database analysis. The sequence alignment shows the consensus Sp1 BS, 
the sequence around the Sp1 BS within the 0.2 kb promoter and the mutation strategy of the Sp1 BS. 
(B) All promoter constructs were transfected into PHK together with 1 µg pLXSN-8E7. Increased 
promoter activity was reached ranging between 1.5-fold to 2.5-fold compared to controls (pFN(1.2 
kb)LUC: 1.5-fold, *p=0.02; pFN(0.5 kb)LUC: 1.5-fold; **p=0.0018; pFN(0.2 kb)LUC: 2.5-fold, *p=0.0295). 
Due to the mutation of the Sp1 BS, the pFN(0.2 kb)LUC-Sp1mut reporter construct could not be 
stimulated by 8E7 anymore (*p=0.05). Firefly luciferase activity was normalised to co-transfected renilla 
luciferase. Relative promoter activity of the controls was set as 1. NF-Ya: nuclear transcription factor Y 
alpha, RREB: Ras responsive element binding protein 1, Churchill: Churchill domain containing 1, Sp1: 
specificity protein 1. 
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4.3.5 Fibronectin linked integrin regulation is associated with HPV8-E7 
mediated invasion 
4.3.5.1 Identification of integrin α3 chain on HPV8-E7 cells grown on 
fibronectin  
Normal skin homeostasis is influenced by cell-ECM interactions, where changes are 
associated with disease (Watt and Fujiwara 2011). Keratinocytes are connected to the 
ECM via cell-matrix adhesion molecules, known as integrins, a family of glycoprotein 
receptors (Watt and Fujiwara 2011). Deregulation of several integrin chains has been 
associated with invasion and tumour development (De Franceschi et al. 2015). To 
analyse a correlation between altered integrin expression levels on the cell surface of 
8E7 expressing keratinocytes with invasion, N/TERT-8E7 cells were cultured on 
collagen IV, laminin or fibronectin and analysed via qRT-PCR for integrin α2, α3, α5, 
αv and α6 and β1, β4, β5 and β6 chains. N/TERT-8E7 cells grown on laminin showed 
1.5-fold increased expression levels of α2 (***p<0.001) and α6 (*p=0.05) chains, 
whereas 8E7 cells grown on collagen IV showed significantly increased levels of α2 
(2-fold, ***p<0.001), α3 (3-fold, **p=0.006) and α5 (2.5-fold, *p=0.04, figure 27). 
Interestingly, only minor changes of integrin α chain expression was detected for cells 
grown on fibronectin. Figure 28 shows that β1 and β5 chain expression was 
significantly increased in N/TERT-8E7 cells grown on laminin. Integrin β5 chain mRNA 
expression was increased in N/TERT-8E7 cells grown on collagen IV. Only minor 
changes could be detected in N/TERT-8E7 cells grown on fibronectin.  
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Figure 27. Changes in integrin α chain mRNA expression in N/TERT-8E7 grown on different ECM 
matrices. mRNA expression levels of different integrin α chains (α2, α3, α5, αv and α6) were determined 
by qRT-PCR for N/TERT-8E7 cells grown on collagen IV, laminin and fibronectin. The relative 
expression levels of the matched controls were set as 1 and GAPDH mRNA expression was used for 
normalisation. COL IV: collagen type IV; LAM: laminin; FN: fibronectin 
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Figure 28. Changes in integrin β chain mRNA expression in N/TERT-8E7 grown on different ECM 
matrices. mRNA expression levels of different integrin β chains (β1, β4, β5 and β6) were determined 
by qRT-PCR for N/TERT-8E7 cells grown on collagen IV, laminin and fibronectin. The relative 
expression levels of the matched controls were set as 1 and GAPDH mRNA expression was used for 
normalisation. COL IV: collagen type IV; LAM: laminin; FN: fibronectin 
 
To further address whether integrin α chains are elevated on the cell surface of 8E7 
expressing keratinocytes, cells were analysed via FACS analysis to determine levels 
of integrin α2, α3, α5 and α6 chains. 8E7 and control cells were cultured either on 
laminin, collagen IV or fibronectin and harvested for FACS analysis. For 8E7 cells 
either cultured on collagen IV or laminin, no significant increase in integrin α chain cell 
surface localisation could be measured. Whereas, when the same cells were cultured 
on fibronectin, integrin α3 chain localisation was elevated on the cell surface by 30% 
(***p<0.001, figure 29). Although mRNA expression levels of integrin α3 chain in 8E7 
cells grown on fibronectin showed no changes, elevated levels of integrin α3 on the 
cell surface were measured. 
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Figure 29. Increased expression of integrin α3 chain in HPV8-E7 expressing keratinocytes. Cell 
surface levels of integrin α2, α3, α5 and α6 chains were tested via FACS analysis on N/TERT-8E7 cells 
grown on different matrices. An increase of integrin α3 chain was determined for cells grown on 
fibronectin. The diagram on the left shows the percentage of cells showing increased integrin on the cell 
surface for N/TERT-8E7 cells grown on fibronectin. COL IV: collagen type IV; LAM: laminin; FN: 
fibronectin; C: control 
 
To further verify enhanced integrin α3 expression levels whole cell extracts from 
N/TERT-8E7 cells either grown on Matrigel or fibronectin were used for 
immunoblotting. Figure 30 A shows that increased levels of integrin α3 were detected 
in 8E7-positive cells compared to their matching controls. In addition, fluorescence 
staining of OSCs established with N/TERT-8E7 cells showed enhanced levels of 
integrin α3 chain at the dermal-epidermal junction, whereas a weaker suprabasal 
expression was determined in the control culture (figure 30 B). The expression level of 
integrin α3 chain was also analysed in untreated and UV treated skin of wt and K14-
HPV8-E7ho mice by fluorescence staining. Here, elevated levels of integrin α3 chain 
could be confirmed in chronically irradiated K14-HPV8-E7ho skin throughout basal and 
suprabasal layers compared to a weak suprabasal expression in irradiated wt skin 
(figure 31). Untreated wt and K14-HPV8-E7ho skin showed only very weak expression 
of integrin α3 chain. These findings led to the conclusion that 8E7 is able to regulate 
protein expression and cell surface levels of the integrin α3 chain.  
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Figure 30. Elevated integrin α3 chain levels determined via Western blot and in fluorescence 
staining of OSCs. (A) Representative Western blot analysis of whole cell lysate from N/TERT-8E7 cells 
grown on Matrigel, fibronectin or without any coating. Elevated levels of integrin α3 chain were 
determined for 8E7 cells grown on Matrigel and fibronectin Equal loading was confirmed by 
immunoblotting for tubulin. (B) Immunofluorescence staining of integrin α3 chain (green) on OSCs 
established with N/TERT-8E7 and control cells. Tissue sections were counterstained with DAPI (blue) 
(original magnification 200x). MG: Matrigel; FN: fibronectin; C: control 
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Figure 31. Increased expression of integrin α3 chain levels in chronically irradiated skin of K14-
HPV8-E7ho mice. Representative immunofluorescence staining of integrin α3 chain (green) on skin of 
untreated and UV treated skin of wt and K14-HPV8-E7ho transgenic mice. Elevated levels of integrin α3 
were detected in chronically irradiated skin of K14-HPV8-E7ho mice. Tissue sections were 
counterstained with DAPI (blue) (original magnification 200x).  
 
 
4.3.5.2 Proof of the role of integrin α3 chain in HPV8-E7 mediated invasion 
a) Knockdown of integrin α3 chain  
To confirm whether the elevated levels of the integrin α3 chain are involved in 8E7-
mediated invasion, siRNA knockdown of the α3 chain was performed in N/TERT-8E7 
keratinocytes and tested in Boyden chamber invasion assays. Figure 32 A shows the 
successful knockdown of integrin α3 chain in N/TERT-8E7 and control cells compared 
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to the cells transfected with control siRNA. No phenotypic changes could be observed 
due to siRNA knockdown of integrin α3 chain in N/TERT-pLXSN cells. Figure 32 B 
illustrates a significant reduction of the invasive capacity of N/TERT-8E7 cells due to 
the knockdown of integrin α3 chain compared to control cells. The level is reduced by 
about 50% (*p=0.03). Therefore, elevated levels of integrin α3 chain on the cell surface 
positively influence the invasive capacity of 8E7-expressing keratinocytes.  
 
Figure 32. Integrin α3 chain knockdown is associated with reduced invasive capacity of N/TERT-
8E7 cells. (A) Western blot analysis of whole protein lysates of N/TERT-8E7 and control cells, either 
untransfected, transfected with control siRNA (si-scr) or transfected with siRNA against integrin α3 (si- 
α3) was performed to confirm integrin α3 knockdown. Equal loading was confirmed via immunoblotting 
for tubulin. (B) Invasion was strongly reduced for N/TERT-8E7 cells with integrin α3 knockdown. Invasion 
capacity was determined via Boyden chamber invasion assays based on Matrigel. C: control 
 
b) HPV8-E7 mutant, defective in integrin α3 upregulation, is not able to 
trigger keratinocyte invasion 
No specific region of the HPV8-E7 oncoprotein has been known to be important for the 
control of keratinocyte invasion. The E7 proteins of all HPV types share amino acid 
homology to some extent, therefore an alignment of E7 sequences, including HPV1, 
4, 5, 8, 16, 20 and 38, was performed (figure 33 A). One of the conserved aa in HPV5 
and HPV8 E7 is the L at position 23. A site-directed mutagenesis was performed to 
mutate this conserved L in 8E7 to proof its influence on 8E7-mediated invasion. 
Therefore, we generated the 8E7 mutant L23A (8E7-L23A, figure 33 A). At first, the 
capacity of 8E7-L23A to degrade pRB was determined by immunoblotting to proof the 
functionality of this mutant protein. The degree of degradation of 8E7-L23A was 
comparable to 8E7wt (figure 33 B). Immunoblotting against integrin α3 chain showed 
that the expression was reduced in 8E7-L23A positive cells compared to 8E7wt grown 
on fibronectin (figure 33 C).  
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Figure 33. Integrin α3β1 induces invasive capacity of HPV8-E7 positive keratinocytes. (A) The 
alignment of several HPV-E7 protein sequences identified a conserved amino acid sequence in HPV5 
and HPV8. To test whether this position is important for the invasive capacity, L23 was mutated via site-
directed mutagenesis leading to 8E7-L23A. The arrow indicates the position L23. (B) Western blot 
analysis of whole protein lysates of N/TERT-8E7-wt and N/TERT-8E7-L23A demonstrated the 
degradation of pRB by 8E7wt and 8E7-L23A compared to control cells. (C) Immunoblotting against 
integrin α3 chain showed reduced levels in 8E7-L23A compared to 8E7wt for cells grown on fibronectin. 
Equal loading was confirmed by immunoblotting against tubulin. (D) Cell surface expression of integrin 
α3 chain was measured via FACS analysis in cells grown on fibronectin. N/TERT-8E7wt cells showed 
68% integrin α3 chain positive cells compared to only 41% positivity in N/TERT-8E7-L23A (*p=0.03). 
(E) The invasive capacity of 8E7-L23A positive cells was tested in Boyden chamber assays either based 
on Matrigel or fibronectin. On both matrices N/TERT-8E7wt showed an about 2.5-fold (Matrigel: 
**p=0.003, fibronectin: **p=0.002) increased invasive capacity, however, N/TERT-8E7-L23A cells have 
a reduced invasive capacity (Matrigel: 1.2-fold, **p=0.009, fibronectin: 0.5-fold, ***p<0.001).  
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In addition, the cell surface expression level of integrin α3 chain was reduced on 8E7-
L23A expressing cells grown on fibronectin compared to 8E7wt. For 8E7wt 70% of 
cells were positive for integrin α3, which was reduced to 40% (*p=0.03) in 8E7-L23A 
positive cells (figure 33 D). Furthermore, invasion was tested in Boyden chamber 
assays coated either with Matrigel or fibronectin. The invasive capacity of the 8E7-
L23A was reduced by 60% on Matrigel (**p=0.009) and 80% on fibronectin 
(***p<0.001), compared to 8E7wt (figure 33 E). These results strengthen the findings 
that integrin α3β1 is the integrin mediating invasion of 8E7-positive keratinocytes. 
 
4.3.6 Integrin α3 cell surface localisation on HPV8-E7 positive cells 
correlates with expression of epithelial stem cell markers 
Our group could recently show that 8E7 expressing keratinocytes show cancer stem 
cell-like properties, which were attributed to increased cell surface expression of the 
epithelial stemness marker CD44 and epithelial cell adhesion molecule (EpCAM) 
(Hufbauer et al. 2013). Interestingly, α3β1 is also confined to the stem cells in the 
epidermis and co-immunoprecipitates with CD44 and EpCAM (Jones et al. 1995, 
Schmidt et al. 2004). To determine, whether the increased cell surface levels of integrin 
α3 chain can be associated with stem cell-like traits, cells were analysed by FACS 
analysis for CD44, EpCAM and a3. The top 10% of total control cells analysed for 
CD44 and EpCAM were gated and termed CD44high and EpCAMhigh. The 8E7-positive 
cells revealed a higher CD44high / EpCAMhigh population of about 25% (*p=0.0158, 
figure 34 A). When analysing the CD44high / EpCAMhigh population for α3 chain, an 
increase from 10% in the control cells to 21% in the 8E7-positive cells was observed 
(***p<0.001, figure 34 B).  
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Figure 34. Stem cell-like properties of 8E7 positive cells correlate with increased α3 cell surface 
localisation. (A) For FACS analysis, the total cell population of N/TERT-8E7 and control cells was 
stained for CD44 and EpCAM. The top 10% of control cells were gated and termed CD44high / EpCAMhigh. 
The bar chart indicates the percentage of CD44high / EpCAMhigh N/TERT-8E7 and control cells. (B) The 
CD44high / EpCAMhigh population was further stained against integrin α3 chain. The bar diagram shows 
the percentage of integrin α3-positive cells of the CD44high / EpCAMhigh population of N/TERT-8E7 and 
control cells. C: control 
 
 
4.3.7 HPV8-E7 increases expression of the ECM protein Fibulin-2  
Integrin α3β1 is one of the major epidermal integrins and is highly expressed in 
epidermal keratinocytes (Watt and Fujiwara 2011). The α3β1 integrin is associated 
with the regulation of cell-autonomous and paracrine functions involved in wound 
healing and skin tumorigenesis (Missan et al. 2014). To characterise the influence of 
integrin α3β1 on the regulation of gene expression in transformed keratinocytes, 
Missan and colleagues recently performed a microarray analysis to identify genes 
regulated by integrin α3β1 in immortalised keratinocytes. This analysis identified 
induced expression of the cellular matrix protein Fibulin-2 by integrin α3β1, which 
contributed to the invasion properties of transformed keratinocytes (Missan et al. 
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2014). In addition, a role for integrin α3β1 in BM stability through the induction of 
Fibulin-2 was identified (Longmate et al. 2014). Fibulin-2 is a cellular matrix protein, 
known to bind to ECM proteins such as laminin and fibronectin, thereby participating 
in the organisation of extracellular supramolecular structures (Kobayashi et al. 2007, 
Kinsey et al. 2008). We therefore asked the question whether 8E7-mediated 
upregulation of integrin α3 chain also affects Fibulin-2 levels. Therefore, Fibulin-2 
protein levels were determined in PHK-8E7 via immunoblotting. Fibulin-2 is 
upregulated in PHK-8E7 cells grown on Matrigel and fibronectin compared to their 
matched controls (figure 35 A). Knockdown of integrin α3 chain in PHK-8E7 cells lead 
to a reduction in Fibulin-2 levels, when grown on fibronectin (figure 35 B). To further 
verify enhanced levels of Fibulin-2 fluorescence staining of OSCs established with 
keratinocytes expressing 8E7 and untreated/treated skin of wt and K14-HPV8-E7ho 
mice was performed. In 8E7-positive OSCs Fibulin-2 expression was increased 
throughout the basal and suprabasal layers of the epidermis compared to a weaker 
signal in the more basal layers of the control culture (figure 35 C). Chronically irradiated 
skin of K14-HPV8-E7ho transgenic mice showed a similar staining of the basal and 
suprabasal layers of the epidermis compared the 8E7 positve OSCs. Weaker 
expression was detected in treated wt skin, whereas the skin of untreated wt and K14-
HPV8-E7ho mice was faintly stained (figure 36). We therefore concluded, that 8E7 
expression also leads to an α3β1-dependent upregulation of Fibulin-2.  
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Figure 35. Elevated levels of Fibulin-2 in the presence of HPV8-E7. (A) Western blot analysis for 
Fibulin-2 of whole protein lysates of PHK-8E7 or control cells grown either on uncoated, Matrigel or 
fibronectin plates. Equal loading was confirmed by immunoblotting for GAPDH. (B) Western blot analysis 
for Fibulin-2 of whole protein lysates of PHK-8E7 and control cells when either transfected with control 
siRNA (si-scr) or si-α3 and grown on fibronectin. Equal loading was confirmed by immunoblotting for 
tubulin (C) Immunofluorescence staining of OSCs established with N/TERT-pLXSN or pLXSN-8E7 
positive cells. Tissue sections were counterstained with DAPI (blue) (dashed line represents BM zone, 
magnification 200x). 
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Figure 36. Elevated levels of Fibulin-2 in chronically irradiated skin of K14-HPV8-E7ho mice. 
Representative immunofluorescence staining for Fibulin-2 on FVB/n wt and K14-HPV8-E7ho transgenic 
mice skin sections. Increased levels of Fibulin-2 were detected in chronically irradiated skin of K14-
HPV8-E7ho mice, weaker levels were also detected in treated skin of wt mice. Tissue was counterstained 
with DAPI (blue) (dashed line represents the BM zone, original magnification 200x).  
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4.4 Reduced affinity of HPV8-E7-L23A to cellular targets   
4.4.1 HPV8-E7-L23A binds with low affinity to PTRF and ATP5B when 
compared to HPV8-E7wt 
To identify cellular interaction partners for 8E7wt, C33a cells were transiently 
transfected with pCMV-8E7wt-FLAG and co-immunoprecipitated cellular proteins were 
analysed by mass-spectrometry. In addition, possible 8E7 interaction partners were 
identified in the yeast-two-hybrid (Y2H) system (Grigat 2004, Eker 2005). Predicted 
targets from both assays are presented in table 2. By comparing the results, the ATP 
synthase, H+ transporting, F1-complex, beta-polypeptide (ATP5B) and the   
polymerase I and transcript release factor (PTRF) were identified as matched targets.  
In order to confirm ATP5B and PTRF as 8E7 binding proteins and to test whether 8E7-
L23A shows a different binding affinity to these proteins, FLAG-Co-IP experiments 
were performed. As shown in figure 37, ATP5B and PTRF could be confirmed as 8E7 
binding proteins. Interestingly, 8E7-L23A showed significantly reduced affinity to these 
cellular proteins (figure 37 B).  
To test whether 8E7 alters ATP5B and PTRF expression in PHK, we next probed total 
cell extracts from PHK-8E7wt and PHK-8E7-L23A, grown on fibronectin, for ATP5B 
and PTRF. Immunoblotting against ATP5B showed no changes in protein expression 
(figure 38). Since PTRF and PTRF-associated protein caveolin-1 are both associated 
with cancer cell invasion (Trimmer et al. 2013, Liu et al. 2014), both markers were 
tested by immunoblotting. Whereas, Caveolin-1 levels were not changed upon 8E7wt 
and 8E7-L23A expression, PTRF showed two protein bands in the 8E7wt lane and a 
very weak expression of the second band in the control and 8E7-L23A-positive 
extracts. In figure 39, immunocytochemical stainings of C33a cells transiently 
transfected with pCMV-FLAG, pCMV-8E7-FLAG and pCMV-8E7-L23A-FLAG 
identified PTRF predominantly in the nucleus. The staining for 8E7wt and 8E7-L23A 
using anti-FLAG antibodies overlapped with PTRF staining in the nucleus. Taken 
together, these results provide the first evidence that 8E7 binds to ATP5B and PTRF 
and that these factors might have a role in keratinocyte invasion.  
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Table 2. Predicted cellular interaction targets of HPV8-E7wt. The results of a yeast-two-hybrid (Y2H) 
assay were compared to the results of the Co-IP/mass spectrometry analysis of C33a cells transiently 
transfected with pCMV-8E7-FLAG or empty vector control. Targets are listed with gene names and 
subcellular localisation. Matches in both assays are indicated in bold red.  
Y2H Co-IP/MS Gene name 
Subcellular 
localisation 
ATP5B ATP5B 
ATP synthase, H+ transporting, F1-
complex, beta-polypeptide 
Mitochondria 
 ATP5A1 
ATP Synthase, H+ Transporting F1 
Complex, Alpha Subunit 1 
Mitochondria 
 ATP5C1 
ATP Synthase, H+ Transporting,  F1 
Complex, Gamma Polypeptide 1 
Mitochondria 
 ATP5F1 
ATP Synthase, H+ Transporting, Fo 
Complex, Subunit B1 
Mitochondria 
 ATP5L 
ATP Synthase, H+ Transporting, Fo 
Complex, Subunit G 
Mitochondria 
MT-CO2  cytochrome c oxidase II Mitochondria 
MT-CO3  cytochrome c oxidase III Mitochondria 
ARFIP1  
ADP-Ribosylation Factor Interacting 
Protein 1 
Mitochondria 
PARP  Poly (ADP-Ribose) Polymerase 1 Mitochondria 
PTRF PTRF 
polymerase I and transcript release 
factor 
Nucleus, cell 
membrane 
NCOA4  nuclear receptor coactivator 4 Nucleus 
BLM  Bloom Syndrome, RecQ Helicase-Like Nucleus 
AP1B1  
Adaptor-Related Protein Complex 1, 
Beta 1 Subunit 
Cytoplasm 
RPL26  Ribosomal Protein L26 Cytoplasm 
 RPL10 Ribosomal Protein L10 Cytoplasm 
 RPL12 Ribosomal Protein L12 Cytoplasm 
 RPL13a Ribosomal Protein L13a Cytoplasm 
 RPL23 Ribosomal Protein L23 Cytoplasm 
 RPL31 Ribosomal Protein L31 Cytoplasm 
 RPLP0 Ribosomal Protein, Large, P0 Cytoplasm 
ALMS1  Alstrom Syndrome Protein 1 Cytoplasm 
GHITM/Derp2  
growth hormone inducible 
transmembrane protein 
Cytoplasm 
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Figure 37. Identification of ATP5B and PTRF as HPV8-E7 binding partners. (A) Left blots: 
Representative input immunoblots of whole protein lysates of C33a cells either transfected with pCMV-
FLAG empty vector or pCMV-8E7-FLAG and pCMV-8E7-L23A-FLAG. Equal loading was confirmed via 
immunoblotting for tubulin. Right blots: Cell extracts were incubated with M2-FLAG agarose beads and 
co-immunoprecipitated PTRF and ATP5B bound to FLAG-8E7 was detected by immunoblotting with 
specific antibodies. The expression of FLAG-8E7 was confirmed by a Western blot analysis against the 
FLAG. (B) Binding affinity of PTRF and ATP5B to 8E7wt and 8E7-L23A was determined by protein band 
quantification. Binding affinity of 8E7wt was set as 100%.  
 
 
Figure 38. Expression levels of ATP5B, PTRF and 
Caveolin-1 in PHK-8E7wt and 8E7-L23A. Representative 
immunoblots of total cell extracts from PHK-8E7wt and PHK-
8E7-L23A probed against ATP5B, PTRF and Caveolin-1. 
Equal loading was confirmed via immunoblotting against 
tubulin. 
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Figure 39. PTRF and 8E7wt/L23A co-localise in the nucleus of C33a cells. Representative images 
of immunocytochemical stainings of C33a cells transiently transfected with pCMV-FLAG, pCMV-8E7-
FLAG or pCMV-8E7-L23A-FLAG were stained against PTRF (green) and 8E7wt or 8E7-L23A (red). 
Immunocytochemical staining with an α-FLAG antibody was performed to visualise 8E7. The 8E7wt and 
8E7-L23A protein is predominantly located in the nucleus, whereas a light staining is also present in the 
cytoplasm. Nuclear HPV8-E7 overlaps with expression of PTRF. Cells were counterstained with DAPI 
(blue) (original magnification 1000x). 
 
 
4.4.2 Modulation of mitochondrial respiratory capacity by HPV8-E7 
ATP5B is a subunit of the mitochondrial ATP synthase, which catalyses ATP synthesis 
during oxidative phosphorylation (Hjerpe et al. 2013). To confirm localisation of 8E7 at 
the mitochondria, C33a cells were transfected either with pCMV-8E7-FLAG, pCMV-
8E7-L23A-FLAG or empty vector control and active mitochondria were stained with 
MitoTracker prior immunocytochemistry. After fixation, the cells were stained against 
8E7 by using an anti-FLAG antibody and a corresponding fluorescently labelled 
secondary antibody. Figure 40 shows that 8E7wt and 8E7-L23A are predominantly 
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localised in the nucleus, however, they also co-localise to mitochondria in the 
cytoplasm. In addition, co-immunofluorescence staining verified co-localization of 
ATP5B with 8E7wt and 8E7-L23A (figure 41). 
 
 
Figure 40. HPV8-E7 is expressed in the nucleus and cytoplasm and overlaps with mitochondrial 
staining. Representative images of C33a cells stained for mitochondria (green) by using a MitoTracker 
(MT) dye and against HPV8-E7 using an α-FLAG antibody (red). The top row shows the staining of 
empty C33a cells fixed after 48h. C33a cells were transiently transfected with pCMV-FLAG, pCMV-8E7-
FLAG or pCMV-8E7-L23A-FLAG, stained for mitochondria after 48h and fixed with 4% 
paraformaldehyde. Immunocytochemical staining with an anti-FLAG antibody was performed to 
visualise HPV8-E7. The 8E7wt and 8E7-L23A protein is predominantly located in the nucleus, whereas 
a light staining is also present in the cytoplasm. The cytoplasmic 8E7 staining overlaps in some areas 
with the mitochondrial staining. Cells were counterstained with DAPI (blue) (magnification 1000x).  
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Figure 41. ATP5B and HPV8-E7 are co-localised in the cytoplasm. Representative images of 
immunocytochemical stainings of C33a cells transiently transfected with pCMV-FLAG, pCMV-8E7-
FLAG or pCMV-8E7-L23A-FLAG against ATP5B (green) and 8E7 (red). The top row shows the staining 
of empty vector C33a cells fixed after 48h, only positive for ATP5B. Immunocytochemical staining with 
an α-FLAG antibody was performed to visualise 8E7. The 8E7wt and 8E7-L23A protein is predominantly 
located in the nucleus, whereas a light staining is also present in the cytoplasm. The cytoplasmic 8E7 
stainings overlap in some areas with the staining against ATP5B. Cells were counterstained with DAPI 
(blue) (original magnification 1000x).  
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Since, in addition to ATP5B, additional mitochondrial proteins have also been predicted 
as potential 8E7 binding proteins (see table 2), we next asked the question whether 
the mitochondrial respiratory chain performance is affected by E7. Therefore, N/TERT-
8E7wt cells were analysed using the Seahorse XFe96 Extracellular Flux Analyser. 
Preliminary data of one experiment, performed in triplicate, could only be performed 
with cells cultured in RM+ media. In the Seahorse XF Mito Stress Test the basal 
respiration, the spare respiratory capacity, proton leak and ATP production were 
determined (figure 42 A). These parameters represent different functions of 
mitochondrial respiration, which can be determined by the oxygen consumption rate 
(OCR) during the specific experimental phases. Basal respiration was found to be 
slightly higher in N/TERT-8E7 compared to control cells (figure 42 B and C) and 
associated also with a slight increase in total ATP production. The addition of FCCP 
led to unhindered electron flow and maximal oxygen consumption of the cells allowing 
maximal respiration. The difference between maximal and basal respiration, named 
spare respiratory capacity, was found to be almost zero. Interestingly, a strong 
increase in spare respiratory capacity could be determined for N/TERT-8E7 cells 
(figure 42 B and C), suggesting that E7 might be able to drive the cell into a state where 
it can respond to increased energy demand. 
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Figure 42. HPV8-E7 cells show modified mitochondrial functions. (A) Schematic diagram of the 
course of the Seahorse XF Cell Mito Stress Test. This assay uses the oxygen consumption rate (OCR) 
to analyse parameters of mitochondrial function. Different modulators (oligomycin, FCCP and 
rotenone/antimycin A) are serially added to the cells in the XF 96-well microtiter plate to modulate 
respiration by targeting the electron transport chain in the mitchondria determining basal respiration, 
ATP production, maximal respiration and non-mitochondrial respiration. The level of non-mitochondrial 
respiration is substracted from all parameter. (B) First results (n=1 in triplicate) of N/TERT-8E7 (grown 
in RM+ media) and control cells analysed by Cell Mito Stress assay. (C) Bar charts show OCR levels 
representing specific parameters of the mitochrondrial respiratory performance. All measurements were 
normalised to protein levels. 
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4.4.3 HPV8-E7wt and HPV8-E7-L23A differ in their binding affinity to 
phospholipids 
4.4.3.1 HPV8-E7wt binds to the phospholipid phosphatidylserine 
Recent studies indicated that phosphatidylinositides and their metabolizing enzymes 
are associated with various pathophysiological disorders, including cancer. They 
control various aspects of cell biology in part by interacting with and regulating 
downstream protein partners (Fiume et al. 2015). 
To analyse possible phospholipid binding properties of 8E7, a protein-lipid overlay 
assay system on PIP-Strips (Echelon Biosciences, Salt Lake City, USA) was used. 
This assay has 15 different phospholipids spotted on a nitrocellulose membrane, which 
was overlaid with total cell extracts of C33a cells either transfected with pCMV-8E7wt-
FLAG, pCMV-8E7-L23A-FLAG or empty vector control. FLAG antibodies were used to 
develop the overlay assay. 8E7wt showed a strong binding specificity to 
phosphatidylserine (PS), which was significantly reduced in strength for 8E7-L23A 
(figure 43).  
 
Figure 43. Identification of phosphatidylserine as HPV8-E7 binding phospholipid. (A) 
Representative image of PIP-Strips incubated with total cell extracts of C33a cells transiently transfected 
with pCMV2-FLAG, pCMV2-8E7-FLAG or pCMV2-8E7-L23A-FLAG. Membranes were washed and 
lipid-bound 8E7-FLAG and 8E7-L23A-FLAG was detected with a monoclonal anti-FLAG antibody. 
Binding affinity for 8E7-L23A compared to 8E7 was reduced by 50%. (B) Schematic diagram of the 
nitrocellulose membrane with immobilised phospholipids in 100 picomole spots (PIP-Strip) is shown, 
with the positive result for 8E7-FLAG to bind to phosphatidylserine. LPA: lysophosphatidic acid; LPC: 
lysophosphocholine; PI: phosphatidylinositol; PI(3)P: phosphatidylinositol (3) phosphate, PI(4)P: 
phosphatidylinositol (4) phosphate, PI(5)P: phosphatidylinositol (5) phosphate  PE: 
phosphatidylethanolamine; PC: phosphatidylcholine; SIP: sphingosine-1-phosphate; PI(3,4)P2: 
phosphatidylinositol (3,4) biphosphate, PI(4,5)P2: phosphatidylinositol (4,5) biphosphate, PI(3,4,5)P3: 
phosphatidylinositol (3,4,5) triphosphate, PA: phosphatidic acid; PS: phosphatidylserine.  
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4.4.3.2 HPV8-E7 induces PI(4,5)P2 production probably by PIP5KIγ 
Our group recently demonstrated that HPV8-E6 expression leads to the increase of 
nuclear phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) with a potential clinical 
significance for HPV induced cancer development (Marx and Akgül, unpublished). 
PI(4,5)P2 is a membrane phospholipid, which is indirectly involved in the process of 
cell invasion (Wu et al. 2011, Goni et al. 2014). PI(4,5)P2 is synthesised in mammalian 
cells either due to the phosphorylation of phosphatidylinositol-4-bisphosphate (PI5P) 
by phosphatidylinositol-5-phosphate-4-kinase type II (PIP4KII) or, primarily, by type I 
phosphatidylinositol 4-phosphate 5-kinase (PIP5KI), which phosphorylates 
phosphatidylinositol-4-phosphate (PI(4)P). Three isoforms of PIP5KI, namely PIP5KI-
α, -β and –γ, exist in humans (Wu et al. 2011).  
 
Figure 44. Increased PI(4,5)P2 levels in HPV8-E7 positive OSCs. Representative 
immunofluorescence staining of OSCs established with keratinocytes expressing either 8E7 or empty 
vector control against PI(4,5)P2 (green). Increased cytoplasmic levels of PI(4,5)P2 were detected for 8E7 
positive OSCs compared to control. Tissue was counterstained with DAPI (blue) (magnification 200x). 
 
Although 8E7 did not bind to PI(4,5)P2 in the PIP-Strip assay, we still analysed whether 
elevated levels of PI(4,5)P2 can be found in 8E7 positive keratinocytes. Therefore, 
immunofluorescence staining against PI(4,5)P2 on OSCs and murine skin was 
performed. The regenerated epithelium of OSCs established with N/TERT-8E7 
expressing keratinocytes showed indeed elevated levels of cytoplasmic PI(4,5)P2, 
compared to empty vector control (figure 44). For untreated K14-HPV8-E7ho skin, only 
a fussy fluorescent signal was determined. However, chronically irradiated skin of K14-
HPV8-E7ho mice showed strongly elevated levels of cytoplasmic PI(4,5)P2 throughout 
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the suprabasal layers of the skin, whereas chronically irradiated wt skin showed only 
neglectable changes (figure 45). Unfortunately, no data could be generated for the 
effect of 8E7-L23A on PI(4,5)P2 due to the lack of OSCs and transgenic skin.  
 
 
Figure 45. Elevated levels of PI(4,5)P2 in UV treated skin of K14-HPV8-E7
ho mice. Representative 
immunofluorescence staining of untreated and UV treated skin of wt and K14-HPV8-E7ho mice against 
PI(4,5)P2 (green). Increased levels of PI(4,5)P2 were detected in basal and suprabasal layers of treated 
K14-HPV8-E7ho skin, located in the cytoplasm. Tissue was counterstained with DAPI (blue) 
(magnification 200x).  
 
To determine whether increased PI(4,5)P2 levels can be associated with changes in 
PIP5KI expression levels, qRT-PCRs were performed for N/TERT-8E7 grown on 
Matrigel and fibronectin. In figure 46, expression levels for PIP5KIγ were measured in 
N/TERT-8E7 cells and significant increases were detected for cells grown on Matrigel 
(1.5 fold) and fibronectin (2-fold) compared to control cells. The 2-fold increase of 
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PIP5KIγ in N/TERT-8E7 on fibronectin was reduced to 0.5-fold, in N/TERT-8E7-L23A 
cells grown on fibronectin. Taken together, these data indicate that enhanced levels of 
PI(4,5)P2 and PIP5KIγ may be involved in 8E7-mediated invasion. 
 
Figure 46. Increased expression of PIP5KIγ in HPV8-E7 positive keratinocytes. Expression levels 
of PIP5KIγ were determined via qRT-PCR in N/TERT-8E7, N/TERT-8E7-L23A and empty vector cells 
grown on plastic, Matrigel or fibronectin for 4 days. On the left, a significant increase in PIP5KIγ 
expression levels was determined in N/TERT-8E7 cells either grown on Matrigel (increase to 1.5-fold, 
**p=0.0094) or fibronectin (increase to 2-fold, **p=0.0057) compared to their matched controls. The right 
image shows that the PIP5KIγ mRNA levels were reduced in N/TERT-8E7-L23A cells to 0.5-fold when 
grown on fibronectin (**p=0.0057). Relative expression levels of the corresponding controls were set as 
1. MG: Matrigel, FN: fibronectin, C: control 
 
4.5 Effect of HPV8-E7wt and HPV8-E7-L23A on HPV8 replication 
To finally analyse the effect of 8E7-L23 on the viral life cycle, we analysed its effect on 
DNA replication. In a previous study, Iftner and colleagues demonstrated that 
replication efficiency was higher in the presence of 8E7 leading to the suggestion that 
8E7 positively acts on viral replication (Iftner et al. 1988).  
To test whether 8E7-L23A has a different effect on HPV8 replication compared to 
8E7wt, we mutated the HPV8 genome containing plasmid pVE34 (Steger et al. 1990) 
and transfected pVE34wt and pVE34-L23A in RTS3b cells to allow transient 
replication. After 72h, episomal DNA was extracted, halved whereby one half was 
digested with DpnI to cut the transfected bacterially generated input DNA. The number 
of replicated pVE34 was quantified by using HPV8-E2 specific PCR primers. 
Interestingly, the number of pVE34-L23A plasmids increased 5-fold, when compared 
to pVE34wt (figure 47). This led to the conclusion that the position L23 in 8E7 is not 
only crucial for invasion, but also surprisingly impeding genome replication.  
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Figure 47. Increased replicative capacity of HPV8-E7-L23A 
determined in transient replication assays. RTS3b cells were 
transfected either with pVE34 (including the whole HPV8 genome) or with 
pVE34-L23A, harvested after 72h and qRT-PCR was performed on 
episomal DNA to test the number of replicates. A 5-fold increase in the 
number of replicates was determined for cells transfected with pVE34-
L23A compared to the pVE34wt.   
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5. Discussion 
 
To unravel the oncogenic mechanism of HPV8-E7 in vitro and in vivo, different 
experimental approaches were used analysing the effects of ECM proteins and 
coupled downstream processes on keratinocyte invasion. The K14-HPV8-E7 
transgenic mice, generated within this study, spontaneously developed skin tumours 
characterised by keratinocyte hyperplasia in 43% of animals within the observation 
period of 28 months, although E7 mRNA levels were relatively low. A single UV 
treatment was successfully used in previous studies of K14-HPV8-E2, K14-HPV8-E6 
and K14-HPV8-CER transgenic animals (Schaper et al. 2005, Pfefferle et al. 2008, 
Marcuzzi et al. 2009) to induce papilloma growth by activating the human K14-
promoter and increasing oncoprotein levels (Hufbauer et al. 2010b). Six UV irradiations 
led to an increase of HPV8-E7 mRNA levels and to the development of flat to polypus 
skin tumours, characterised by strong hyperplasia and areas with carcinoma in situ. 
Interestingly, no papilloma formation was observed in E7 mice, which was a strong 
characteristic of the E2, E6 and CER animals. We speculate that the E7-associated 
effects within the CER animals could not be specified after UV irradiation due to fast 
E6-associated papilloma formation. The observation that E7-mediated severity of 
tumour grade was dose-dependent is in line with the previously described association 
between E2-mRNA levels and tumour formation rate in K14-HPV8-E2 mice, leading to 
the suggestion that a certain threshold of oncogene expression is critical for tumour 
formation (Pfefferle et al. 2008). The establishment of the K14-HPV8-E7 transgenic 
mouse line was associated with difficulties allowing the generation of only one low-
level expressing founder animal. In addition, only minor differences of E7 expression 
levels were determined between hemizygous and homozygous animals. For HPV16, 
it could be demonstrated that E7 is able to increase apoptosis (Stöppler et al. 1998, 
McLaughlin-Drubin and Münger 2009). Therefore, it might be suggested that high 
levels of E7 are associated with lethality and thereby represent some kind of natural 
selection for low E7 levels. However, the development of carcinoma in situ in mice with 
low E7 expression levels clearly indicates a strong carcinogenic potential of this viral 
oncoprotein. Nevertheless, it remains to be verified that metastatic SCCs can develop 
in E7-positive mice and whether mutagenic effects of UV may have contributed to 
carcinoma in situ formation. In line with observations of the K14-HPV8-E7 mice, K14-
HPV38-E6/E7 (another betaHPV type) mice developed only minor skin alterations after 
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single UV treatment, but actinic keratosis and SCCs after chronic UV irradiation 
(Viarisio et al. 2011). Recent case control studies led to the suggestion that betaHPV 
infection associated with SCC development in the general population implicates its role 
in cancer initiation rather than its maintenance, which was strengthened by increased 
prevalence and viral loads of betaHPV in precancerous lesions (Weissenborn et al. 
2005, Iannacone et al. 2014, Howley and Pfister 2015). Therefore, to strengthen the 
fact that HPV8 is involved in SCC development due to its presence in the early stages 
of tumour initiation, the generation of inducible transgenic mouse models for HPV8 
should be considered. In addition, an inducible HPV8-E7 system will probably solve 
the difficulties to establish transgenic mouse lines with higher E7 expression levels. 
The quantitative and time-controlled expression of HPV8 early proteins will provide 
further evidence for the role of HPV8 in skin cancer initiation and development. 
 
The invasive phenotype of cells is the result of a gradual process including several 
intermediate steps, including changes in cell-cell interactions. During the dissolution of 
cell-cell interactions in EMT, β-catenin is no longer able to interact with E-cadherin and 
is either degraded or protected from degradation in response to Wnt signalling 
(Lamouille et al. 2014). OSCs established with HPV5-E7 and HPV8-E7 showed a 
strong overexpression of cytoplasmic and mainly membrane-tethered β-catenin levels 
in the granular layer. However, elevated levels of β-catenin could not be associated 
with the activation of the canonical Wnt pathway. This disagrees with the findings of β-
catenin relocalisation from the plasma membrane to the nucleus in the presence of 
HPV16-E6/E7 (Uren et al. 2005, Stenner et al. 2011). However, in line with our 
observation, increased β-catenin levels were localised at plasma membranes in 
respiratory papilloma caused by HPV6 or 11 (Lucs et al. 2014). In addition, β-catenin 
is also important for the organisation of the actin cytoskeleton by the interaction with 
α-catenin, thereby recruiting actin to the plasma membrane (Baum and Georgiou 
2011). Enhanced actin staining of HPV5-E7 and HPV8-E7 positive tissues may 
indicate that the E7 proteins disturb β-catenin functions in the differentiation-dependent 
anchoring of actin-filaments to cell junctions. This is in association with the 
identification of deregulated proteins involved in the organisation of the actin 
cytoskeleton, which were determined in HPV8-E7 expressing cells by 2D-DIGE 
experiments (Akgül et al. 2009).  
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The interaction between occludin and ZO-1 is important to maintain the structure of 
tight junctions, in which occludin is linked to the actin cytoskeleton. The tight junction 
protein ZO-1 is also found outside of distinct membrane structures, suggesting tight 
junction-structure-dependent and structure-independent functions (Brandner et al. 
2015). ZO-1 is described to be downregulated in most cancer tissues, allowing 
increased motility (Kalluri and Weinberg 2009). However, first evidence of upregulated 
expression levels of ZO-1 in cancer were identified in human melanoma, in which 
increased ZO-1 expression contributed to the oncogenic behaviour (Smalley et al. 
2005), which supports our finding of increased levels of ZO-1 in association with HPV5-
E7 and HPV8-E7 expression. A broader expression pattern of ZO-1 in epidermal layers 
has previously been shown in skin SCCs, which suggests that ZO-1 contributes to 
tumour progression, largely in a tight junction independent manner (Morita et al. 2004, 
Brandner et al. 2015). Thus HPV5-E7 and HPV8-E7 induced ZO-1 levels may be 
involved in cellular processes enabling keratinocyte invasion, whereby the classical 
downregulation of ZO-1 during EMT does not play a role. Elevated expression of β-
catenin and ZO-1 in the skin of transgenic HPV8 mice and EV lesions supports a 
possible clinical relevance of these data. Taken together, changes in β-catenin and 
ZO-1 expression in betaHPV-positive epithelia may disturb adherens and tight junction 
composition, thereby unbalancing cell homeostasis and contributing to HPV5 and 
HPV8 mediated carcinogenic processes. This is in line with the description of partial 
EMT, that invading cells do not necessarily need to possess all EMT characteristic 
changes (Lamouille et al. 2014).  
 
Cell invasion is not only achieved by the dissolution of cell-cell adhesion, but also due 
to the reorganisation of cell-ECM interactions, whereby the loss of epithelial cell 
characteristics is associated with the gain of mesenchymal-like properties, 
representing another hallmark of cancer (Guan 2015, Aneta et al. 2016). Migrating 
cells utilise different modes of cell migration, including collective and single cell 
invasion, which are associated with differently expressed epithelial and mesenchymal 
cell characteristics (Aneta et al. 2016). The expression of HPV8-E7 led to a reduction 
of E-cadherin in the suprabasal cell layers of OSCs. This observation is in line with a 
weak expression of E-cadherin in skin SCCs and their precursor lesions (Kurtz et al. 
2006, Margulis et al. 2006) and further corroborates to recent data showing that 16E7 
decreased E-cadherin levels and induced the expression of N-cadherin in PHK grown 
Discussion 
107 
 
as monolayer cultures (Hellner et al. 2009). In contact with ECM proteins, 8E7 probably 
induces different modes of invasion. Without inducing a cadherin switch, 8E7 might 
promote collective cell invasion in contact with collagen IV and laminin, whereby 8E7-
positive cells, when grown on fibronectin induce a cadherin switch and EMT. The 
presence of fibronectin has an important effect on the ability of the epidermal 
keratinocytes to migrate (Juhasz et al. 1993), whereby adhesion of cancer cells to 
fibronectin is known to enhance their tumorigenicity (Han and Roman 2006). The EMT-
mediated invasion of 8E7 cells may be associated with single-cell invasion, a mode 
accepted to increase metastatic efficiency of a cancer (Krakhmal et al. 2015). 
The ECM protein fibronectin is organised into a fibrillary network through direct 
interactions with different cell surface receptors, including integrins, and is secreted 
from different cells as a soluble, inactive, disulphide-bonded dimer, responsible for 
matrix stability (Mao and Schwarzbauer 2005, Sabatier et al. 2009). Different 
fibronectin isoforms are generated by alternative splicing containing an extra domain 
A (EDA) or B (EDB). FibronectinEDA has been implicated in the regulation of wound 
healing and is more potent in promoting cell spreading and migration irrespective of 
the presence or absence of EDB (Grinnell 1984, Manabe et al. 1997, Sun et al. 2014). 
8E7 stimulates fibronectin and fibronectinEDA expression and secretion in 
keratinocytes, as well as fibronectin expression in fibroblasts, both of which may have 
contributed to the deposition of fibronectin in the peritumoral stroma of betaHPV-
positive skin SCCs. Interestingly, 8E7 was able to increase fibronectin promoter 
activity, which was reduced to normal levels due to a mutated Sp1 site of the fibronectin 
promoter. It needs to be clarified, whether E7 controls fibronectin promoter activity in 
cis, in a complex with Sp1, or in trans, through controlling Sp1 levels by the amount of 
pRB (Kim et al. 1992, Rey et al. 2000, Akgül et al. 2007). However, currently it cannot 
be excluded that other transcription factors are involved in E7-mediated fibronectin 
promoter regulation. In line with these observations it could be shown that 16E7 and 
18E6/E7 can also stimulate fibronectin expression (McCormack et al. 1997, Hellner et 
al. 2009). In 18E6/E7-immortalised keratinocytes fibronectin expression was paralleled 
by increased expression and activity of the FAK, which is an early mediator of integrin-
mediated signalling regulating cell motility and proliferation (McCormack et al. 1997, 
Chen et al. 2010). 
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Changed cell adhesion to the ECM, in conjunction with integrin interaction, is an 
important regulator of keratinocyte invasion, whereby upregulated integrin subunits 
can be used as an indicator for invasive cells (Pawelek and Chakraborty 2008). 
Therefore, a further link to invasion is the ability of 8E7 to induce the cell surface levels 
of the integrin α3 chain. The mechanistic link is supported by the effect of siRNA-
mediated α3 knockdown, depleting the invasive character of 8E7-positive 
keratinocytes. Furthermore, the invasion-defective mutant 8E7-L23A showed reduced 
levels of integrin α3 on the cell surface. Therefore, a role of integrin α3 chain in 8E7-
mediated invasion could be confirmed. Numerous studies using primary or 
immortalised keratinocytes have identified a role of integrin α3β1 in a range of cell 
functions including tumour progression, ECM organisation and invasion (Margadant et 
al. 2010, Aggarwal et al. 2014, Missan et al. 2014). The involvement of α3β1 in skin 
tumorigenesis has recently been demonstrated in vivo in epidermal-specific deletion 
leading to reduced tumour development. However, tumours which developed in those 
mice progressed more rapidly to invasive carcinoma, indicating a requirement for 
increased α3β1 cell surface location in tumour initiation and early growth, and reduced 
integrin α3β1 levels during the progression of skin SCC at later stages. In addition, in 
vitro analysis of cell lines representative of several stages of skin carcinogenesis 
described that integrin α3 chain is inversely correlated with the progression stage 
(Sachs et al. 2012). Although integrin α3β1 is known to bind predominantly to     
laminin-5, it also binds weaker to collagen IV and fibronectin (DiPersio et al. 1997). A 
previous study described integrin α3β1 as a trans-dominant inhibitor of the main 
fibronectin receptor integrin α5β1 in non-migratory keratinocytes, whereby a migratory 
mode can be reached by altered interactions of laminin-5 with integrin α3β1, due to 
conformational changes in both proteins, relieving trans-dominant inhibitory functions 
on integrin α5β1 (Hodivala-Dilke et al. 1998). Whether high levels of α3β1 lead to 
conformational changes of laminin-5 and thereby drive E7 cells into a migratory mode 
needs to be determined. Therefore, increased levels of integrin α3β1 in presence of 
8E7 enable a stronger migratory phenotype, inhibiting other integrins on the cell 
surface, which occurs simultaneously with increased activation of the fibronectin 
promoter by 8E7. 
EMT has been identified to generate cells that either exhibit stem-cell like properties 
or are poised to enter into the stem cell state. This acquisition of stem cell-like 
properties holds important implications for the successful completion of the invasion-
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metastasis cascade by disseminated cancer cells (Mani et al. 2008, Tam and Weinberg 
2013). A universal surface marker for epithelial stem cells has not been identified yet. 
However, in cutaneous SCC cell lines, the epithelial cancer stem cell population can 
be identified by high cell surface expression of CD44 and EpCAM (Biddle et al. 2011). 
A recent study of our group could show that 8E7 confers cancer stem cell-like traits on 
keratinocytes, which could be attributed to the pool of CD44high/EpCAMhigh cells 
(Hufbauer et al. 2013). Here, the CD44high/EpCAMhigh cell population of 8E7-positive 
cells showed a higher proportion of integrin α3 chain positivity. This finding suggests 
that 8E7 may generate invasive malignant stem-like cells through integrin α3β1 cell 
surface presentation.  
A wide range of potential mechanisms, whereby integrins may regulate tumour cell 
behaviour is known. Interestingly, Missan and colleagues demonstrated that SV40 
largeT antigen transformed keratinocytes show high cell surface levels of α3β1, which 
promotes expression of Fibulin-2 and thereby promoted keratinocyte invasion. Fibulins 
are a family of extracellular glycoproteins, with the largest protein, Fibulin-2, localised 
at basement membranes, elastic fibres and other connective tissue structures. 
Furthermore, Fibulins possess overlapping binding sites for several BM proteins, 
including fibronectin, participating in the formation of supramolecular structures (Timpl 
et al. 2003). Fibulin-2 has been described as a promoter of malignancy and as tumour 
suppressor (Schiemann et al. 2002, Ramaswamy et al. 2003, Gallagher et al. 2005). 
In adenocarcinoma, Fibulin-2 was found to be associated with metastasis and with 
malignant progression of lung adenocarcinoma (Ramaswamy et al. 2003, Baird et al. 
2013). 8E7 was able to induce increased levels of Fibulin-2, which was verified in 8E7 
positive OSCs and in the skin of K14-HPV8-E7 mice. Knockdown experiments of 
integrin α3 chain verified that 8E7-mediated upregulation of Fibulin-2 was α3-
dependent. Therefore, one might suggest that the mechanism of integrin α3-mediated 
induction of Fibulin-2 and the resulting invasion may share functional similarities in 
SV40 largeT antigen and HPV8-E7 positive keratinocytes. Surprisingly, increased 
levels of Fibulin-2 were located in basal and suprabasal layers of the epidermis, rather 
than in the ECM, which might lead to the suggestion that 8E7 is able to block        
Fibulin-2 secretion from keratinocytes. Measuring invasion of 8E7 positive cells on a 
fibronectin matrix and knocked down Fibulin-2 expression will clarify the role of    
Fibulin-2 in E7-mediated invasion. 
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The position L23, located few amino acids in front of the conserved pRB binding motif 
LXCXE (figure 48), has so far not been described to be involved in any protein-protein 
interactions. Compared to the list of 16E7 interaction partners, only a few interacting 
proteins are known for 8E7. To gain more insight into possible 8E7 molecular 
processes, Y2H and Co-IP/MS experiments led to the identification of ATP5B, 
mitochondrial ATP synthase beta subunit, and PTRF/cavin-1 as E7 interaction factors. 
Mitochondria play a central role in the physiology of eukaryotic cells, whereby 
malfunctioning is implicated in the pathogenesis of different human diseases, including 
cancer (Willers et al. 2010).  
 
 
Figure 48. Schematic diagram of the HPV8-E7 protein and interacting cellular proteins (adapted 
from Münger et al. (2001)). Schematic representation of the HPV8-E7-protein with the CR1, CR2 and 
C-terminal domains. The CR1 and CR2 domains are homologous to the conserved region 1 and 2 of 
Adenovirus E1A protein. The pRB binding site (LXCXE) is located within the CR2 domain. Biochemical 
and/or functional interaction domains with cellular proteins are indicated by blue bars. Green bars 
indicate the nuclear localisation signal (NLS) and the nuclear export signal (NES). The red arrow 
indicates an amino acid exchange leading to the mutational variant HPV8-E7-L23A (Full-length blue 
bar: no specific binding motif was determined; asterisks: newly identified 8E7 interaction partner). 
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To support transformation, differentiation and invasion of malignant cells, cancer cells 
produce ATP mainly via aerobic glycolysis (Phelan et al. 2014). The ATP synthase is 
involved in ATP synthesis during oxidative phosphorylation being a catalyst by creating 
an electrochemical proton gradient across the inner membrane of mitochondria (Senior 
2007). Decreased expression of ATP5B is associated with different types of tumours 
(Willers et al. 2010). Interestingly 8E7-L23A not able to trigger keratinocyte invasion 
showed also weaker affinity to ATP5B, when compared to 8E7wt. Since, we could 
confirm co-localisation of E7 with ATP5B at the mitochondria, we next tested the 
mitochondrial respiratory chain performance of 8E7 cells. Preliminary data suggest that 
8E7 cells have an increased respiratory capacity, which might be used to respond to 
increased energy demands, required during invasive cell growth and probably during 
the viral life cycle.   
PTRF, also known as cavin-1, belongs to the protein family of cavins, which forms 
together with caveolins, a complex network establishing the formation of caveolae. 
Interestingly, PTRF has, like 8E7, a high binding affinity for PS, which promotes the 
incorporation of PTRF into caveolae (Low and Nicholson 2014). Increased expression 
of these proteins has been reported to be associated with the development of different 
diseases and cancer by mediating focal adhesion turnover and FAK stabilization (Urra 
et al. 2012, Faggi et al. 2015). In addition, PI(4,5)P2, PIP5KIγ and fibronectin, all 
upregulated by 8E7, can also target FAK activity during migration (Ling et al. 2007, van 
den Bout and Divecha 2009, Goni et al. 2014) This might envision a scenario at the 
cells leading edge, an area of focal adhesion formation, in which 8E7 may manipulate 
caveolae formation and focal adhesion turnover leading to an enhanced invasive 
capacity of 8E7 positive cells. This scenario can be strengthened by the observation 
that the invasive-defective 8E7-L23A binds weaker to PTRF and does not target 
PIP5KIγ expression. In line with this hypothesis, a previous study demonstrated that 
depletion of PIP5KIγ reduces strength of cell adhesion to fibronectin and thereby 
inhibits invasion of colon cancer cells, which coincided with reduced levels of PI(4,5)P2 
(Wu et al. 2011).  
Additionally to its cell transforming activities, 8E7 is also known to positively influence 
E1/E2-dependent viral replication (Iftner et al. 1989). Interestingly, the HPV8 
replication plasmid containing the 8E7-L23A showed a higher replication efficiency 
compared to E7wt containing vectors. As higher replication rates would probably 
destroy the natural adaptation of HPV8 in the skin by the activation of immune 
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responses, the mutation at position L23 did not become prominent as a result of natural 
selection. Since betaHPV-E7 is expressed in basal as well as differentiating 
keratinocytes within an EV lesion, the characterisation of cellular factors, differentially 
binding to E7wt and E7-L23A (probably factors characterised in figure 48), will shed 
light on the differentiation-dependent maintenance and amplification phases of HPV8 
DNA replication (Haller et al. 1995). 
 
Figure 49. Schematic representation of cellular targets deregulated by 8E7. Red arrows indicate 
new identified interacting cellular targets of HPV8-E7. Blue arrows indicate all cellular targets 
deregulated by HPV8-E7.   
 
The aim of this study was to identify and clarify possible molecular processes involved 
in 8E7-mediated keratinocyte invasion. Several key events of EMT, associated with 
the development of an invasive phenotype, were identified to play an important role in 
the invasive capacity of 8E7-positive keratinocytes. The transgenic mouse model, 
despite low 8E7 expression levels, was useful to strengthen the oncogenic potential of 
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8E7. This study led to new insights into changed ECM protein composition induced by 
8E7, whereby the understanding of the role of 8E7-targeted cellular pathways would 
probably help to develop new therapeutic strategies against betaHPV associated skin 
cancer.  
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Abstract 
 
High-risk patient groups, such as immunosuppressed organ-transplant recipients and 
patients with the inherited skin disease Epidermodysplasia verruciformis, exhibit 
cancerisation of the skin, which are positive for human papillomaviruses (HPV) of the 
genus beta (e.g. HPV8). Transgenic mouse models, expressing either all HPV8 early 
proteins (E1, E2/E4, E6, E7) or E2 and E6 individually, develop skin papillomas with 
varying degrees of dysplasia and squamous cell carcinoma. The specific contribution 
of the viral E7 protein to tumour formation and the molecular mechanism for HPV8 
induced keratinocyte invasion was not known. During this study, a transgenic mouse 
model expressing the HPV8-E7 oncoprotein in the murine epidermis under the control 
of the keratin-14 promoter was generated and proved a carcinogenic potential of 
HPV8-E7 in vivo. It could previously be shown that HPV8-E7 induces keratinocyte 
invasion in organotypic skin cultures (OSCs), which were based on de-epidermalised 
dermis, whereby invasion could not be triggered in OSCs based on collagen type I. 
Therefore, it was hypothesised that the composition of the extracellular matrix (ECM) 
enables HPV8-E7 mediated keratinocyte invasion. We now could show, that the 
adherens and tight junction proteins β-catenin and zona occludens-1 are strongly 
upregulated in E7 positive keratinocytes in OSC, in the skin of HPV8-E7 transgenic 
mice and in betaHPV positive human skin lesions. When cells were grown on a 
fibronectin matrix, E7-positive keratinocytes acquired an invasive cell phenotype which 
was accompanied by an epithelial-mesenchymal-transition mediated cadherin switch 
leading to E-cadherin down-, and N-cadherin up-regulation. In addition, E7-positive 
keratinocytes displayed enhanced fibronectin expression and secretion and stimulated 
dermal fibroblasts to express fibronectin. When grown on fibronectin, E7-positive 
keratinocytes exhibited increased cell surface levels of the integrin α3 chain. Functional 
blocking of α3 using siRNA confirmed α3 as a critical molecule sufficient to induce E7-
mediated invasion. This mechanistic link was further supported by the fact that the 
invasion-deficient E7-mutant L23A did not target cell surface levels of α3. Furthermore, 
high α3 levels were coupled with an upregulation of the fibronectin-associated ECM 
protein Fibulin-2, known to mediate a transformed cell phenotype. Using E7wt and E7-
L23A positive cell extracts and Co-IP/mass spectrometric analysis the cellular factors 
ATP5B, PTRF/cavin-1 and phosphatidylserine could be identified as possibly important 
for keratinocyte invasion.  
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These findings highlight the importance of cell-cell and epithelial-ECM interactions 
required for keratinocyte invasion and provide mechanistic evidence for the role of 
betaHPV in skin carcinogenesis. 
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Zusammenfassung  
 
Sowohl Patienten mit der erblichen Hautkrankheit Epidermodysplasia verruciformis, 
als auch immunsuppremierte Organtransplantatempfänger stellen Patientengruppen 
dar, die ein erhöhtes Risiko zur Bildung von Hautkrebs vorweisen. Diese Karzinome 
sind positiv für humane Papillomviren des Genus beta, wie z.B. HPV8. Transgene 
Mausmodelle, die entweder alle frühen Proteine von HPV8 (E1, E2/E4, E6, E7) oder 
nur das E2 oder E6 Protein exprimieren, entwickeln Papillome unterschiedlicher 
Schweregrade und Plattenepithelkarzinome der Haut. Der spezifische Einfluss des 
viralen E7 Proteins auf die Tumorentwicklung und der molekulare Mechanismus der 
HPV8 induzierten Keratinozyten-Invasion war bisher nicht bekannt. In dieser Studie 
wurde ein transgenes Mausmodel generiert, welches das HPV8-E7 Protein unter der 
Kontrolle des Keratin-14 Promotors exprimiert, womit ein karzinogenes Potential für 
E7 in vivo nachgewiesen werden konnte. In vitro konnte bisher gezeigt werden, dass 
HPV8-E7 positive Keratinozyten nur in organotypischen Hautkulturen invadierten, die 
auf de-epidermierter Dermis basierten, wohingegen auf Kollagen I basierter Matrix 
keine Invasion beobachtet werden konnte. Diese Befunde führten zur Hypothese, dass 
Bestandteile der extrazellulären Matrix die HPV8-E7 induzierte Keratinozyten-Invasion 
ermöglicht. Wir konnten nun zeigen, dass die Adhesion- und Tight-Junction Proteine 
β-catenin und Zona Occludens-1 in E7 positiven organotypischen Hautkulturen, sowie 
in HPV8-E7 transgener Maushaut als auch in betaHPV-positiven humanen 
Hautläsionen stark hochreguliert sind. Nach der Kultivierung von Keratinozyten auf 
Fibronektin, entwickelten E7 positive Zellen einen invasiven Zellphänotypus, der mit 
einer epithelialen-mesenchymalen Transition und einem ‚Cadherin -Switch‘ verbunden 
war, was zu einer Runterregulierung von E-Cadherin und einer Hochregulierung von 
N-Cadherin führt. Außerdem zeigten E7-positive Keratinozyten eine erhöhte 
Fibronektin-Expression sowie Sekretion und stimulierten die Fibronektin-Expression in 
dermalen Fibroblasten. Auf einer Fibronektin-Matrix kultivierte E7 positive 
Keratinozyten wiesen ein erhöhtes Level der Integrin α3 Untereinheit auf der 
Zelloberfläche auf. Die Runterregulation des Integrin α3 durch siRNA verdeutlichte die 
entscheidende Rolle von α3 in der E7 induzierten Invasion. Diese mechanistische 
Verknüpfung wurde durch die Tatsache bekräftigt, dass die Invasions-defiziente E7-
L23A Mutante keine veränderte Integrin α3 Menge auf der Zelloberfläche zeigte. Des 
Weiteren war eine erhöhte Menge von α3 mit der Hochregulierung des Fibronektin-
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assoziierten Matrixproteins Fibulin-2 verbunden, was bekannter Weise einen 
transformierenden Zellphänotypus unterstützt. Mit Hilfe von E7wt und E7-L23A 
positiven Zellextrakten und Co-IP/massenspektrometrischer Analysen wurden die 
zellulären Faktoren ATP5B, PTRF/Cavin-1 und Phosphatidylserin als mögliche 
wichtige Faktoren für die Keratinozyten-Invasion identifiziert.  
Zusammenfassend konnte in dieser Studie gezeigt werden, dass sowohl Zell-Zell als 
auch Zell-Matrix-Interaktionen durch E7 moduliert werden, wodurch die Invasion von 
Keratinozyten ermöglicht wird. Somit konnten weitere mechanistische Ergebnisse für 
die Rolle von betaHPV in der Entstehung des Plattenepithelkarzinoms erbracht 
werden. 
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µg Microgram 
µl Microlitre 
aa Amino acid 
AIDS Acquired Immune Deficiency Syndrome 
ATP Adenosine triphosphate 
ATP5B ATP synthase, H+ transporting, F1-complex, beta-
polypeptide 
ATR ATR Serine/Threonine Kinase 
BCA Bicinchoninic acid 
BM Basement membrane 
bp Base pairs 
BS Binding site 
BSA Bovine serum albumin 
CER Complete early region 
CKII Casein kinase II 
Co-IP/MS Co-immunoprecipitation/mass spectrometry 
CR Conserved region 
DAPI 4',6-diamidino-2-phenylindole 
dH2O Distilled water 
ddH2O Double-distilled water 
DMBA 7,12-dimethylbenzanthracene 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dATP, dCTP, dGTP 
dNTP, dTTP 
Deoxyadenosine triphosphate, deoxycytidine  
triphosphate, deoxyguanosine triphosphate, 
deoxynucleoside triphosphate, deoxythymidine 
triphosphate 
DTT Dithiothreitol 
E1, E2, E4, E5, E6, E7 Early genes 1, 2, 4, 5, 6, 7 of HPV 
E6AP E6 associated protein 
EBV Epstein Barr virus 
ECAR Extracellular consumption rate 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylene diamine tetraacetic acid 
EMT Epithelial-mesenchymal transition 
EtBr Ethidiumbromide 
EtOH Ethanol 
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EV Epidermodysplasia verruciformis 
FACS Fluorescence-activated cell sorting 
FAK Focal adheson kinase 
FCCP Carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone 
FCS Fetal calf serum 
g Gram 
g Relative centrifugal force 
HBS Hepes buffered saline 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
he hemizygous 
HE Haematoxylin and eosin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human immunodeficiency virus 
HNSCC Head and neck squamous cell carcinoma 
ho homozygous 
HPV Human Papillomavirus 
HSPG Heparin sulphate proteoglycans 
hTERT Human telomerase reverse transcriptase 
HTVL-1 Human T cell lymphotrophic virus, type-1 
Hz Hertz 
IARC International Agency for Research on Cancer 
ICC Immunocytochemistry 
IHC Immunohistochemistry 
J Joule 
K10 Keratin10 
K14 Keratin14 
kb Kilo base pairs 
kD Kilo Dalton 
KSHV Kaposi’s sarcoma herpes virus 
L1/L2 Late gene 1/2 of HPV 
LANA Latency-associated nuclear antigen 
LB Luria-Burtani 
LCR Long control region 
LMP1 Latent membrane protein 1 
LPA Lysophosphatidic acid 
LPC Lysophosphocholine 
LTR Long terminal repeat 
M Mol l-1 
MAGUK Membrane-associated guanylate kinase homologs  
MAML1 Mastermind-like transcriptional co-activator 1 
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MCPyV Merkel cell polyomavirus 
MT1-MMP Membrane type1-MMP 
min Minute(s) 
ml Millilitre 
mM Milli mol L-1 
MMP Matrix metalloproteinase 
MSM Men who have sex with men 
mRNA Messenger RNA 
NCR Non-coding region 
nM Nano mol l-1 
NMSC Non-melanoma skin cancer 
NS3 Nonstructural protein 3 
NS4B Nonstructural protein 4B 
NS5A Nonstructural protein 5A 
OCR Oxygen consumption rate 
OD Optical density 
OPSCC Oropharyngeal squamous cell carcinoma 
ORF Open reading frame 
OSC Organotypic skin culture 
OTR Organ-transplant recipient 
PBS Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PC Phosphatidylcholine 
PDZ domain PSD95/Dlg/ZO-1 motif containing domain 
PE Phosphatidylethanolamine 
PHK Primary human keratinocytes 
PI Phosphatidylinositol 
PI(3)P Phosphatidylinositol (3) phosphate 
PI(3,4)P2 Phosphatidylinositol (3,4) biphosphate 
PI(4,5)P2 Phosphatidylinositol (4,5) biphosphate 
PI(3,4,5)P3 Phosphatidylinositol (3,4,5) triphosphate 
PI(4)P Phosphatidylinositol (4) phosphate 
PI(5)P Phosphatidylinositol (5) phosphate 
PMSF Phenylmethylsulfonyl fluoride 
pRB Retinoblastoma protein 
PS Phosphatidylserine 
PTRF Polymerase I And Transcript Release Factor 
PV Papillomavirus 
qRT-PCR Quantitative real-time polymerase chain reaction 
RNA Ribonucleic acid 
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RT Reverse transcriptase 
rt Room temperature 
s Second(s) 
SCC Squamous cell carcinoma 
SDS Sodium dodecyl sulfate 
SIP Sphingosine-1-phosphate 
siRNA Small interferring RNA 
Sp1 Specificity protein 1 
SV40 Simian virus 40 
TBST Tris buffered saline tween 
TCF T-cell factor 
TEMED Tetra methyl ethylene diamine 
TPA 12-O-Tetradecanoylphorbol-13-acetate 
U Units 
URR Upstream regulatory region 
UV Ultraviolet 
VLP Virus-like particle 
w/v Weight per volume 
Y2H Yeast to hybrid 
ZO-1 Zona Occludens 1 
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